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Increasing antibiotic resistance in pathogens is a serious public health challenge, with 
over two million antibiotic resistant infections in the United States leading to at least 23,000 
deaths and an estimated $55 billion in excess healthcare and societal costs. Antibiotic resistance 
has risen steadily in both pathogenic and benign bacteria since antibiotics’ introduction to 
agriculture and medicine 70 years ago. A dramatic reduction in the number of antibiotics 
approved for human use has accompanied this rise in antibiotic resistance, leading to the 
alarming prospect of a post-antibiotic era. Understanding the evolutionary origins, genetic 
contexts, and molecular mechanisms of antibiotic resistance in diverse environments is crucial to 
anticipating and mitigating the spread of antibiotic resistance. It is similarly critical to understand 
the effect of antibiotic exposure on the microbial communities, such as the human gut 
microbiota, which serve as reservoirs for antibiotic resistance genes available for horizontal 
transfer to pathogenic organisms. In this work, I take a multipronged biochemical, microbiologic, 
and genomic approach to surveil existing and emerging antibiotic resistance threats in 
xiv 
 
environmental and human-associated microbial habitats, and understand the effects of antibiotic 
perturbation on microbial community and resistome dynamics.  
To understand the effect of antibiotic perturbation on microbial community and resistome 
dynamics, I examined a population of very and extremely preterm infants who received 
extensive antibiotic exposure during their hospitalization in the neonatal intensive care unit. I use 
complementary sequencing and culture-based methods to analyze 448 stools collected 
longitudinally over the first 20 months of life from 41 preterm infants, as well as 17 antibiotic-
naïve near term infants that served as developmental controls. Using random forests, I define a 
program of healthy microbiota assembly in antibiotic naïve infants, and demonstrate acute but 
transient deviations from this program in antibiotic treated preterm infants. With a combination 
of sequencing isolates cultured from infant stool and functional metagenomics, I show that a 
consequence of early life antibiotic treatment in preterm infants is prolonged carriage of 
multidrug resistant Enterobacteriaceae and an enriched gut resident resistome.  
I address the emergence of antibiotic resistance from environmental and commensal 
reservoirs to pathogens through the lens the tetracycline destructases, a family of flavoenzymes 
capable of inactivating diverse tetracycline substrates. I conduct a bioinformatic survey of 
functionally selected metagenomes to show that these enzymes are widespread in diverse 
microbial communities, and characterize their spectrum of activity and mechanism of action to 
confirm that these enzymes are functionally and biochemically novel and illuminate sequence-
function relationships underlying the family. I identify an inhibitor of these enzymes that 
prevents tetracycline degradation in vitro and rescues tetracycline activity against resistant 
bacteria, and show that this inhibitor works by both competing for substrate binding and 
sterically restricting critical FAD cofactor dynamics. Lastly, I identify a Pseudomonas 
xv 
 
aeruginosa clinical isolate from a cystic fibrosis patient that encodes a functional tetracycline 
inactivator with 100% nucleotide identity to one previously identified in our bioinformatic 
survey, signaling the clinical arrival of this family of enzymes.  
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Chapter 1: Introduction 
1.1 Next-generation approaches to understand and combat 
the antibiotic resistome 
Antibiotic resistance is a natural feature of diverse microbial ecosystems. Although recent 
studies of the antibiotic resistome have highlighted barriers to horizontal transfer of antibiotic 
resistance genes between habitats, the rapid global spread of resistance genes to carbapenem, 
colistin, and quinolone illustrates the dire clinical and societal consequences of such events. Over 
time, the study of antibiotic resistance has grown from a focus on single pathogenic organisms in 
axenic culture to a study of antibiotic resistance in pathogenic, commensal, and environmental 
bacteria at the level of microbial communities. As the study of antibiotic resistance advances, it 
is important to incorporate this comprehensive approach to inform global antibiotic resistance 
surveillance and antibiotic development. It is increasingly becoming apparent that although not 
all resistance genes are risks for geographic and phylogenetic dissemination, the threat presented 
by those that are is serious and warrants an interdisciplinary research focus. Here, I highlight 
seminal work in the resistome field, discuss recent advances in the studies of resistomes, and 
propose a resistome paradigm that can pave the way for improved proactive identification and 
mitigation of emerging antibiotic resistance threats.  
1.1.1 The promise of antibiotics and the threat of resistance  
Antibiotics have revolutionized modern medicine and have saved millions of lives since 
their discovery at the beginning of the 20th century. These crucial drugs are invaluable owing to 
their ability to kill or inhibit the growth of bacteria without damaging host cells and tissues2,9. 
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Aside from directly curing deadly infectious diseases, antibiotics have enabled physicians to 
pursue new treatments such as surgery, organ transplantation, and cancer chemotherapy that 
were previously infeasible or unsafe owing to the high collateral risk of infection10. Antibiotics 
remain one of the most commonly prescribed classes of drugs, with over 70 billion clinical doses 
given globally in 2010, which represents a 36% increase in antibiotic consumption compared to 
200011. Although the first antibiotics were synthetic compounds, most antibiotics are natural 
products or derivatives thereof12. Many antibiotics were recovered from cultured soil 
microorganisms, particularly those belonging to the Streptomyces genus10. As might be expected 
given their origins as natural products of bacterial secondary metabolism, many antibiotics can 
be detected at low levels in pristine environmental samples and have been found in samples 
predating human antibiotic use13,14.  
Because of the ubiquity of antibiotic production by environmental microorganisms, 
defense mechanisms against these antibiotics and thus resistance also appear to be ancient. 
Sequencing of ancient environmental DNA preserved in 30,000 year old permafrost sediments 
has detected genes that confer resistance to several classes of antibiotics15, and direct screening 
of bacteria cultured from a cave that had no anthropogenic contact for the past four million years 
revealed extensive resistance against fourteen antibiotics16. Similarly, the host-associated 
microbiome of previously uncontacted indigenous people in South America was found to encode 
several antibiotic resistance genes17. This indicates that resistance to antibiotics far predates 
appropriation of these small molecules for human use. 
The collection of resistance genes in a given environment, which is termed the 
‘resistome’18,19, encompasses both intrinsic and acquired resistance genes, as well as proto-
resistance genes and silent or cryptic resistance genes. It is thought that many clinically relevant 
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antibiotic resistance genes have their evolutionary origins in environmental microorganisms, 
which we define for the purposes of this article to be composed of microorganisms not generally 
associated with humans. This hypothesis was pioneered by Benveniste and Davies, who in 1973 
noted biochemically identical resistance-conferring kanamycin acetyltransferases in 
environmental Streptomyces and in clinical isolates of pathogenic Escherichia coli20. Further 
evidence was provided by a recent functional screen of soil metagenomes, which revealed the 
presence of environmental antibiotic resistance genes with >99% nucleotide identity to resistance 
genes in pathogenic isolates4. Synteny of these genes with other resistance genes and mobility 
elements suggests that they are likely candidates for past or future dissemination by horizontal 
gene transfer (Fig. 1.1b). 
The ancient origin of antibiotics and antibiotic resistance makes it unsurprising that large-
scale clinical and agricultural use of these compounds has selected for increasing resistance 
across the bacterial domain of life. Robust evidence for mounting environmental resistance exists 
in decades old soil samples, in which increasing levels of antibiotic resistance genes correlate 
with industrial scale production and use of these drugs21. The resulting deterioration of the 
efficacy of our antibacterial armamentarium has come with substantial costs that are expected to 
rise over the next decades. Worldwide, it has been estimated that at least 700,000 people die 
annually due to resistant infections, a figure that is predicted to increase to 10 million annual 
deaths by the year 2050 if the current trajectory is not altered. Over the next decades, the 
cumulative global cost of antibiotic resistance is predicted to exceed 100 trillion US dollars22. 
The recent spread of mcr-1, kpc, blaNDM-1, qnr and other plasmid-borne resistance 
determinants underscores two themes. The first is that in the antibiotic arms race against bacteria, 
humanity is rarely ahead. This was illustrated with the first widely used antibiotics, the sulfa 
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drugs, against which resistance was observed only six years following their mass introduction1. 
More recently, resistance to tigecycline was identified even before its approval for human use, let 
alone its introduction into the clinic23. It is therefore either a sign of hubris or a lack of 
understanding of evolutionary principles when new antibiotics are advertised as being resistance-
proof. The second theme has been our relatively myopic (albeit understandable) focus on 
resistance in human pathogens. It is a tautology that antibiotics are most effective at treating 
human pathogens. They would not be antibiotics if they failed to effectively treat pathogens, but 
our emphasis on a few pathogen ‘trees’ initially resulted in the field of antibiotics being blind to 
the ‘forest’ of environmental bacteria. The targets of most antibiotics are both highly conserved 
and essential across bacterial taxa, and have therefore made excellent subjects of intra-kingdom 
communication and competition among prokaryotes throughout biological history24. When our 
view is expanded to include the vast diversity of non-pathogenic bacteria it is not surprising to 
see that all genera of the prokaryotic kingdom have evolved resistance mechanisms that protect 
these vital processes.  
Here, I will examine these themes across three eras of antibiotic resistance research. The 
first era, which coincides with the golden age of antibiotics, is characterized by a focus on 
resistance in pathogens in the clinic and by the ready supply of new antibiotics and diverse 
antibiotic mechanisms of action. In this era, drawing inspiration from Koch, the research priority 
was on single resistance genes and enzymes primarily from pathogenic organisms in axenic 
culture. In the second era of antibiotic resistance studies, we slipped the restrictive bonds of 
Koch’s postulates and shifted our attention to resistomes. Antibiotic resistance of both benign 
and pathogenic bacteria was studied at the microbial community level, and metagenomic 
approaches were incorporated to discover resistance determinants from diverse habitats. As we 
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enter the next era of antibiotic resistance research, we should acknowledge the ubiquity of 
antibiotic resistance and take steps to improve development of new antibiotic therapies and 
surveillance of emerging resistance threats, focusing on resistance genes that are the most likely 
candidates for horizontal transfer to pathogens. In the remainder of this introduction, I will 
provide brief overviews of the previous eras of resistome studies, and outline how distinct 
philosophies from each of these generations could be integrated to improve the translational 
impact of resistome research going forward. 
1.1.2 Common mechanisms of antibiotic action and antibiotic resistance 
Antibiotic targets are generally conserved across the bacterial domain of life and are 
absent from or sufficiently different in eukaryotes. Although hundreds of such targets exist in 
theory, our current antibiotic arsenal generally attacks the bacterial ribosome (inhibiting protein 
synthesis, for example, aminoglycosides), cell wall synthesis and lipid membrane integrity 
(compromising membrane integrity or lysing bacterial cells, for example, β-lactams), single-
carbon metabolic pathways (inducing metabolic disruption, for example, sulfa drugs), and DNA 
maintenance (interfering with bacterial replication and genomic integrity, for example, 
quinolones)1,9,25 (see Fig. 1.1, top). 
Bacteria typically resort to one of a few common strategies to resist antibiotics26 (see Fig 
1.1, bottom). One resistance mechanism involves inactivation of the antibiotic through enzymatic 
degradation or modification of the antibiotic scaffold, which renders it ineffective. Examples of 
this mechanism include chloramphenicol acetyltransferases27, tetracycline inactivating enzymes 
such as Tet(X)28,29, and, most notably, the widespread β-lactamases30,31. A second strategy for 
resistance is protection, alteration, or overexpression of the antibiotic target. This approach is 
used by vancomycin resistant enterococci (VRE), which enzymatically modify peptidoglycan, 
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thus decreasing the affinity of vancomycin for its target32, and by methicillin resistant 
Staphylococcus aureus (MRSA), which expresses a redundant, methicillin-insensitive variant of 
the native penicillin-binding protein33. Two additional resistance mechanisms rely on keeping the 
antibiotic out of the bacterial cell, either through efflux or altering cell membrane permeability. 
By expressing either a generalist multidrug efflux pump34-37 or an antibiotic-specific exporter 
such as the tetracycline efflux pumps38, bacteria keep the intracellular concentration of the 
antibiotic below inhibitory levels. Alternatively, some bacteria reduce cell membrane or cell wall 
permeability to prevent antibiotics from entering the cell by decreasing porin expression or 
expressing a more selective porin variant39,40. In some cases, bacteria will use several 
Figure 1.1: Common mechanisms of antibiotic action and resistance. 
Antibiotics generally function by one of a few common mechanisms (top). These 
include inhibition of protein synthesis, inhibition of cell wall or membrane 
synthesis or integrity, disruption of single-carbon metabolism, or disruption of 
DNA replication and integrity. Likewise, bacteria resort to one of several strategies 
to resist antibiotics (bottom). These strategies include enzymatic degradation or 
modification of the antibiotic, alteration or occlusion of the antibiotic target, active 




complementary mechanisms to achieve high-levels of resistance. For example, high level 
carbapenem resistance in clinical isolates of Enterobacter cloacae that lack any known 
carbapenemase can be achieved through a combination of porin mutations to decrease 
carbapenem uptake and increased expression of a chromosomal non-carbapenemase β-
lactamase41.  
1.1.3 The golden age of antibiotics 
Both Sir Alexander Fleming and Gerhard Domagk, the discoverers respectively of 
penicillin and prontosil, warned of the danger of bacterial resistance developing following 
improper use of their antibiotics42,43. One of the first reports of antibiotic resistance was the 
finding that a cell-free extract from a coliform bacterium that was impervious to penicillin was 
able to inactivate penicillin, which indicated enzymatic degradation of the drug44. In the 
following decades, extensive use of penicillin in hospitals led to widespread resistance in 
Staphylococcus aureus and resulted in the 1953 penicillin-resistant S. aureus phage-type 80/81 
pandemic, which represented the world’s first superbug until the release of methicillin ended the 
threat45. Soon after, the emergence of multi-drug resistant strains of Shigella spp. following 
apparent horizontal gene transfer from fecal E. coli strains was reported. Remarkably, there was 
evidence for such transfers occurring in hospitalized patients during the course of their antibiotic 
treatment 46.   
The first era of resistance studies was concomitant with the golden age of antibiotics. 
During this period, all modern major classes of antibiotic were discovered. Within years, many 
were rendered obsolete in at least some organisms through the acquisition and spread of 
resistance1. For a period, novel or previously known mechanisms of resistance that arose in new 
pathogens were commonly dealt with through the development and release of a new antibiotic. 
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Indeed, resistant bacteria were even welcomed by Domagk as an opportunity to increase 
antibiotic market share42. During this era, resistance genes and bacteria were largely identified 
Figure 1.2: Next-generation sequencing and functional metagenomic 
selection accelerate cataloging of known and novel resistance genes. (a) The 
catalog of resistance genes has increased exponentially in the second era of 
antibiotic resistome studies owing to improvements in next-generation 
sequencing. This trend is exemplified by the tetracycline efflux pump tetA, the β-
lactamase family of enzymes (bla), and by chloramphenicol acetyl transferase 
(CAT). Data from the UniProt database5 were accessed October 12, 2016 based 
on searches using E.C. numbers (bla 3.5.2.6, CAT 2.3.1.28) or by family name 
(tetA major facilitator superfamily tcr tet family). Data for sequencing costs from 
National Human Genome Research Institute webpage6. (b) Functional 
metagenomics is a powerful tool for ascribing antibiotic resistance function to 
known gene products. Antibiotic resistance proteins identified by functional 
metagenomic selection of the preterm infant gut microbiome have high amino 
acid identity to proteins in NCBI, but low amino acid identity to proteins in 
antibiotic resistance databases. (c) Additionally, functional metagenomics can 
reveal entirely sequence-novel resistance determinants. β-lactamases that were 
identified by functional metagenomic selection of two human gut resistomes (red 
squares) encompassed greater phylogenetic diversity than all previously identified 
classes of β-lactamases (blue squares). Part b adapted from Gibson et al. 20167, 
part c adapted from Sommer et al. 20098. 
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one gene and one strain at a time using culture-based methods. This low-throughput approach, 
combined with incompletely exhausted reserves of natural antibiotics, disguised the otherwise 
apparent threat that antibiotic resistant bacteria were destined to become. 
1.1.3 High-throughput resistance discovery 
The second era of resistome studies has been characterized by a broader ecological view 
of resistance, which was enabled by several breakthrough technologies. In the past decades, the 
new ecological resistome philosophy that recognized the environment as the plausible original 
source of resistance genes and as the reservoir of resistance gene diversity has been driven by the 
technical advances in molecular biology and nucleic acid sequencing. 
Sequencing-based resistance discovery.  
The development of genomic techniques that allow the culture-independent study of 
diverse environmental microbial communities has been a critical driver of the paradigm shift in 
resistome studies6,47-49. This is illustrated by the growth of the catalog of known resistance genes, 
concomitant with the steep drop in sequencing costs. A survey of resistance proteins in the 
UniProt database5 demonstrates that since 1986 there has been an exponential increase in the 
number of hypothetical resistance determinants classified as β-lactamases, chloramphenicol 
acetyltransferases, or tetracycline efflux pumps (Fig. 1.2a). The surfeit of sequencing data 
exemplifies the second era of resistance studies although, in many cases, the lack of functional 
validation of these genes calls into question whether all are resistance determinants. Similarly, 
the sequence diversity that is captured using cutting-edge techniques may not translate into 
functional diversity. One technique that has proven useful in discovery of resistance 
determinants that are novel, diverse, and validated is functional metagenomics (Fig. 1.3), which 
is a technique developed to mine metagenomes for a variety of phenotypes without a need for 
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culturing50. Functional metagenomics has proven essential for characterizing antibiotic 
resistomes. Briefly, this technique consists of cloning metagenomic DNA into expression vectors 
and screening for a phenotype of interest (for example, antibiotic resistance) in a facile host 
organism. This bypasses the bottleneck that is imposed by difficult to culture bacteria and 
explicitly selects for genes that are a threat for horizontal transfer, as only phenotypes 
transferable to a heterologous host are detected. However, resistance to antibiotics that results 
from mutation of the antibiotic target, an important contributor to resistance in many organisms 
such as M. tuberculosis51,52, may not be always be detected in functional metagenomic screens as 
a single wild-type copy of these genes in the expression host often confer a dominant susceptible 
phenotype. This is the case for quinolone resistance resulting from mutations in the DNA gyrase 
enzyme51, although analysis of evolutionary patterns in such genes may allow for antibiotic 
resistance risk estimates to be made53-55. Furthermore, the artificial action of extracting and 
cloning DNA can lead to the transfer of genes that otherwise might not be mobilizable, which 
Figure 1.3: Functional metagenomic approaches for characterizing resistomes. A graphical 
overview of the functional metagenomic experimental and computational workflow. 
Metagenomic DNA is shotgun cloned into an expression system, selected for antibiotic 
resistance, and resistant transformants are sequenced, assembled, and annotated in high 
throughput to identify resistance determinants in a sequence- and culture-unbiased manner. 
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possibly raises concerns over the spread of resistance in cases where actual risk may be low, but 
may also result in the underestimation of sequences related to mobility elements, which are not 
explicitly selected for in screens for antibiotic resistance.  
 Functional metagenomics is a powerful culture- and sequence-unbiased tool.56 A 
metagenomic library is created by extracting total metagenomic DNA from a microbial 
community, shearing the DNA to a target size distribution, and cloning these fragments en masse 
into a screening vector. The metagenomic library is then transformed into a heterologous host 
and selected for a phenotype of interest, for example by culturing with antibiotics at a 
concentration that is lethal to the wild-type host49,57 (Fig. 1.3). Pairing functional metagenomic 
selection with next-generation sequencing and better sequence assembly and annotation 
algorithms4 has simultaneously decreased the cost and increased the throughput of functional 
metagenomic experiments, which facilitated the characterization of resistomes from diverse 
habitats3,7,17,23,58. Importantly, there is no need to culture members of the target microbial 
community and novel resistance genes can be discovered. Furthermore, the genes discovered by 
functional metagenomics are by definition threats for horizontal transfer, as they must be 
functional in a heterologous host.  
 However, there are several limitations. For a gene to be identified in a functional 
metagenomic screen, it must be functional in a heterologous host. Common hosts such as E. coli 
likely present a poor system for discovery of resistance genes that originated from Gram-positive 
organisms. Indeed, poor overlap has been reported between clones recovered from the same 
functional metagenomic library subjected to the same screen but in different hosts59,60. In 
addition, it is generally difficult to screen Gram-positive-specific antibiotics in E. coli or other 
common Gram-negative platforms owing to their innate resistance, although in some cases this 
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may be overcome61. Thus, there is a clear need to develop and screen functional libraries in 
phylogenetically diverse heterologous hosts56,62. Furthermore, functional metagenomic 
experiments may oversample resistomes, as the method struggles to distinguish resistance genes 
that pose clinical threats from those that are unlikely to spread beyond their current environment. 
Genes that confer antibiotic resistance when overexpressed in a heterologous host similarly may 
not be genuine resistance genes in their native contexts55. To reduce the risk of false positives, it 
is important that ‘novel’ resistance genes are validated using complementary microbiological and 
biochemical methods and crosschecked against existing databases. Finally, removal of an 
antibiotic resistance gene from its genomic context often also removes positional information 
that is pertinent to assessing its risk dissemination. This can be overcome, in part, by altering 
insert size, as larger inserts may contain informative regions flanking resistance genes, including 
mobility elements or plasmid sequences that might indicate risk for spread (that is, the 
mobilome)3,58,63.  
The coupling of functional metagenomic selections with high throughput sequencing and 
computational methods has facilitated an increase in our ability to catalog resistomes from 
diverse habitats. Importantly, functional metagenomics can both ascribe resistance function to 
known genes that were not previously identified as resistance determinants and uncover 
resistance genes with novel sequences. For example, a recent analysis of functionally discovered 
resistance genes found that, whereas many of the gene products had high amino acid identity to 
known enzymes, most had low identity to known resistance determinants7 (Fig. 1.2b). Similarly, 
the utility of functional metagenomics in uncovering entirely new resistance functions is 
highlighted by its recent application to discover novel rifamycin phosphorylases64, dihydrofolate 
reductases65, and tetracycline-inactivating enzymes29. 
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The resistomes of different habitats.  
Functional metagenomics was first described in 2000 as a method for accessing the 
diverse biochemical activities encoded in the uncultured soil metagenome50. In an early 
application of functional metagenomics for the explicit purpose of screening for antibiotic 
resistance genes, a library, which contained 5.4 Gb of metagenomic DNA from a remnant oak 
savannah site, was selected against a panel of aminoglycoside antibiotics, as well as tetracycline 
and nalidixic acid66. Ten resistant clones were sequenced, and all but one were found to contain 
novel resistance determinants. Since these initial studies, functional metagenomics has been 
widely used to screen a diverse array of soil metagenomes, including remote arctic soils67-69, 
apple orchard soils70, alluvial soils71,72, wetland soils73, agricultural soils58,65, and urban soils74, 
and has identified novel antibiotic resistance genes to diverse classes of antibiotics. Agricultural 
resistomes are of particular interest because the selective pressure of heavy antibiotic use and 
extensive anthropogenic interaction make this a high-risk habitat for antibiotic resistance 
selection and dissemination. Indeed, the mcr-1 plasmid-mediated colistin resistance determinant 
was first discovered on a Chinese pig farm75, although it has since been detected in new and 
banked clinical and environmental samples across the globe76-84.  
Global spread of plasmid-borne resistance. 
In the past several decades, a variety of new antibiotic resistance threats have emerged 
and spread worldwide. In particular, the emergence and spread of plasmid-borne resistance genes 
(Fig. 1.5), which pose serious threats for horizontal gene transfer, have jeopardized many last 
line antibiotic therapies, including the cephalosporin and carbapenem families of β-lactam 
antibiotics, quinolones such as ciprofloxacin, and an antibiotic of last resort, colistin12. 
Cephalosporins have been compromised by resistance owing to extended spectrum β-lactamases 
14 
 
(ESBLs), which were first reported in 197985 and subsequently spread phylogenetically across 
the Enterobacteriaceae and geographically across the globe86. As a result, many infections that 
were previously treated by drugs such as cefotaxime must now be treated with the carbapenem 
class of antibiotics. However, the spread of carbapenemases87, particularly the New Delhi 
metallo-β-lactamase-1 (NDM-1)88-90 and Klebsiella pneumoniae carbapenemases (KPC)91 since 
their respective discoveries in 2006 and 2001, have similarly rendered these antibiotics 
vulnerable92.  
A similar development has been observed with the quinolones, which were originally 
touted to be at low risk of the type of transferable resistance that has beleaguered the β-lactam 
antibiotics. Indeed, whereas chromosomal resistance can readily develop to this class of 
antibiotic through DNA gyrase mutations, transferable resistance was slow to develop following 
Figure 1.4: Recent global dissemination of plasmid-borne resistance. Resistance 
genes encoded on plasmids represent particular threats for broad dissemination. In recent 
years, resistance genes to quinolones, carbapenems, and polymixins have been observed 
in clinical isolates worldwide not long after their first identification. Location of first 




clinical introduction of these antibiotics in the 1960s. Nonetheless, plasmid-mediated resistance 
through the Qnr proteins, first described in 1998, has emerged from quinolone overuse and 
subsequently spread worldwide. In searching for the origins of Qnr resistance determinants, a 
PCR screen of Gram-negative organisms found homologs in the aquatic bacterium Shewanella 
algae with almost 99% amino acid identity93. Shewanella species that lack these homologs were 
found to have 4- to 8-fold greater sensitivity to quinolone antibiotics, which indicates the ability 
of the qnr-related genes to confer some antibiotic resistance even in their native contexts in 
which they likely function to bind DNA for some other purpose9,93. The hypothesized horizontal 
transfer of qnr homologs from environmental to pathogenic bacteria corroborates hypotheses that 
many resistance genes may have been coopted by pathogens from the environmental 
resistome4,20,93,94. Quinolone efficacy has been further reduced by the emergence in Shanghai in 
2003 of the plasmid-borne bi-functional aminoglycoside and quinolone resistance gene aac(6’)-
Ib-cr95. This gene, which differs from a classical aminoglycoside transferase by only two base-
pairs, is notable in its ability to modify fluoroquinolones as well as aminoglycosides through 
acetylation. Alarmingly, aac(6’)-Ib-cr is often colocalized with other resistance genes such as 
ESBLs96 on multi-drug resistance plasmids. 
The spread of the aforementioned resistance mechanisms leave only a few classes of 
antibiotics approved for the treatment of infection by carbapenem-resistant Enterobacteriaceae. 
One of these, the polymyxin class of peptide antibiotics, was first used in the 1960s, but was 
abandoned in favor of other antibiotics owing to its toxicity. Recently, the polymyxin colistin has 
been revived owing to its efficacy against several multidrug resistant Gram-negative pathogens97. 
However, transferable resistance has now begun to threaten colistin. In 2015, an E. coli isolate 
from a pig farm in Shanghai with colistin resistance was found to contain mcr-1 — a plasmid-
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born gene that encodes a phosphoethanolamine transferase75. This finding, and the subsequent 
discovery of mcr-1 on plasmids worldwide76-84, foreshadows the fall of colistin as the final 
antibiotic of last resort without transferable plasmid-encoded resistance. With high levels of 
antibiotic prescription in medicine and unregulated use in agriculture around the world it is likely 
only a matter of time before completely pan-resistant plasmids are found that combine the above 
resistance mechanisms. Indeed, the coexistence of NDM-1 and MCR-1 in Enterobacteriaceae has 
already been observed80,98, and a recent report documented the co-transfer of mcr-1 and ndm-5 
on a mobile hybrid IncX3-X4 plasmid99.  
In addition to soil habitats, human-associated resistomes have been a recent focus of 
functional metagenomic investigations. The first human-associated microbial community to be 
queried for antibiotic resistance by functional metagenomic selection was the oral microbiome. 
Screening of a small functional library constructed from dental plaque and saliva samples against 
tetracycline resulted in the discovery of tet(37), a gene encoding a tetracycline-inactivating 
enzyme with low sequence identity to any previously described tetracycline resistance 
determinant, as well as other resistance genes100. A larger follow-up study revealed resistance 
against tetracycline, gentamicin and amoxicillin in the oral microbiota101. The first report of a 
functional metagenomic interrogation of the human gut resistome screened metagenomic DNA 
from the saliva and stool of two healthy humans against a panel of 13 antibiotics. Ninety-five 
unique inserts, which together conferred resistance to all 13 antibiotics screened, were sequenced 
and found to be largely dissimilar from the closest known resistance genes. For example, ten 
novel β-lactamases were identified in just two gut microbiomes, indicating that these 
microbiomes encompassed greater phylogenetic β-lactamase diversity than all previously 
described β-lactamases (Fig. 1.2c)8. Additional studies have examined the gut microbiomes of 
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diverse human populations, including healthy adults102, healthy twins and their mothers23,103,104, 
preterm infants7, uncontacted antibiotic-naïve Amerindians17, and families, as well as livestock 
and pets, from developing countries in Latin America3. Importantly, these studies have made it 
clear that although the resident human-associated resistome is enriched after antibiotic therapy7, 
the gut harbors an extensive resistome even in the absence of anthropogenic antibiotic use3,17.  
Limitations of resistome studies.  
Although these studies are extremely valuable in cataloging the genetic diversity of the 
global resistome, they have been largely descriptive or philatelic exercises with substantial 
requirements for downstream mechanistic validation. It is important to emphasize that just 
because a gene confers resistance when it is overexpressed in a heterologous host, it may not be a 
bona fide resistance gene in the original host. Indeed, nuanced definitions of antibiotic resistance 
should consider the function of resistance determinants in their native contexts and risk for 
transmission between bacterial species55. There is extensive evidence that resistome composition 
is strongly correlated with the phylogenetic structure of a microbial community, and that synteny 
of antibiotic resistance genes with mobility elements is observed less frequently in environmental 
metagenomes (for example, from soil) than in sequenced pathogen genomes58,105 (Fig. 1.5b). 
Nonetheless, the discovery of identical resistance genes in multiple genomic and environmental 
contexts suggests historical transfer and/or dissemination events. For example, a recent 
functional metagenomic study uncovered an identical TEM-1 β-lactamase in 25 different habitats 
and genetic backgrounds3 (Fig. 1.5a). This research, when viewed in light of recent emerging 
resistance threats, underscores that, although not all resistance genes are threats for widespread 
dissemination, we should pay close attention to the ones that are. A focus of future studies on 
antibiotic resistomes should be a quantification of risk for horizontal gene transfer to pathogens 
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based on ‘metadata’ associated with a given resistance gene (for example, synteny with mobility 
elements, plasmid-borne or chromosomal, in a close relative of human pathogen) to model the 
risk for transmission54,55.  
Figure 1.5: Synteny of antibiotic resistance genes provide historical context and 
foreshadow future threats. The genetic context of antibiotic resistance genes can provide 
important evidence of the likelihood of past or future horizontal gene transfer. (a) A single β-
lactamase (TEM-1) was found in 25 different genetic contexts in a recent cross-habitat resistome 
study, which provided a historical record of past mobility. Five contexts are shown here. Habitats 
in which gene was discovered are indicated on the left (human: human-associated microbial 
community, animal: animal-associated microbial community, WWTP: wastewater treatment 
plant, latrines:  composting latrine). (b) Four resistance determinants that were discovered in 
functional selections of soil metagenomic libraries (bottom) have high identity with resistance 
genes from clinical pathogenic isolates. Shading indicates >99% nucleotide identity, which 
suggests recent horizontal transfer. Resistance genes in pathogens are syntenic with mobility 
elements and other resistance genes, which suggests that they may be present on a mobile 
multidrug resistance cassette and pose a threat for horizontal gene transfer. Part a adapted from 





1.1.4 Next-generation approaches to resistance  
Strategies to combat antibiotic resistance will require substantial changes to both the 
antibiotic pipeline and stewardship practices and antibiotic resistance surveillance. The ubiquity 
of antibiotic resistance suggests that the drug development pipeline must include proactive 
screens for existing environmental resistance threats to new drugs and should explore alternative 
strategies for combating resistance outside of the traditional antibiotic pipeline. Additionally, it is 
the responsibility of the wider medical and scientific communities to apply the fruits of the first 
two eras of resistome studies towards efforts to surveil potential antibiotic resistance hotspots for 
emerging resistance threats before they spread.  
Next-generation therapeutics.  
A key aspect for the next-generation of antibiotic resistance studies is the proactive 
development of therapeutic strategies to counteract emerging antibiotic resistance. One side of 
this approach involves improved development of new antibiotics with a greater focus on 
resistance potential. Current antibiotic discovery and development pipelines only take into 
account resistance mechanisms that are already prevalent in the clinic. In retrospect, we know 
that this strategy is doomed to fail, as resistance has been observed for every antibiotic that has 
been implemented for human use1. Going forward, we should improve on the current reactive 
strategies by screening promising lead compounds for resistance against diverse functional 
metagenomic libraries. This will illuminate existing mechanisms of resistance that are likely to 
disseminate to the clinical setting upon the introduction of the antibiotic for clinical use (Fig. 
1.6). 
In the near future, our understanding of the resistome will be sufficiently mature to 
enable the development of strategies that actively combat resistance mechanisms themselves in 
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contrast to current strategies that side-step resistance through the expensive development of new 
antibiotics that immediately select for new mechanisms of resistance. This approach, in our 
opinion, provides a higher likelihood of success than searching for a fabled ‘silver bullet’ 
antibiotic to which resistance is unlikely to develop. One such strategy is the repurposing of 
existing antibiotics in synergistic combinations. Consider, for example, the triple β-lactam 
combination of meropenem, piperacillin, and tazobactam, which was found to synergistically kill 
methicillin-resistant Staphylococcus aureus (MRSA) N315 in vitro and in a mouse infection 
model. The combination of these three antibiotics was collaterally sensitive and thus suppressed 
the evolution of further resistance106. Treatment regimens that induce collateral sensitivity not 
only enable the elimination of resistant bacteria, but also subject resistant bacteria to selective 
pressure to discard their resistance gene107. Inverting the selective advantage of antibiotic 
resistance is a promising approach for slowing the rate at which resistance evolves in a 
population. A recent highlight in the search for selection-inverting compounds involved a screen 
of nearly 20,000 small molecules for compounds that select against the tetracycline efflux pump 
TetA. This screen identified two candidates that successfully selected for loss of the tetA gene108. 
Perhaps more important are drugs under development and in early phase testing that target AcrA-
AcrB-TolC type efflux complexes in Gram-negative bacteria. Unlike TetA proteins, which are 
tetracycline-specific, AcrA-AcrB-TolC pumps have broad substrate tolerance and can confer 
multi-drug resistance, in particular in Gram-negative bacteria109. 
A final strategy that has already proven effective in opposing widespread resistance is the 
inhibition of antibiotic resistance enzymes110. Small molecules that lack antibiotic activity but 
enhance the efficacy of antibiotic therapy are broadly termed antibiotic adjuvants111. β-lactamase 
inhibitors and Tet(A) efflux selection inversion108,110,112 fall in this category, as do promising 
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examples from recent studies that paired antibiotics with repurposed drugs already on the market 
for other indications such as the opioid-receptor agonist loperamide which facilitates tetracycline 
uptake and the ADP receptor antagonist ticlopidine which inhibits teichoic acid 
biosynthesis10,111,113,114. Continued discovery of antibiotic adjuvants is facilitated and informed 
by resistome studies that comprehensively describe the universe of possible resistance genes. 
Consider, for example, the recently described E. coli-hosted array of >40 mechanistically distinct 
and functionally validated resistance genes. This platform, which represented resistance to 16 
classes of antibiotics, was used to screen a limited small molecule library for compounds that 
could enhance the antibiotic activity of gentamicin. Of the 27 compounds that exhibited this 
activity, eight were found to block aminoglycoside-2″-O-nucleotidyltransferase (ANT(2″)-Ia) 
mediated resistance. Two compounds selected for further validation exhibited poor antibiotic 
activity alone and were confirmed to inhibit ANT(2″)-Ia in vitro. By screening drug 
combinations against a phenotypic resistome array, the authors were able to identify inhibitors of 
antibiotic resistance genes, demonstrating the utility of leveraging resistome data to discover 
adjuvants that can prolong the efficacy of existing antibiotics115.  
Next-generation surveillance.  
Lastly, it is important to prioritize continued and increased surveillance of the antibiotic 
resistome, in particular, ‘hotspots’ in which there is a high likelihood of resistance gene 
evolution and transfer between organisms (Fig. 1.6). These hotspots include, but are not limited 
to, agricultural settings in which large quantities of antibiotics and human pathogens as well as 
environmental microorganisms intermingle and potentially exchange DNA75, hospitals in which 
selective pressure is omnipresent due to extensive use of antibiotics and antimicrobials, which 
may co-select for antibiotic resistance46, and waste-water and sewage systems in which the 
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human gut microbiota is directly exposed to many pharmaceutical residues3. Surveillance 
requires regular testing of pathogens, commensals, and microbial communities for resistance to a 
broad panel of antibiotics. This can occur using culture-dependent or genomic approaches, and 
necessarily entails the continued development of technologies that will facilitate identification of 
antibiotic resistance determinants.  
Recent computational and bioinformatic advancements have offered substantial 
improvements in our ability to identify antibiotic resistance genes from PCR amplicons and 
whole-genome sequencing (WGS)49. These databases contain nucleotide or protein sequences for 
known antibiotic resistance determinants, and can be queried (by BLAST116, for example) to 
identify the antibiotic resistance genes that are present in a given genome or metagenome. 
Figure 1.6: Integration of next-generation sequencing and screening 
technologies with drug development and resistance surveillance.  
The wide application of functional metagenomic selections and next 
generation sequencing will steadily increase our knowledge of 
functionally annotated antibiotic resistance genes and their genetic 
context. This will allow for more intelligent antibiotic resistance 
surveillance and drug design by accounting for specific mechanisms of 




However, these functional predictions are explicitly based only on sequence data and are 
vulnerable to false positive predictions, particularly when functional assignments are based on 
annotations that are themselves removed from direct biochemical or phenotypic validation. A 
key component of our ability to annotate and predict antibiotic resistance genes from genomic 
data is the continued improvement of antibiotic resistance gene databases through functional 
validation117-122. In addition, improved probabilistic annotation algorithms such as profile hidden 
Markov models (HMMs) have been shown to perform substantially better than pairwise 
sequence alignment in terms of precision and recall123,124. For example, Resfams, a curated 
database of 166 profile HMMs that were constructed from functionally validated resistance 
protein families correctly predicted 45% more β-lactamases in functionally selected 
metagenomic contigs compared to BLAST alignment to antibiotic resistance databases122. In 
another case, nucleotide sequences from metagenomic datasets were used to computationally 
predict qnr genes that might confer quinolone resistance. Although qnr genes display low 
similarity to other resistance determinants and relatively high in-family diversity, the authors 
were able to discover and functionally verify several novel variants125,126. As a result of these 
tools, we are now able to more confidently identify both transferable and intrinsic resistance 
determinants from genomes and metagenomes. Going forward, it is important that these 
databases are regularly updated with the nucleotide and amino acid sequences of functionally 
validated, emerging resistance determinants (Fig. 1.6).  
Despite these advancements, the prediction of resistance phenotype based on genotype 
remains a challenge. WGS-based methods present a promising approach to improve the speed 
and accuracy of diagnostics127-129. An additional advantage of WGS-based diagnostics is the 
possibility for improved identification of antibiotic resistance by target modification, which is 
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often not feasible by existing PCR-based or microarray-based methods129-131. A current highlight 
of sequencing based diagnostics is the Mykrobe predictor, which identified antibiotic 
susceptibility profiles for twelve antibiotics from raw, unassembled Illumina sequencing data 
from Staphylococcus aureus and Mycobacterium tuberculosis isolates as well as from in silico 
simulated heterogeneous populations with high sensitivity and specificity132. A recently 
described alternative approach uses draft genome assemblies as input and a machine learning 
approach to accurately predict resistance profiles for multi-drug resistant Enterobacteriaceae 
isolates124. Although it is currently cost and time prohibitive to use WGS as a clinical diagnostic 
tool, continued reductions in sequencing costs and improvements in computational algorithms 
may soon make this approach feasible. Faster and more accurate diagnostics will importantly 
reduce empiric and unsuitable antibiotic prescriptions, limiting further selection for resistance 
(Fig. 1.6).  
Two recent examples from the literature highlight the important of surveillance efforts as 
we attempt to arrest the spread of antibiotic resistance. These examples pertain to the current 
antibiotics of last resort against carbapenem-resistant Enterobacteriaceae — colistin and 
tigecycline. The first is the emergence of the mcr-1 gene as a transmissible threat to colistin use. 
The seminal example of a plasmid-borne colistin resistance gene was found through an active 
surveillance programme in China monitoring antimicrobial resistance in food animals75. Soon 
after its discovery, several retrospective studies demonstrated that plasmid-borne mcr-1 had 
already spread worldwide and into the clinic133 (Box 2). In this case, surveillance provided 
crucial early detection. The second example of the importance of surveillance relates to 
tigecycline, a semi-synthetic tetracycline antibiotic134. Due to its increased affinity for the 
bacterial ribosome compared to other tetracyclines, and the presence of a glycyl tail, tigecycline 
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is subject to reduced resistance through ribosomal protection or drug efflux135. However, 
tigecycline is vulnerable to the tetracycline-inactivating protein Tet(X)136. Although this protein 
was originally discovered in Bacteroides fragilis — a traditionally non-pathogenic human gut 
commensal, several clinical isolates have recently tested positive for tet(X)137,138, and tetracycline 
inactivation has been discovered to be more widespread in environmental metagenomes than 
previously thought29. Continued surveillance of this apparent emerging resistance mechanism is 
prudent, as tigecycline and other next-generation tetracycline derivatives are being designed to 
exclusively evade resistance through ribosomal protection and efflux139,140. Increased use of next 
generation tetracyclines imposes a strong selective pressure for the acquisition and spread of 
tetracycline-inactivating enzymes from the environmental resistome. Foresight of this event 
should enable the proactive development of next-generation therapeutic strategies before the 
widespread dissemination of a resistance threat. 
1.1.5 Conclusions 
Extensive study of the antibiotic resistome over the past decades has allowed us to begin 
to understand and address existing antibiotic resistance threats. However, it is evident that 
antibiotic resistance will continue to evolve and spread in spite of our best efforts to develop new 
antibacterial agents. Unless current practice is changed, it will be increasingly difficult to 
establish and maintain even a transient lead over bacteria in this arms race. As research into 
antibiotic resistance expands, it is important to adopt an explicitly proactive approach to 
antibiotic resistance identification and surveillance, as well as antibiotic therapy development. 
This proactive approach involves using a combination of functional metagenomics, next-
generation sequencing, and cutting-edge computational methods to monitor evolution and 
dissemination of resistance before a given resistance determinant emerges in a pathogen or in the 
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clinical setting, as well as proactively developing next-generation therapies that target these 
resistance determinants. The spread of plasmid-borne carbapenem, quinolone, and polymyxin 
resistance in recent years is a sobering reminder of our need to catch up to existing threats, and to 
anticipate emerging resistance mechanisms before they circulate widely in the clinical setting if 
we wish to alter the current grim antibiotic resistance trajectory. Recent advances in the field 
highlight the promise that the next-generation of resistome studies holds for characterizing and 
countering emerging resistance threats.  
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1.2 Genomic and functional techniques to mine the 
microbiome for novel antimicrobials and antimicrobial 
resistance genes: 
Microbial communities contain diverse bacteria that play important functional roles in 
every environment. Advances in sequencing and computational methodologies over the past 
decades have illuminated the phylogenetic and functional diversity of microbial communities 
from diverse habitats. Among the functions encoded in microbiomes are the abilities to 
synthesize and resist small molecules, yielding antimicrobial activity. These functions are of 
particular interest when viewed in light of the public health emergency posed by the increase in 
clinical antimicrobial resistance and the dwindling antimicrobial discovery and approval 
pipeline, and given the intimate ecological and evolutionary relationship between antimicrobial 
biosynthesis and resistance. Herein, I review genomic and functional methods that have been 
developed for accessing the antimicrobial biosynthesis and resistance capacity of microbiomes 
and highlight outstanding examples of their applications.  
1.2.1 Introduction  
Nobel Laureate Joshua Lederberg was the first to propose the term “microbiome”, which 
he defined as “the ecological community of commensal, symbiotic, and pathogenic 
microorganisms that literally share our body space.”141 While Lederberg coined the term in 
reference to the microorganisms that inhabit human body sites, microbial communities can be 
associated with any environmental, clinical, or engineered habitat. Concurrent with the 
expansion in sequencing capacity and the widespread adoption of “omics” technologies, the term 
microbiome was redefined as the collective genetic material of a microbial community, while 
“microbiota” is generally used to refer to the microorganisms themselves.142 Initial studies of 
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microbial communities attempted to characterize the phylogenetic and functional diversity by 
culturing the organisms and performing targeted functional assays. However, culture-based 
assays are inherently biased, as a large fraction of microbes from most habitats are not readily 
cultured using standard methods.94 Fortunately, metagenomic sequencing of microbial 
communities, facilitated by the revolution in genomics over the past several decades, has enabled 
increased investigation and appreciation of the breadth and depth of functions encoded in diverse 
microbiomes.  
The study of antimicrobial resistance and biosynthesis in microbial communities is 
motivated by the ubiquity and diversity of microbes in wide-ranging habitats, the evolutionary 
and ecological origins of antimicrobial resistance, and the global health crisis posed by 
increasing antimicrobial resistance. The human commensal microbiota, harbors approximately 
10trillion microbes,143,144 while the diversity of the soil microbiota has been estimated to be as 
high as 10,000 unique species per gram.145 Both culture-based and culture-independent analyses 
of these and other microbial communities have revealed biosynthetic pathways for small 
molecules with antimicrobial activity146,147 as well as abundant and diverse antimicrobial 
resistance genes.148-150 The collection of resistance genes in a given microbiome, known as the 
antimicrobial “resistome”, consists of acquired, intrinsic, proto, and silent resistance genes.19,151 
It is important to characterize resistomes and biosynthetic pathways from varied microbial 
communities in order to better understand and combat the rise of clinical antimicrobial 
resistance.149 This is ideally achieved by pairing functional and sequence-based genomic 
technologies with traditional culture-based analyses.  
This review is intended to provide an overview of functional and sequence-based 
methods that have been developed for discovery of antimicrobial biosynthesis pathways and 
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resistance genes from microbial communities. We will critically evaluate these methods and 
highlight outstanding examples of their applications, with a specific focus on the advantages and 
disadvantages that each method provides. 
1.2.2 Rise in Antimicrobial Resistance and Decline in Antimicrobial Discovery 
The World Health Organization has described antimicrobial resistance as the single 
greatest challenge in infectious disease today, posing a serious public health threat on a global 
scale.152 Clinical and environmental antimicrobial resistance have been increasing since the 
widespread anthropogenic deployment of antimicrobials. Indeed, clinical resistance is now 
frequently observed within a year of deployment of a new antimicrobial.1,2 (Fig. 1.7) 
Furthermore, PCR based surveys of archived soils have revealed that the prevalence of 
environmental antimicrobial resistance genes has been on the rise since 1940.21,94 In the USA 
alone, 2 million people currently acquire serious infections that are resistant to the antimicrobials 
designed to treat those infections, resulting in an estimated 23,000 deaths.153 Incidences of 
multidrug resistance in human pathogens are also increasing.153 The proportion of clinical 
isolates that are resistant to antimicrobials, including deadly MRSA (methicillin-resistant 
Staphylococcus aureus), VRE (vancomycin-resistant Enterococcus), and FQRP 
(fluoroquinolone-resistant Pseudomonas aeruginosa) strains has been steadily increasing since 
the 1980s.154 The economic burden of antimicrobial resistance is also tremendous, with an 
estimated 8 million additional hospital days resulting in $20 billion in direct healthcare costs and 
$35 billion in lost productivity in the US alone.153,155 If the current trajectory is not altered, it is 
estimated that worldwide deaths from antimicrobial resistance could climb to 10 million each 
year by 2050.22  
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Compounding the problem posed by antimicrobial resistance, the “golden age” of 
antimicrobial discovery (ca. 1940-1960) was followed by a substantial innovation gap spanning 
1962-2000, in which no new classes of antimicrobials were introduced (Fig. 1.7).2,156 Only three 
new antimicrobials were approved for human use during the first decade of the 21st century.157 
The decrease in antimicrobial discovery can be partially attributed to low incentives for research 
and development of new drug classes.152 While most antimicrobial products currently in the 
pipeline are active against at least some of the pathogens identified by the FDA as posing a 
‘serious threat to public health’, barely a third (16 drugs) show significant activity against 
multidrug resistant Gram-negative species.152 The issue is complicated by the collateral damage 
from excessive antimicrobial use: when an antimicrobial is administered clinically or 
agriculturally, it provides selective pressure for increased antimicrobial resistance in all microbes 
in those habitats, not simply the targeted pathogen(s), and thus has a negative societal impact.158 
To counter the withdrawal of pharmaceutical companies from the antimicrobial market, the US 
Congress is considering legislation to create a streamlined antimicrobial approval pathway. This 
would approve drugs to treat life-threatening infections based on smaller (and hence faster) 
clinical trials, provided that they meet the same Phase I safety and efficacy standards as other 
drugs.159 While these measures are being considered, it is imperative that we continue to better 
understand the ecological and evolutionary dimensions of antimicrobial production and 
resistance, to support the improved stewardship of both our current and future arsenals of 
antimicrobial compounds. 
1.2.3 Brief History of Antimicrobials  
 Antimicrobials are defined as chemicals that either kill (bacteriocidal) or inhibit the 
growth of (bacteriostatic) bacteria at defined concentrations, and function by targeting systems 
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critical to bacterial physiology. The five major modes of antimicrobial action are: (i) inhibition 
of cell wall synthesis; (ii) inhibition of protein synthesis via the bacterial ribosome; (iii) 
inhibition of DNA or RNA synthesis; (iv) inhibition of the folic acid pathway of nucleic acid 
synthesis; and (v) disruption of cell membrane integrity.2,26,160-162 
Antimicrobials have likely been naturally produced by environmental microbes as a 
means for communication and defense for billions of years.163-165 Residues of antimicrobials 
were discovered in human skeletal remains dating from 350-550 CE, suggesting that humans 
have been exposed to antimicrobials for thousands of years.9,166,167 However, it was not until the 
20th century that natural-product antimicrobials were deliberately repurposed for human use, 
revolutionizing our treatment of infectious diseases. Up to the 1920s, infectious diseases were 
the leading cause of death, with pneumonia, influenza, gastrointestinal infections, and 
tuberculosis accounting for a combined 540 deaths per 100,000 deaths in the US during the first 
decade of the 20th century.168 Ehrlich’s discovery of arsphenamine, an organoarsenic drug, a 
compound that could cure syphilis-infected rabbits9,169 and Fleming’s subsequent serendipitous 
discovery of penicillin, a β-lactam,170 signaled the advent of the antimicrobial era. The “golden 
age” of antimicrobial discovery began in the 1940s and lasted through the 1960s, fueled by 
Selman Waksman’s rapid antimicrobial discovery platform.1,171 Waksman was awarded the 
Nobel Prize for the development of this method,172 and the drugs developed during the golden 
age of antimicrobial discovery substantially improved the treatment of infectious disease.  
Many natural-product antimicrobials were found to have pharmacological or 
toxicological drawbacks, or eventually became obsolete due to evolution and spread of 
resistance.10 Synthetically altering natural product antimicrobials to improve pharmacology or 
evade resistance launched a new era of medicinal chemistry. Many antimicrobials were 
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synthesized by modifying molecular scaffolds of antimicrobials previously discovered during the 
golden era. As a result, amphenicol, tetracycline, aminoglycoside, macrolide, glycopeptide, and 
quinolone classes were introduced or expanded, further improving our treatment of infectious 
diseases.1,9,156,173,174 
1.2.4 Brief History of Antimicrobial Resistance  
The introduction of antimicrobials to the clinic resulted in a precipitous drop in mortality 
worldwide from infectious disease.175 However, the selective pressure placed on bacterial 
systems targeted by antimicrobials due to the extensive use of antimicrobials in clinical and 
agricultural settings soon led to the steady evolution and increase of antimicrobial resistance, 
systematically compromising each of the antimicrobials in our arsenal (Fig. 1.7).13,25,26,176  
The strategies that bacteria use to resist antimicrobials can be divided into four general 
categories: (i) drug efflux, (ii) reducing permeability of cell wall or membrane, (iii) target 
overexpression, modification or protection, and (iv) enzymatic inactivation of the drug.26,177 In 
the first resistance mechanism of drug efflux, bacteria pump out the antimicrobial, keeping the 
intracellular concentration low and preventing the drug from reaching inhibitory concentrations. 
This mechanism encompasses efflux pumps that are both specific to single antimicrobials or 
classes, such as the tetracycline efflux pumps,38 as well as nonspecific, multidrug resistance 
efflux pumps.34-37 The second resistance strategy, thematically related to the first, involves 
reducing the permeability of the cell wall or cell membrane to the antimicrobial, thereby 
preventing it from reaching its target. This can occur via reducing porin expression or expressing 
a more selective porin variant.39,40 The third resistance strategy is overexpression, modification, 
or protection of the drug target in the bacterium, enabling survival. This mechanism is used by 
methicillin resistant Staphylococcus aureus (MRSA) which expresses PBP2a, a redundant and 
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methicillin-insensitive version of the native PBP2 penicillin-binding protein, encoded by the 
mecA gene.33 The final (fourth) resistance strategy involves enzymatic inactivation of the drug, 
by either degrading or modifying the antimicrobial compound such that it no longer has activity. 
Examples of this mechanism include β-lactamases, which degrade β-lactam antimicrobials,30,31 
tetracycline destructases such as Tet(X),28,29 and chloramphenicol acetyltransferases.27  
While we primarily evaluate antimicrobial resistance in terms of its effects on clinical use 
of antimicrobials, the capacity to resist such compounds is in fact a natural and ancient feature of 
all microbial communities.15,16 It is important to consider that the genes that we refer to as 
“resistance genes” may have had functions unrelated to clinical antimicrobial resistance in their 
original context, but could be repurposed for resisting antimicrobials when they are encountered 
in a new context. The original functions of such genes may include cell wall biosynthesis (e.g. β-
lactamases), export of signaling molecules, metabolic intermediates, or plant produced 
compounds (e.g. multidrug efflux pumps), or detoxifying the original host from the antimicrobial 
Figure 1.7: Timeline of antibiotic deployment and resistance observation. The introduction 
of an antimicrobial to the clinic (green) is rapidly followed by the first observation of resistance 




that it is producing (e.g. tetracycline efflux pump induced just-in-time by its biosynthetic 
precursor anhydrotetracycline112).178 The discovery of β-lactam, tetracycline, and vancomycin 
resistance genes in 30,000 year-old Beringian permafrost sediments confirms that genes that 
confer resistance to antimicrobials preceded the clinical use of antimicrobials by several 
thousand years.15 Furthermore, while the first enzymatic degradation of penicillin was described 
in 1940 when researchers noted that extracts of certain bacterial cells were capable of 
inactivating penicillin,44 it is estimated that environmental β-lactamases have existed for over 2 
billion years.179,180 Intensive human use of antimicrobials in clinical, agricultural, and industrial 
settings over the past 80 years have led to the fairly recent exaptation of such genes with 
resistance-conferring potential for surviving in the presence of antimicrobials.181,182  
Since the introduction of antimicrobials to the clinic, the study of antimicrobial resistance 
has been largely focused on isolates of human pathogens, and has relied on information gathered 
from culturing these organisms.8 However, it is thought that most clinical antimicrobial 
resistance has its evolutionary origins in the aforementioned genes with resistance-conferring 
potential encoded by benign environmental and human-associated bacteria. Furthermore, a recent 
study identified numerous resistance genes from benign soil bacteria with 100% nucleotide 
identity to resistance genes that were present in diverse human pathogens, suggesting the 
relatively recent sharing of resistance genes via horizontal gene transfer.4 This finding highlights 
the need to study antimicrobial resistance in benign as well as pathogenic bacteria and in the 
context of microbial communities as well as isolates, as horizontal gene transfer is the 
mechanism by which most pathogens become resistant to antimicrobials.183 
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1.2.5 Culture-based methods underestimate functional diversity of 
microbiomes 
Discovering novel antimicrobials and resistance from microbial communities through 
culture-based methods is challenging and limited to the cultivable minority of bacteria.184 
Genomic technologies offer the promise of substantial performance improvements for 
characterizing the functional capacity of microbiota, which has implications in both the basic 
science and translational realms.184,185 For example, characterizing antimicrobial resistance using 
current culture-based methods can take approximately 1 – 3 weeks versus the proposed less than 
Figure 1.8: Function and sequence-based methods for mining microbiomes. DNA is 
isolated from source material (center), which can then be mined for antimicrobial resistance 
genes (left) or antimicrobial biosynthetic pathways (right). Functional metagenomic methods 
(top) typically entail shotgun cloning metagenomic DNA into an expression vector, and 
selecting for a desired phenotype (e.g. antimicrobial resistance or antimicrobial activity). 
Sequence-based methods (bottom) customarily involve sequencing metagenomic DNA and 




12 hours using genomic technologies.184 Whole genome sequencing has the potential to reduce 
exposure to ineffective drugs and the evolution of resistance by reducing diagnosis to days 
instead of weeks as seen in the case of drug resistant Mycobacterium tuberculosis. 185,186 
 Depending on the habitat, traditional culturing efforts may capture as little as 1% of a 
microbial community.94 The other 99% includes species that are recalcitrant to culture by 
standard methods.187 This severe undersampling has motivated considerable recent 
advancements in culturing methods to enable improvements in the proportion of microbial 
communities that can be cultured. However, these methods, which may leverage microfluidic 
technologies,188,189 clever simulations of natural growth conditions,189,190 or exhaustive sampling 
of culture conditions,191 can be technically challenging and are not yet part of standard culturing 
workflows. Culture-based methods are further hindered by the possible unreliable identification 
of the cultured organisms, which is dependent on the expertise of the researcher. Culture-based 
methods are also riddled with irreproducibility on non-selective media.192 It is often difficult to 
recapitulate the phenotype of resistance of a targeted bacterium from selective media to non-
selective media.  
Advancements in genomic and computational technologies and the concomitant dramatic 
reductions in sequencing costs over the past decades have allowed for an explosion of microbial 
genome and metagenome sequencing, illuminating the diversity of microbial communities and 
the breadth and depth of functions encoded therein.6,184,193-198 Genomic technologies can 
overcome culture-based limitations and facilitate the discovery of novel antimicrobials and 
resistance determinants. The remaining review details the functional and sequencing-based 




1.2.6 Function based methods for resistance discovery 
Hybridization/PCR-based Methods 
In addition to functional metagenomics, a powerful method described in Section 1.1 (Fig. 
1.3), hybridization and PCR based methods are promising approaches for functional 
identification of resistance genes. One method that integrates culturing and sequencing for 
resistance characterization is a new technology that utilizes molecular padlock probes.199 In this 
method, which shows particular clinical promise in predicting the antimicrobial susceptibility 
profile of patient samples, the microbial community is exposed to the antimicrobial of interest 
for a short period of time, after which metagenomic DNA is extracted.199 The metagenomic 
DNA is then mixed with complementary biotinylated oligonucleotides of targeted rRNA gene 
sequences and streptavidin-coated magnetic beads. This is to ensure the capture of the relevant 
rRNA gene sequences. The mixture is then hybridized and ligated to the designed padlock 
probes, usually designed to detect certain positions in the 16S rRNA gene.199 The probes are then 
amplified through rolling circle amplification.199 After amplification, the final product is 
fluorescently labeled and DNA copy number is quantified using a high-performance 
fluorescence detector.199 An antimicrobial susceptibility profile can be determined by using DNA 
copy number of the sample without antimicrobials and comparing with the DNA copy number of 
the sample after exposure to antimicrobials.199 If there is an increase in DNA copy number after 
exposure to antimicrobials, this indicates resistance. If there is no significant growth after 
exposure to antimicrobials, this indicates susceptibility.199 This method has been used to 
characterize the antimicrobial susceptibility profile of uropathogens from complex urinary tract 
infection samples.199 Researchers accurately predicted the antimicrobial susceptibility profile for 
55 out of 56 samples, highlighting the clinical utility of this method.199 An advantage that the 
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padlock probe method presents is short turnaround time, leveraging high throughput to give 
results in a matter of hours and help clinicians prescribe correct antimicrobials to patients with 
bacterial infections. However, the probes that are used in the assays have to be designed for 
individual bacterial species and antimicrobials that are targeted to be used in the assay, and 
cannot characterize novel resistance genes.  
1.2.7 Sequence-based methods for resistance discovery  
While function-based methods have been valuable in identifying novel resistance 
determinants from diverse microbiomes, they are limited in throughput and are ideally 
complemented by sequence-based methods, which we will review here. The ability to analyze 
bacterial communities through culture-independent shotgun metagenomic sequencing has 
revolutionized our ability to characterize resistomes.3,200-202 These analyses have benefited from 
databasing projects, including the 35,000+ public metagenomes which have been uploaded to the 
Metagenomics Rapid Annotations using Subsystems Technology server (MG-RAST).203 
Shotgun metagenomic sequencing involves extracting and sequencing total metagenomic DNA 
from a microbial community. Once sequenced, a specific subset of informative marker genes 
from the metagenome can be used to infer phylogeny and functions that are present in the 
microbial community of interest.204 To predict antimicrobial resistance from shotgun sequencing, 
most studies have relied on pair-wise comparisons (e.g. by Basic Local Alignment Search Tool 
(BLAST)116) of sequences to databases of known or predicted resistance genes.205-209 Many 
antimicrobial resistance databases are highly biased toward human-associated organisms; 
therefore, environmental antimicrobial resistance is comparatively ignored.122 Prediction 
algorithms based on hidden Markov models (HMMs) trained on functionally-validated resistance 
genes from diverse environments have proven to be superior to traditional pair-wise annotators 
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in both precision and accuracy of resistance gene annotation, since HMM profiles allows for the 
discovery of highly diverse and understudied antimicrobial resistance genes.122   
Antimicrobial Resistance Gene Databases 
A number of databases that store nucleotide and protein sequence information for 
antimicrobial resistance genes have been developed. Query sequences are aligned to sequences 
of known antimicrobial resistance determinants in the databases by BLAST,116 which performs a 
strict pairwise DNA or protein sequence alignment, to catalog the antimicrobial resistance gene 
content of a genome or metagenome. These databases have dramatically advanced the field of 
genomic and metagenomic analyses of antimicrobial resistance by allowing the sequence-based 
identification of known resistance determinants.120   
The Antibiotic Resistance Gene Database (ARDB) is a manually curated antimicrobial 
resistance database.118 ARDB provides a comprehensive ontology which creates a resistance 
profile by matching specific genes and mechanism of actions. It uses BLAST to identify and 
annotate antimicrobial resistance genes. Many studies have used ARDB as their sole method to 
identify antimicrobial resistance genes210-212 and have revealed that a majority of antimicrobial 
resistance genes cluster based on ecology.205,211,213 Although this database was the first of its 
kind, it has not been updated since 2009.  
The Comprehensive Antibiotic Resistance Database (CARD) is a collection of known 
resistance determinants and associated antimicrobials.119 It is designed to predict known 
antimicrobial resistance from genome sequence data by using a BLAST-based pairwise sequence 
alignment to known antimicrobial resistance genes in the database. The database is organized 
based on ontologies, linking genes to their function. This is an ideal database to use if the 
antimicrobial resistance mechanism of interest has been previously thoroughly researched. 
40 
 
However, it is not suited for the detection of point mutations in chromosomal target genes known 
to be associated with antimicrobial resistance genes.214 Many studies have annotated 
antimicrobial resistance using CARD alone or in combination with ARDB.208,209,215,216 Unlike 
ARDB, the CARD database is actively managed and periodically updated. 
The Bush-Jacoby β-lactamase list is a curated database that matches β-lactamase gene 
sequences to resistance to β-lactam antimicrobials. This database will soon be hosted on the 
NCBI website. This database was originally focused heavily on TEM, SHV and OXA type β-
lactamases, only a subset of β-lactam antimicrobial resistance genes. Other β-lactamases that are 
now included in the database are CTX-M, CMY, AmpC, CARB, IMP, VIM, KPC, GES, PER, 
VEB.120  
The Lactamase Engineering Database (LacED)217 is an extension of the Bush-Jacoby β-
lactamase list. This database includes a way to predict TEM, SHV, and class B enzymes by 
merging the information from both NCBI peptide database and the TEM mutation table. LacED 
builds protein families from these databases and integrates protein sequence and structure 
information using DWARF.218  
 The Repository of Antibiotic Resistance Cassettes (RAC) takes advantage of the fact that 
resistance genes are often syntenic with mobile genetic elements, forming resistance cassettes. 
This database was the first to simultaneously automate identification of antimicrobial resistance 
genes and place the genes in their broader genetic context.219  
 ResFinder121 combines the Bush-Jacoby β-lactamase list with ARDB and other published 
antimicrobial resistance gene sequences.  Similar to other resistance databases, query sequences 
are matched to the sequences in the database via BLAST. The difference between ResFinder and 
most other resistance gene databases is the ability for the user to tailor the identity and length 
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coverage thresholds. This allows the user to specify settings that are suited for the depth and 
quality of sequencing for each project. The current challenge with using ResFinder and 
previously described databases is the inability to classify chromosomal mutations which can lead 
to antimicrobial resistance or to classify novel resistance genes, and is thus limited to resistance 
genes commonly acquired through horizontal gene transfer.214  
The Antibiotic Resistance Gene-Annotation (ARG-ANNOT) 214 uses a BLAST-enabled 
search on a curated antimicrobial resistance gene database compiled from Bush-Jacoby β-
lactamase list, Resfinder121, ARDB118 and others. A main difference between this program and 
others is the ability to additionally predict resistance function based on chromosomal point 
mutations. ARG-ANNOT contains a curated database focused on mutations found in many 
chromosomal genes (i.e. rpoB, gyrA1, gyrA2, parC) that can confer resistance to antimicrobials.   
It is difficult to identify novel resistance genes when using pairwise comparisons (e.g. by 
BLAST) to resistance databases which are largely based on resistance genes from cultured 
bacterial isolates, and are especially biased towards human associated pathogens. Resfams 
implements an alternative method in order to identify known and novel resistance genes with 
high precision and accuracy.122 Resfams is a curated database of profile HMMs built on 
resistance proteins compiled from CARD119, LacED217, and Jacoby and Bush’s collection of 
curated β-lactamases, based on the gene ontology from the CARD database. Additionally, the 
Resfams profile HMMs incorporate antimicrobial resistance genes from environmental, human 
commensal, and pathogenic bacteria which have been discovered through culture-independent 
functional metagenomic selections. The HMM approach is superior to pairwise annotation 
approaches in both precision and accuracy. Pairwise BLAST searches against resistance gene 
databases were unable to identify over 60% of resistance genes identified by Resfams from a 
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functionally-validated resistance gene test set.122 Perhaps more importantly, differences in 
HMM-based versus BLAST-based pairwise resistome analyses of the same data can lead to 
significantly different (and sometimes completely contradictory) biological conclusions. For 
instance, comparison of resistome predictions from over 6,000 bacterial genomes by Resfams 
versus predictions by pair-wise alignment of resistance gene databases revealed that pair-wise 
methods are inaccurately biased in both their phylogenetic and ecological distributions towards 
the relatively oversampled human-associated environments which they represent.122  
These myriad resistance gene databases are clearly important tools for interrogating 
microbiomes for antimicrobial resistance genes, but some challenges in their use and 
opportunities for their improvement exist. An important limitation to both HMM- and BLAST-
based searches is the implicit requirement for users to determine the accuracy of the predicted 
resistance gene function, especially when the exact sequence being annotated has not been 
previously functionally assayed. Additionally, many of these databases do not incorporate 
information on the host-specific functionality of some antimicrobial resistance genes.220  For 
example, most Gram-negative bacteria are intrinsically resistant to important classes of Gram-
positive specific drugs (e.g. vancomycin, linezolid, and macrolides) because they cannot cross 
the Gram-negative outer membrane.177 Accordingly, it is likely inappropriate to annotate 
homologs of genes which provide resistance to these antimicrobials in Gram-positive bacteria 
when they are identified in Gram-negative bacteria. An important future goal in these databases 
is a species-dependent risk estimator for horizontal gene transfer to quantify the likelihood of 
resistance gene dissemination between species and habitats. Additionally, it is important that 
environmental or “non-clinical” resistance genes which are currently underrepresented these 
databases be included122. Because most clinical resistance originated in the environment, this will 
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facilitate the surveillance of emerging resistance mechanisms as they disseminate beyond benign 
organisms. Despite the inherent limitations in ascribing resistance function based on sequence 
alone, antimicrobial resistance databases play a key role in curating sequences of known 
resistance determinants. It is crucial that these databases are regularly updated and 
simultaneously cross-validated to maintain accuracy and relevance. Continued maintenance and 
improvement of these databases, including the ongoing incorporation of novel, functionally 
validated resistance determinants and associated metadata from diverse habitats, will ensure that 
they remain valuable resources for the antimicrobial resistance community for years to come.  
It is likely that the selective pressure that drove the evolution of most antimicrobial 
resistance genes is the incredible biosynthetic potential of microbial communities to synthesize 
natural products with antimicrobial activity. This motivates the need to understand antimicrobial 
resistance in microbial communities in the context of antimicrobial biosynthesis, and vice versa. 
Paralleling recent improvements in methods to characterize resistomes, there have also been 
significant advances in functional and sequence-based methods for discovering novel 
antimicrobial biosynthesis machinery, which we will review below.  
1.2.8 Function-based methods for antimicrobial discovery from microbiomes 
Function-based methods for the discovery of antimicrobials from microbiomes present a 
clear advantage over sequence-based methods in that no a priori knowledge of the sequence of a 
natural product biosynthetic pathway is required. This facilitates the discovery of novel natural 
products that are produced by biosynthetic pathways that are divergent from previously 
characterized pathways and provides access to novel chemical diversity. This unbiased approach 
has been successfully used for the discovery of natural products with antimicrobial activity.221,222 
The method depends on shotgun cloning of metagenomic DNA from a given environment into 
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an expression vector, heterologous expression of pathways encoded in the metagenomic DNA in 
an appropriate host, and screening for production of bioactive natural products.223  
Despite the advantages that this unbiased approach provides, there are several challenges 
that have hindered the discovery of natural product antimicrobials using functional 
metagenomics. The main disadvantage is construction and heterologous expression of large 
insert libraries is technically challenging.224 Strategies to improve the heterologous expression of 
biosynthetic pathways, including overexpression of alternative sigma factors in E. coli, have 
proven successful for heterologous production of polyketides and hold promise for the 
development of improved metagenomic screening hosts.225 Additionally, nontraditional 
heterologous hosts such as Streptomyces lividans have demonstrated utility in the discovery of 
bioactive natural products from metagenomic libraries.226 A final challenge inherent in functional 
metagenomic antimicrobial discovery lies in the fact that antimicrobial production is a more 
complicated phenotype to select for than antimicrobial resistance, for reasons which we will 
detail below. This necessitates the use of clever screening strategies to identify and isolate clones 
of interest.224 
One screening strategy that successfully enables discovery of antimicrobial biosynthesis 
from metagenomic libraries is to directly assay for antimicrobial activity against an indicator 
strain using a double-agar layer method.227 In this method, the heterologous host of the 
metagenomic library is allowed to grow on plates, after which top agar containing the indicator 
strain is overlaid. This method was used to discover two clones from a 113,500 member fosmid 
library representing 4 Gb constructed from a soil metagenome that were able to inhibit the 
growth of Bacillus subtilis. The clones encoded a biosynthetic pathway that produced indigo and 
indirubicin, pigments that were confirmed to be responsible for the observed antibacterial 
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activity.221 Another application of this method resulted in the identification of 65 clones with 
antibacterial activity from a 700,000 member soil library. A small molecule from the clone with 
the highest apparent bioactivity was purified and identified as a long chain N-acyl amino acid. 
This represented the first report of the antibacterial activity of long chain N-acyl amino acids, as 
well as the first identification of genes involved in long chain N-acyl amino acid biosynthesis, 
highlighting two key advantages of the functional metagenomic approach to antimicrobial 
discovery.222 
An alternative approach that extends traditional culturing methods uses the innovative 
‘iChip’,   a multichannel, microfluidic diffusion growth chamber.189  This device was recently 
used to discover a novel non-ribosomal peptide with antimicrobial activity from a soil microbial 
community.228 The iChip requires that input microbial community samples are diluted such that 
each channel receives approximately one bacterial cell. The device is sealed with a 
semipermeable membrane and returned to the source so that nutrients and growth factors from 
the natural environment of the source organisms can diffuse into the chamber, increasing the 
likelihood of culturing fastidious organisms.189 This high-throughput method was used to culture 
10,000 diverse isolates from a soil sample, which were predicted to be recalcitrant to culture 
using traditional methods. Screening of extracts from these isolates for antimicrobial activity 
revealed the presence of a non-ribosomal peptide, named teixobactin, synthesized by a 
previously uncultured betaproteobacterial species. Teixobactin was isolated and characterized, 
and found to have activity against multi-drug resistant Gram-positive pathogens in vitro, as well 
as in animal models for MRSA and Streptococcus pneumoniae.228 Although this method relied 
on classical antimicrobial screening platforms, innovative culture methods facilitated the 
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discovery of a novel antimicrobial and revealed the biosynthetic potential of the uncultivable 
fraction of microbial communities.  
1.2.9 Sequence-based methods for antimicrobial discovery from microbiomes 
Sequence-based methods for discovery of antimicrobial biosynthetic pathways from 
microbiomes depend on homology between the query sequence and known biosynthetic 
pathways. A clear advantage of this method is throughput. Advancements in annotation and 
prediction algorithms coupled with the abundance of microbial genome and metagenome 
sequences have made feasible the analysis of sequence data for identification of biosynthetic 
gene clusters that may encode novel bioactive natural products. A disadvantage of this strategy is 
that prediction of the structure of a small molecule from the sequence of a biosynthetic gene 
cluster is nontrivial, as is prediction of a small molecule’s activity from its structure.  
 One of the first attempts to identify biosynthetic pathways from an uncultured community 
relied on PCR amplification of ketosynthase genes from Streptomyces isolates as well as from 
metagenomic DNA isolated from soil.229 The amplicons were purified, cloned into an expression 
vector, and sequenced. Of 20 randomly selected transformants that were sequenced, only two 
had similarity to any known ketosynthase gene products. Four of the novel ketosynthases were 
shown to be functional when expressed in a Streptomyces lividans or Streptomyces glaucescens 
host as part of a hybrid polyketide synthase pathway (that is, the native ketosynthase was 
replaced with the newly discovered ketosynthase). The polyketide products of the hybrid 
biosynthetic pathways were purified and characterized to be novel octaketide and decaketide 
natural products. This highlights the utility of culture-free methods for identifying novel, 
sequence-divergent genes involved in biosynthetic pathways to expand access to novel natural 
products with diverse bioactivities, including potential antimicrobial activity.  
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 Tools for identifying genes involved in natural product biosynthesis from sequence data 
represent a significant advancement over targeted PCR-based studies. One of the resources 
developed for mining genomic data for biosynthetic gene clusters is antiSMASH.230 antiSMASH 
makes use of the ClusterFinder algorithm,231 which is an HMM based algorithm for the 
discovery of biosynthetic gene clusters from genomic data. The ClusterFinder algorithm consists 
of a four-step prediction pipeline that can identify biosynthetic gene clusters in genomic data. 
The use of an HMM-based, probabilistic algorithm allows identification of biosynthetic gene 
clusters that lack high similarity in domain structure to any known biosynthetic gene clusters, 
circumventing the problem that had previously been posed in identification of biosynthetic gene 
clusters from sequence data. antiSMASH also includes an Active Site Finder module that 
identifies conserved amino acid motifs in the active sites of key biosynthetic enzymes including 
those involved in polyketide biosynthesis. A final, key feature of antiSMASH is an algorithm 
that predicts the structure of a natural product synthesized by the annotated biosynthetic gene 
cluster. Furthermore, the development of a web-based server has democratized the process of 
identifying biosynthetic gene clusters, because it is available to those without access to high 
throughput computing facilities.230  
 The ClusterFinder/antiSMASH workflow was successfully used to identify a natural 
product with antimicrobial activity from metagenomic sequencing data generated as part of the 
NIH Human Microbiome Project. 2,430 genomes of members of the human microbiota were 
queried using ClusterFinder to identify over 14,000 putative biosynthetic gene clusters. 
Metagenomic reads from 752 samples representing five body sites of healthy subjects were 
mapped to the 14,000 predicted biosynthetic gene clusters. Among the natural products predicted 
was a thiopeptide from the vaginal commensal Lactobacillus gasseri. The thiopeptide, named 
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lactocillin, was purified and characterized. Lactocillin was found to have antimicrobial activity 
against Gram positive bacteria including Enterococus faecalis, Gardnerella vaginalis, 
Staphylococcus aureus, and Corynebacterium aurimucosum. The discovery and characterization 
of the structure and bioactivity of lactocillin from human microbiome metagenomic sequencing 
data demonstrates the potential that diverse metagenomes hold for encoding natural products 
with antimicrobial activity.147  
 A current shortcoming of software available to identify biosynthetic gene clusters from 
metagenomic sequencing data is that assembly of short read data into genomes or large contigs is 
required. Although there have been recent advancements in metagenomic assemblies of this 
type,232-234 it remains a challenge. One way to circumvent the requirement for metagenomic 
assembly is the use of ShortBRED,235 which finds short, unique amino acid markers from 
reference proteins of interest and maps metagenomic sequencing reads to these markers. This 
tool has been successfully implemented for the identification of antimicrobial resistance genes200 
and has potential for the identification of genes involved in natural product biosynthesis directly 
from short read metagenomic sequencing data.  
 An alternative method that can be used to access the biochemical diversity of 
microbiomes without the necessity for metagenomic assembly uses short DNA sequences that 
are conserved between biosynthetic gene clusters. PCR amplification of these conserved 
biosynthetic motifs from a metagenomic source using degenerate primers followed by amplicon 
sequencing can provide an overview of the biosynthetic capabilities of a given microbiome, and 
highlight promising leads for heterologous expression and further characterization.236 A 
bioinformatics platform for mapping short DNA sequence tags to known biosynthetic gene 
clusters, termed Environmental Surveyor of Natural Product Diversity (eSNaPD), has been 
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developed to facilitate analysis of amplicon sequencing data in the context of natural product 
biosynthesis.237 This strategy has been successfully used in the identification of novel bioactive 
small molecules, including some with antimicrobial activity.236,238 
 A final, promising method for sequence-based identification of biosynthetic gene clusters 
from microbiomes involves assembly of complete or near-complete genomes using single-
molecule, real-time sequencing (SMRT),239 followed by annotation with antiSMASH or a similar 
annotation pipeline. This approach was successfully applied in tandem with short-read data 
reference-independent assembly of a high-quality Corynebacterium simulans genome de novo 
from a skin microbiota sample. This previously uncharacterized genome was annotated with 
antiSMASH, revealing predicted nonribosomal peptide synthetases, type I polyketide 
synthetases, terpene synthases, and bacteriocin production genes.240 Interestingly, the bacteriocin 
production locus was homologous to the locus for biosynthesis of lactococcin, a bacteriocin 
which is known to be bactericidal.241 Although the natural products whose biosynthetic gene 
clusters were identified in this study were not isolated or confirmed for bioactivity, the authors 
demonstrate the power of metagenomic assembly in the identification of biosynthetic gene 
clusters from microbiomes.  
1.2.10 Future directions in antimicrobial and antimicrobial resistance 
discovery  
The increasing threat to human health from multi-drug resistant pathogens underscores 
the need to develop tools to interrogate microbiomes for novel antimicrobials and to understand 
and mitigate the evolution and transmission of resistance genes. A more complete understanding 
of antimicrobial resistance in the context of microbial communities will advance our treatment of 
antimicrobial-resistant infections and help us choose therapies that will reduce selection for 
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resistance. Additionally, novel antimicrobials discovered within microbial communities will lay 
the groundwork for narrow-spectrum, next generation antimicrobials that reduce collateral 
microbiome damage. Given that most clinical antimicrobial resistance genes originated in 
environmental microbes, and most antimicrobials are natural products or derivatives thereof, it is 
critical that these two microbial functions be studied in tandem and in the context of microbial 
communities in order to understand the dynamics governing the evolution and transmission of 
antimicrobial resistance and biosynthetic capacities.  
Advances in sequencing technology will facilitate discovery of complex functions from 
metagenomes based on sequence alone. For example, long read sequencing technologies such as 
the NanoPore Minion and the PacBio SMRT will help to overcome the challenges currently 
posed by metagenomic assembly from short read data, providing greater information about 
functions encoded in large operons, such as biosynthetic and multidrug resistance gene 
clusters.233,242,243 Furthermore, cheaper sequencing will allow for deeper sequencing, improving 
our ability to assemble metagenomes and profile antimicrobial resistance and biosynthetic 
capacities.6 Single-molecule sequencing, particularly when combined with short-read shotgun 
metagenomic data,  may also improve metagenomic assembly and allow for better identification 
of biosynthetic gene clusters.240 In addition to progress resulting from improvements to DNA 
reading, advancements in DNA writing will likely benefit the field. Dramatic reductions in the 
cost and efficiency of DNA synthesis may soon make synthesis and recoding of entire 
biosynthetic gene clusters feasible, simplifying heterologous expression in genetically tractable 
hosts and downstream characterization of bioactive natural products.244,245 An integration of 
functional and genomic techniques, aided by these and other inevitable technical and 
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computational developments, will help us better understand the delicate interplay between 
antimicrobial biosynthesis and resistance in microbiomes. 
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1.3: Antibiotics and the preterm infant gut microbiome and 
resistome 
1.3.1 Introduction  
The infant gut microbiota is shaped by both prenatal and postnatal factors246,247. 
Following birth, the infant gut microbiota undergoes a patterned maturation process248-250. This 
process begins with a few taxa, but this population inexorably expands in content and 
concentration until it approaches an adult-like microbial configuration dominated by 
Bacteroidetes and Firmicutes248,251-253. Perturbation of the gut microbiota during this key 
developmental window can have lasting effects on host physiology and disease risk254-259. One of 
the most common perturbations during this period, antibiotic therapy258,260, can substantially alter 
the gut microbiota and infant physiology255,261-266. Because preterm infants are at high risk for 
infection, antibiotics are the most commonly prescribed medications in neonatal intensive care 
units (NICUs) in the United States (Fig. 1.9)260,267,268 accounting for three of the top six 
medications with the greatest relative increase in use in NICUs in the United States between 
2005 and 2010269. Antibiotic-induced gut microbiota dysbioses in this population have been 
linked to the pathogenesis of necrotizing enterocolitis270-272, late onset sepsis273,274, and other 
adverse health outcomes275. While these correlations exist, the underlying etiologies remain 
unclear, motivating the study of microbiota development in the context of antibiotic therapy in 
this vulnerable population that accounts for nearly 10% of all births in the United States276. 
1.3.2 Techniques for studying development of the infant gut microbiota and 
the developing resistome 
Microbial ecology studies, especially those focused on the gut microbiota, have 
flourished because of widespread adoption of sequencing-based studies, either using the 16S 
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rRNA gene or metagenomic shotgun sequencing, resulting in a deeper appreciation of 
microbiome diversity249,265,272,277-279. Until recently, similar efforts to characterize the preterm 
infant gut reservoir of antibiotic resistance genes (the resistome) have been largely culture or 
PCR-based. While these methods can provide a high level overview of the resistome, they 
underestimate diversity, are limited to previously known resistance genes, and are only semi-
quantitative. In contrast, deep sequencing of microbiomes paired with functional metagenomics 
offers an unbiased method to identify functional resistance determinants in a stool, and can 
provide quantitative information on microbiome and resistome architecture23,57. Gibson et al. 
recently used this suite of techniques to develop a sequence-unbiased account of the effects of 
antibiotic therapy on the preterm infant microbiota with respect to phylogeny and antibiotic 
resistance gene distribution200.  
 
Figure 1.9: Prescription data in the NICU. Data adapted from 
Clark et al. Pediatrics 200623. Frequency defined as the number 
of times a unique medication name was reported in the 
medications table in 220 NICUs in the United States and Puerto 
Rico between January 1996 and April 2005. Antibiotics are the 
most prescribed medications in the neonatal intensive care unit. 
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1.3.3 A longitudinal, sequencing based interrogation of the preterm infant gut 
microbiota 
To assess the effects of antibiotics on the dynamics of the preterm infant gut microbiota, 
Gibson et al. assembled a cohort consisting of 84 preterm infants, of whom 82 received 
antibiotics within the first 24 to 48 hours of life, as is common practice in the NICU. However, 
39% received no further antibiotic therapies after the first week of life, allowing them to serve as 
controls to study the effects of antibiotic treatment on preterm infants in the first weeks of life. 
All infants in the cohort were low birthweight and born prematurely, with a median gestational 
age of 27 weeks and a median birthweight of 865 grams. This sample set was complemented by 
robust metadata including detailed histories of all antibiotic exposures, overall health indications 
including infections, delivery mode, postmenstrual age, hospital environment, enteral feeding, 
other medications, and maternal health.  
A total of 401 stools from these infants, collected longitudinally during their stay in the 
NICU and ranging from day 6 to day 158 of life, were interrogated by shotgun metagenomic 
sequencing. In total, Gibson et al. sequenced and analyzed 551 gigabases (Gb) of preterm infant 
gut metagenomes (1.37 +/- 1.17 Gb per sample) and a total of 107 Gb of functionally selected 
preterm infant resistomes (5.1 +/- 3.6 Gb per sample). Unique clade-specific marker genes from 
approximately 17,000 reference genomes were used to assess the phylogenetic composition 
allowing both species-level resolution and accurate relative abundance estimations of bacterial 
species composition of these communities, an advantage over traditional 16S rRNA marker gene 
sequencing204,280. This represents the largest metagenomic sequencing-based study of the preterm 
infant gut microbiota to date, providing the statistical power to address questions of microbiota 
and resistome development in preterm infant populations subject to heavy antibiotic exposure.  
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1.3.4 Antibiotics disrupt the preterm gut microbiota richness and composition 
  Gut microbial species richness, defined as the number of species present in a microbiota, 
is widely used as a measure of microbiome health. Decreased species richness in infancy has 
been associated with a number of host pathologies and is widely used as a measure of 
microbiome perturbation258,270,281,282. To identify factors that significantly contribute to species 
richness, Gibson et al. developed a generalized linear mixed model with individual included as a 
random effect, leveraging available metadata including infant health (e.g. CRIB II (Clinical Risk 
Index for Babies) score, day of life, gestational age, birthweight, delivery mode, and presence of 
positive culture), medications (e.g. antibiotics, caffeine, and iron), and maternal health (e.g. 
preeclampsia and premature membrane rupture). While postmenstrual age and breast milk 
significantly contribute to increased species richness, the opposite was true with high CRIB II 
score, meropenem treatment, cefotaxime treatment, and ticarcillin-clavulanate treatment 
significantly contributing to decreased species richness. Cumulative antibiotic exposure in 
infants was associated with a significant reduction in species richness and, with the exception of 
gentamicin, all antibiotics were associated with reduced species richness. This decrease in 
species richness occurred over intervals during which the gut microbiota of age-matched, 
antibiotic-naïve preterm infants was increasing in richness, and was accompanied by disruption 
of microbiota composition (Fig. 1.10). For example, one individual had a ~25% decrease in 
observed species following meropenem treatment, while over the same period a matched control 
had a 20% increase (Fig. 1.10a). Similar age-matched comparisons can be made for combined 
vancomycin and meropenem treatment (Fig. 1.10b) and for ticarcillin-clavulanate treatment (Fig. 
1.10c). Antibiotic-induced perturbations of microbiota phylogenetic composition were observed 
for these infants as well (Fig. 1.10a-c).  
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1.3.5 Antibiotic therapy enriches for antibiotic resistance genes and multidrug 
resistant bacteria 
 For further insight into the effects of antibiotics on the resistome of the preterm infant gut 
microbiota, Gibson et al. constructed functional metagenomic libraries from 21 representative 
fecal samples. Functional metagenomics is a valuable technique for identifying functional 
resistance determinants in microbiomes. Because functional metagenomics circumvents the bias 
introduced by culture and the need for a priori knowledge of resistance function, the method 
provides a high throughput, sequence-unbiased characterization of reservoirs of antibiotic 
resistance genes in a given environment and can identify novel resistance genes57,66. These 
libraries, representing a total of 107 Gb of bacterial DNA, were screened against 16 antibiotics, 
Figure 1.10: Antibiotic treatment alters preterm infant gut microbiota development. 
Preterm infant gut microbiota species richness (top) and composition (bottom) for the three 
individuals with samples analyzed directly before and after depicted antibiotic treatments for 
(A) meropenem, (B) vancomycin and meropenem, and (C) ticarcillin-clavulanate. Red bars 
represent species richness for example individual. Black bars represent average species 





including those routinely used in NICUs. Of the 794 functionally identified antibiotic resistance 
genes, 42% were encoded by E. coli, Enterobacter cloacae, and K. pneumoniae, taxa which 
include many pathogenic strains implicated in nosocomial infections in preterm infants279,283. 
Interestingly, the sequences of the majority of resistance determinants uncovered by the 
functional metagenomics screens were already present in protein databases. However, they were 
not found in antibiotic resistance specific databases, indicating that they had not previously been 
ascribed a resistance function and highlighting a key advantage of using functional 
metagenomics.  
One third of the antibiotic resistance genes identified by functional selections conferred 
resistance to multiple antibiotics, often across classes, or were co-selected with another antibiotic 
resistance gene. For example, the loci selected by piperacillin also conferred resistance to other 
-lactam antibiotics. In fact, many -lactamases identified in this study conferred resistance to 
multiple classes of -lactam antibiotics. In addition to these genes, which may be extended 
spectrum -lactamases (ESBLs), Gibson et. al. identified multiple Ambler class A -lactamases, 
and -lactamases that conferred resistance to both penicillins and 2nd and 3rd generation 
cephalosporins. ESBLs are of particular concern due to their increasing abundance in community 
acquired infections and in clinical settings such as the NICU, often in Enterobacteriaceae family 
members, including those that Gibson et. al. identified as dominant members of the preterm 
infant gut microbiota284. In addition to cross resistance among -lactam antibiotics, Gibson et. al. 
also observed contigs that conferred resistance across classes of antibiotic. For example, many 
tetracycline resistance genes also conferred resistance to both chloramphenicol and cefoxitin. 
Our findings suggests that many of these genes may be present in the context of a multidrug drug 
resistance cassette and are threats for dissemination via horizontal gene transfer. Multidrug-
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resistance is one of two key features associated with spread of antimicrobial resistance in the 
preterm infant gut microbiota. The other feature is mobility, or the likelihood of horizontal gene 
transfer. In order to investigate the potential mobility of resistance genes in the preterm infant gut 
microbiome Gibson et al. assembled metagenomic contigs from shotgun reads, and found 
widespread plasmid and chromosomally encoded multidrug resistance clusters. Alarmingly, the 
authors identified plasmid-associated antibiotic resistance genes encoding resistance to more 
than six antibiotic classes in 96% of preterm infant gut samples. Furthermore, the preterm infant 
resistome was found to be highly resilient. Over the course of time represented by the 
longitudinally sampled resistome, only about one fifth of the resistance gene classes showed 
significant change, implying that early life antibiotic therapy may select for a lasting expansion 
of the gut resistome. 
1.3.6 The predictable response of the preterm infant gut microbiota to 
antibiotic therapy 
 To quantify changes to the gut microbiota before and after antibiotic treatment Gibson et 
al. utilized metagenomic shotgun sequencing to interrogate the phylogenetic architecture of the 
bacterial community. While meropenem, cefotaxime, and ticarcillin-clavulanate each 
significantly and immediately reduced species richness, gentamicin and vancomycin (two of the 
most commonly used antibiotics in preterm infant populations, and which are often co-
administered) resulted in variable species richness responses. Using random forests 
classification, the direction of species richness response to vancomycin and gentamicin treatment 
can be predicted based on the relative abundance of only two species (Staphylococcus aureus 
and E. coli) and two antibiotic resistance genes (cpxR and cpxA) with an error rate of only 15%. 
We hypothesize that this finding might be due to the innate vancomycin-resistance of Gram-
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negative bacteria such as E. coli and the innate vancomycin-susceptibility of S. aureus, coupled 
with the ability of cpxR and cpxA to confer gentamicin resistance to E. coli285. These analyses 
reveal significant antibiotic-specific microbial and compositional responses of the preterm infant 
gut microbiota. For a commonly prescribed antibiotic regimen, co-therapy with vancomycin and 
gentamicin, Gibson et al. identified important species and antibiotic resistance gene biomarkers 
that can predict with high accuracy the short-term species richness response and therefore 
potential for disruption of the developing preterm infant gut microbiota. 
1.3.7 Implications for future research  
It is evident that use of specific antibiotics in the NICU, such as next generation -lactam 
antibiotics, acutely (but perhaps not durably) perturb the gut microbiota while others, such as 
gentamicin, are less disruptive. Going forward, it is important to understand the enduring effects 
of antibiotics on the preterm infant gut microbiota and resistome. Recent studies have observed 
that multidrug resistant clones present in preterm infants in the NICU are absent at two years of 
age, suggesting that the preterm infant gut may recover following discharge to home286. On the 
other hand, resistance genes persist for months or years after antibiotic therapy in adults287-289. 
Sequence-based characterizations of gut microbiota composition and resistome of preterm 
infants after they enter the community are needed to fully understand the longitudinal effects of 
antibiotics on microbiota composition, multidrug resistant organism persistence, and resistance 
gene carriage. Longitudinal studies also provide the opportunity to correlate dysbioses that 
originate in the NICU with health outcomes that are manifest later in life. Additionally, it is 
important to consider the effect of prenatal and intrapartum antibiotics, and prenatal exposure to 
microbes, on the infant gut microbiota. This is of particular note in preterm infants, one in four of 
whom are born to mothers with an intrauterine infection290, and in light of the increasing 
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recognition that the uterus is a nonsterile environment. It is necessary to validate the results of 
this study and others outside of the preterm human infant context. Murine models of antibiotic 
use have been invaluable in informing microbiome research. Humanized gnotobiotic models in 
particular have benefited the field greatly255,261,291, Development of a humanized infant mouse 
model for preterm antibiotic therapy would allow for testing of clinical antibiotic protocols in a 
controlled environment in order to discern their relative impacts on the developing gut 
microbiota. Such analyses would build on the foundation laid by Gibson et al. to provide an 
evidence-base supporting a personalized medicine approach to antibiotic treatment, wherein 
antibiotic use in preterm infant populations will be tailored to limit collateral microbiota 
disruptions and selection for resistance. 
1.4 Scope of the thesis 
Countering the public health crisis posed by antibiotic resistance requires, among other 
aspects, a comprehensive understanding of the distribution of antibiotic resistance genes across 
microbial communities, as well as a unified framework for comprehending the response of these 
microbial communities to antibiotic perturbation. This entails identifying and characterizing 
emerging resistance determinants that are not yet prevalent in the clinical setting anticipating 
their ensuing dissemination under the strong selective pressure imposed by antibiotics. Such 
early identification allows for proactive development of strategies to counter the eventual clinical 
impact of pathogens bearing these resistance genes. An additional crucial component of 
addressing antibiotic resistance in light of the pervasive use of antibiotics in the clinical, 
agricultural, and industrial settings, is illuminating how microbial communities react to antibiotic 
exposure. A particularly important microbial community is the human microbiota, which 
mediates critical aspects of human health and disease144, is frequently exposed to therapeutic 
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concentrations of antibiotics292, and is recognized as an important reservoir of resistance genes8. 
Integration of these aims could advance our understanding of the factors governing the 
emergence of antibiotic resistance through the lens of microbial ecology and evolution. 
A crucial component of antibiotic resistance surveillance is the study of the resistome in 
microbial communities across diverse habitats. A habitat that is particularly interesting is the 
human gut, which houses a microbial community that is both critical to human health and 
routinely exposed to antibiotics. Of particular interest is the gut microbiota of preterm infants, 
who account for 12% of U.S. births and receive nearly universal and often extensive antibiotic 
therapy. While the acute effects of antibiotics on the preterm infant gut microbiome are well 
documented293, the long-term effects are not yet thoroughly understood. In Chapter 2, I seek 
broadly to identify the long-term effects of antibiotic perturbation on microbial communities. To 
this end, I conducted an integrative analysis of the gut microbiota of antibiotic treated extremely 
and very premature infants over the first twenty months of life using a combination of shotgun 
metagenomic sequencing, stool culturing and isolate sequencing, functional metagenomics, and 
machine learning. In total, I sequenced nearly 1.2 Tb of metagenomic DNA from 444 stools 
collected longitudinally from 58 infants to define a program of healthy microbiota assembly in 
antibiotic naïve infants, and show acute but transient deviations from this program in antibiotic 
treated preterm infants. By sequencing >500 isolates cultured, I demonstrate that antibiotic 
treatment selects for persistent gastrointestinal colonization by multidrug resistant 
Enterobacteriaceae in preterm infants. Likewise, I use functional metagenomics to reveal an 
enriched gut antibiotic resistome and disrupted patterns of resistome development in preterm 
infants compared to antibiotic naïve near term infants. Lastly, I develop a classifier which can 
distinguish with high accuracy between antibiotic treated preterm infants and antibiotic naïve 
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near term infants based on microbiota composition later in life, thus revealing a persistent and 
possibly pathogenic metagenomic signature of early life antibiotic treatment in preterm infants.  
A crucial component of addressing the growing clinical problem of antibiotic resistance 
is the discovery and improved mechanistic understanding of novel antibiotic resistance 
determinants in environmental bacteria at risk for acquisition by pathogens. In Chapters 3 and 4, 
I explore an emerging mechanism of tetracycline inactivation using complementary 
bioinformatic, microbiological, biochemical, and structural biology approaches. The work 
described in these chapters will improve fundamental knowledge of the structure/mechanism 
relationship of tetracycline inactivating enzymes with respect to catalysis and inhibition. Further, 
this work addresses critical gaps in our understanding of the origins and evolution of an 
emerging family of clinically-relevant tetracycline inactivating enzymes. While most tetracycline 
resistance currently occurs by efflux or target (ribosomal) protection, we identified a family of 
tetracycline inactivating enzymes through tetracycline and tigecycline selections of soil and gut 
metagenomes29. I show that these genes are more widespread than previously thought in both gut 
and environmental microbial communities. Using a combination of biochemistry and structural 
biology, I characterize the mechanism of action of these enzymes, advancing our understanding 
of tetracycline resistance by inactivation and flavoenzyme biology more broadly. I identify an 
inhibitor of these enzymes that is sufficient to prevent tetracycline degradation and restore 
antibiotic efficacy in the face of these resistance enzymes294. Lastly, I sequence and characterize 
a Pseudomonas aeruginosa isolate from a cystic fibrosis patient in Pakistan bearing a gene 100% 
nucleotide identity to a gene first identified in our functional selections. I show that this gene is 
responsible for tetracycline resistance in this isolate, thus signaling the clinical arrival of this 
tetracycline resistance by inactivation in the clinical setting.  
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This body of work contributes substantially to the fields of microbiology, antibiotics, and 
resistance. The identification of enduring effects of antibiotics on the gut microbiota has promise 
to inform antibiotic treatment regimens in vulnerable population such as preterm infants such 
that infections are effectively treated while lasting collateral damage to the microbiota is 
minimized. Additionally, consideration of adverse effects of antibiotics during infection 
management will improve antibiotic stewardship in intensive care unit settings. My work on 
emerging tetracycline resistance by inactivation has expanded our understanding of the 
principles governing dissemination of antibiotic resistance from environmental to clinical 
settings. Furthermore, the identification of environmental resistance genes prior to their clinical 
emergence and proactive development of strategies (e.g. inhibitor coadministration) to counter 
their eventual impact is a paradigm broadly applicable to the antimicrobial development space 
that will enable sustainable development and deployment of our antibiotic arsenal.  
1.5 Acknowledgments  
This chapter was synthesized from work in which I made first author contributions done 
in collaboration with Terence S. Crofts, Boahemaa Adu-Oppong, Molly K. Gibson, Phillip I. 
Tarr, Barbara B. Warner, and Gautam Dantas. Sections of this chapter were published in 
Gasparrini, Crofts et al. (Gut Microbes, 2016), Adu-Oppong, Gasparrini et al. (Annals of the 




Chapter 2: Persistent metagenomic 
signatures of early life antibiotic treatment in 
the infant gut microbiota and resistome 
2.1 Introduction 
2.1.1 Abstract 
Because hospitalized preterm infants are vulnerable to infection, they receive frequent 
and often prolonged exposures to antibiotic therapy. It is not known if the short-term effects of 
antibiotics on the preterm infant gut microbiota and resistome persist after discharge from 
neonatal intensive care units. Here, we use complementary metagenomic, culture based, and 
machine learning techniques to interrogate the gut microbiota and resistome of antibiotic-
exposed preterm infants during, and after, hospitalization, and compare these readouts to 
antibiotic-naïve healthy infants sampled synchronously. We find a persistently enriched 
gastrointestinal antibiotic resistome, prolonged carriage of multidrug resistant 
Enterobacteriaceae, and distinct antibiotic-driven patterns of microbiota and resistome assembly 
in extremely preterm infants who received early life antibiotics. Our results demonstrate lasting 
collateral damage of early life antibiotic treatment and hospitalization in preterm infants and urge 
alternative strategies for infection management in highly vulnerable neonatal populations.  
2.1.2 Introduction 
Gut microbes play important roles in host health and disease throughout life, and are 
particularly important in infancy295. During this period, gut microbes exclude pathogens, 
synthesize vitamins and amino acids, and promote immune system maturation295. Infant gut 
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microbiota assembly accelerates in the first months of life, following inoculation by organisms 
from mothers and the environment296, but stabilizes by approximately three years of age248. 
Antibiotics in this interval may disproportionately damage the host-microbiota 
ecosystem248,255,282. Indeed, emerging data suggest that early-life gut microbial alterations 
correlate with a variety of chronic metabolic and immune disorders in childhood and later 
life255,263-265,295,297-304, including allergies305, psoriasis306, adiposity307, diabetes308 and 
inflammatory bowel disease309-311. For most of these disorders, a causal link between antibiotic-
mediated microbiota disruption and onset of pathology is lacking. However, antibiotics have 
been linked to permanent immune alterations306,312 and inflammatory bowel disease in later 
childhood311, highlighting the damaging long-term potential of early life antibiotic treatment. 
 Over 11% of live births worldwide occur preterm313, and preterm birth and its sequelae 
are prominent causes of childhood morbidity and mortality worldwide314. Because bacterial 
infections are serious and frequent complications of preterm birth315, nearly all infants in 
neonatal intensive care units (NICUs) receive antibiotics269. We have shown that severe, acute 
perturbation of the preterm infant gut microbiota immediately following antibiotic treatment is 
characterized by decreased alpha diversity, increased abundance of Enterobacteriaceae, and 
antibiotic-specific enrichment of antibiotic resistance genes (ARGs) and multidrug resistant 
organisms (MDROs)7. Because microbiota perturbation during early life is hypothesized to be 
disproportionately damaging272,316, it is imperative to study the lasting effects of antibiotics on 
the preterm infant gut microbiota. Prior studies of preterm infants report gut microbiota recovery 
concomitant with NICU discharge286,317,318. However, a shortcoming of these studies is their 
reliance on exclusively culture based or amplicon sequencing (e.g. 16S rRNA) based analysis, 
which are limited in resolution and focus only on taxa present in the microbiota rather than the 
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functions collectively encoded by those taxa. Here, we analyze ~ 1.2 terabases of metagenomic 
DNA, culture and sequence 500 bacterial isolates, and functionally select an additional 300 
gigabases of metagenomic DNA for expressed antibiotic resistance, to investigate thoroughly 
and in high resolution the long-term consequences of antibiotic treatment on the preterm infant 
gut microbiota. 
2.2 Results 
2.2.1 Metagenomics based analysis of effect of antibiotics on the preterm 
infant gut microbiota  
 To understand the lasting effects of early life antibiotics on infant gut bacterial 
communities, we whole metagenome shotgun sequenced 444 fecal metagenome samples from 58 
infants over the first 21 months of their life (1.18 terabases metagenomic DNA; Supplementary 
Fig. 2.3; see Methods). Our cohort included 41 preterm infants sampled while they resided in the 
NICU and following discharge to home. One subset of this cohort (n=9) received scant antibiotic 
therapy in their neonatal period or subsequently (total duration of antibiotic therapy < 7 days). 
The remaining 32 preterm infants received 255 total additional courses of antibiotics over the 
first 21 months of life (median (interquartile range (IQR)) 29.5 days (41.6, 68.3 days) antibiotic 
therapy). All infants in this cohort were classified as being born very or extremely preterm 
(median (IQR) gestational age at birth of 26 weeks (25, 27 weeks)) and had extremely or very  
low birth weights (median (IQR) 840 g (770, 960 g)). Additionally, 17 antibiotic-naïve, healthy 
early term319 or late preterm320 (median (IQR) gestational age at birth 36 weeks (36, 37 weeks); 
hereafter referred to as “near term”) infants of the same chronological age range, sampled 




Table 2.1.  Clinical characteristics of infant cohorts analyzed in this study 













Birth weight, g, median (IQR) 1080 (880, 1270) 830 (698.75, 897.5) 2529 (2359.5, 2966.5) 
Gestational age at birth, weeks, 
median (IQR)  
27 (26, 27) 25 (24, 26) 36 (36,37) 
Gender, M/F 4/5 15/17 4/13 




Antibiotic exposure, n courses       
Gentamicin 9 74 none 
Ampicillin 9 37 none 
Vancomycin none 67 none 
Clindamycin none 16 none 
Meropenem  none 14 none 
Cefepime none 11 none 
Cefotaxime  none 10 none 
Mupirocin none 7 none 
Trimethoprim-sulfamethoxazole none 4 none 
Ticarcillin-clavulanate none 3 none 
Oxacillin none 3 none 
Cefoxitin none 3 none 
Cefazolin none 2 none 
Amoxicillin none 2 none 
Metronidazole none 1 none 
Penicillin G none 1 none 
Bacterial culture positive, n        
Blood 0 22 0 
Tracheal 0 30 0 
Urine 0 17 0 
 
We inferred bacterial taxonomic composition from shotgun metagenomic data using 
MetaPhlAn 2.0280. Across all infants, Shannon diversity increased during an apparent 
developmental phase before stabilizing (Fig. 2.1a). Near term infant microbiota Shannon 
diversity increased rapidly in the first month of life before reaching a plateau, while preterm 
infant microbiota diversity increased more gradually and with greater variation (Fig. 2.1a). At the 
family level, Enterobacteriaceae and Enterococcaceae dominated the preterm infant gut 
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microbiota in the first months of life. In contrast, early colonization by Enterobacteriaceae in 
near term infants precedes robust colonization with Bifidobaccteriaceae (Fig. 2.1b). Notably, 
there is a near absence of Enterococcaceae early in life (<4 months chronological age) in the 
near term infants, and a similar absence of Prevotellaceae later (>8 months chronological age) in 
preterm infants. In contrast, we observed predicted microbiota functional stability both over time 
and between groups (Fig. 2.1c), as inferred by HUMAnN2278. 
Low gut microbiota diversity is associated with adverse health outcomes in infancy321-323, 
childhood282, and adulthood324. To identify clinical features of our cohort that were associated 
with microbiota diversity, we regressed Shannon diversity on clinical variables including 
antibiotic treatment (Methods) using a generalized linear mixed model with subject defined as 
individual effect to control for repeated samplings. All variables were included in initial 
modeling, and a final model was fit by backwards elimination of variables. Following correction 
for multiple comparisons, day of life was significantly associated with increased Shannon 
diversity (p<0.001), while a recent (within 30 days of sample collection) course of vancomycin 
(p<0.001), ampicillin (p<0.001), meropenem (p=0.009), or cefepime (p=0.012) was significantly 
associated with decreased species richness (Fig. 2.1d). In this sparse model, 57% of the variance 
in Shannon diversity was explained by the fixed effects (day of life and antibiotic treatments) 
alone, while an additional 12% of the variance was explained by subject. Across all infants in our 
cohort through the first 110 days of life, Shannon diversity of the microbiota was significantly 
lower in infants who received >1 course of antibiotics in the prior month (Fig. 2.1e). Thus, recent 





2.2.2 Partial microbiota recovery following NICU discharge 
While the taxonomic composition of the preterm infant microbiota clustered by both 
gestational age at birth and antibiotic treatment status (Adonis, p<0.001, Bray–Curtis), 
chronological age was a major driver of microbiota composition across all infants248,250,286 (Fig. 
2.2a). We hypothesized that after early-life antibiotic-induced perturbation7, the gross 
composition of the preterm microbiota will converge towards the profile of the microbiota of 
age-matched healthy, antibiotic naïve, near term infants within the first 21 months of life, but 
that potentially pathological microbiota ‘scars’ from this early-life disruption (e.g., enriched 
ARGs and MDROs) persist.  
 To identify and then quantify the extent of this antibiotic induced perturbation, we used a 
random forests algorithm to regress the relative abundances of species present in the microbiota 
of infants against their chronological age as previously described251. Because of the 
nonparametric assumptions of random forests325, the algorithm detects both linear and nonlinear 
relationships between species in the microbiota and age, thus identifying taxa that distinguish 
different developmental periods in infancy. By assessing model performance with sequentially 
fewer predictors, we determined that 50 was the minimum number of variables required for  
Figure 2.1: Clinical variables including antibiotic exposure predict microbiota diversity.  
(a) Shannon diversity of all near term (n=17) and preterm (n=41) infants in this study, by month 
of life. (b,c) Microbiota species and functional composition of all near term (n=17) and preterm 
(n=41) infants in this study, by month. (d) Day of life is significantly associated with an 
increased microbial Shannon diversity, while vancomycin, ampicillin, meropenem, or cefepime 
treatment within the month prior to sampling is associated with significantly decreased species 
richness (***, p<0.001, ** p<0.01, * p<0.05; GLMM with subject as random effect). Oxacillin 
was included in the model but its association with diversity was not significant after correction 
for multiple comparisons. Error bars indicate s.e. (e) Shannon diversity is significantly lower in 
infants who have received >1 course of antibiotic treatment in the past month compared to 
infants who had not received antibiotic treatment during that time span (**** p<0.0001, ***, 




Figure 2.2 Partial architectural recovery of preterm infant gut microbiota following 
discharge from NICU. (a) Microbiota composition is distinct between near term infants, 
preterm infants with early only antibiotic treatment, and preterm infants with early and 
subsequent antibiotic treatment (Bray-Curtis, p<0.001, Adonis), but chronological age is a major 
driver of microbiota composition. (b) Fivefold cross-validation indicates that 50 variables are 
sufficient for random forests prediction of chronological age of near term infants based on 
microbiota composition. Error bars indicate s.e. (c) The 50 most informative predictors to the 
random forests model, determined over 100 iterations of the model. These species were included 
in a sparse model. Error bars indicate s.e. (d) The sparse random forests model is a good 
predictor of near term infant chronological age, but preterm infant chronological age is predicted 
to be less than actual age across numerous stages of development. Curves are loess regression fit 
to each group. (e) Preterm infant microbiota for age Z-score (MAZ) is significantly lower than 
that of near term infants in the first month of life, indicating early microbiota immaturity (** 
p<0.01, **** p<0.0001). (f) Preterm infant MAZ is statistically indistinguishable from near term 
infant by 12-15 months of life, indicating resolution of microbiota immaturity by this time point. 
72 
 
accurate prediction of age (Fig. 2.2b). Hence, we trained a sparse model comprised of the 50 
most informative predictors (taxa) on the antibiotic naïve, near term infant subset in order to 
model healthy microbiota development, and subsequently refined and validated the model (see 
Methods). The top age discriminatory taxa in the gut microbiota of antibiotic naïve, near term 
infants were Faecalibacterium prausnitzii, Subdoligranulum sp., Ruminococcus gnavus, and 
Oscillobacter sp. (Fig. 2.2c). We used this sparse model to predict the chronological age of an 
infant using only the relative abundance of these 50 species. This prediction, or ‘microbiota age,’ 
provides an approximation of the relative maturity of a microbial community251. We observed a 
linear relationship between the chronological and microbiota ages of antibiotic naïve, near term 
infants, suggesting that the model accurately predicts near term infant microbiota age. For 
preterm infants, however, our model predicted microbiota ages that were younger than 
chronological age across several stages of development, indicating that disruption of microbiota 
development occurs in these infants. To better quantify the extent of disruption, we computed a 
microbiota for age Z-score (MAZ) for each metagenome, as previously described251. Preterm 
infants who receive early-only or early-plus-subsequent antibiotic treatment have significantly 
lower MAZs than do infants born near term gestation as measured in the first months of life (Fig. 
2.2e). However, by months 12-15 of life following discharge from the NICU, the MAZs of 
hospitalized preterm infants closely resemble those of healthy, antibiotic naïve, near term infants 
(Fig. 2.2f). Thus, despite apparent transient early life delays in the development of the preterm 
infant gut microbiota, the bacterial taxonomic composition converges on common structures with 
those of healthy, antibiotic naïve, infants within the first 21 months of life (Fig. 2.2d).  
2.2.3 Antibiotic resistome of preterm infant gut microbiota 
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 To characterize the antibiotic resistome encoded in the gut microbiota of our infant 
cohort, we first conducted a high throughput functional metagenomic analysis4 of 217 preterm 
and near term infant stools, selected to represent the diversity in gestational age at birth, 
chronological age, and antibiotic treatment history in our cohort. We constructed 22 functional 
metagenomic libraries by pooling metagenomic DNA from 9-10 stools per library, encompassing 
396 gigabase pairs (Gb) of metagenomic DNA with an average library size of 18 Gb 
(Supplementary Fig. 2.4; see Methods) and an average insert size of 2-3 kilobase pairs (kb). We 
selected libraries on sixteen antibiotics relevant to neonatal and pediatric populations 
(Supplementary Table 2.2) and recovered resistant transformants for each antibiotic except 
meropenem (Supplementary Fig. 2.4). Alarmingly, we found that the infant gut metagenome 
encoded transferrable resistance even to antibiotics rarely or never used in neonates, such as 
ciprofloxacin and chloramphenicol, and those that represent last lines of defense against 
MDROs, such as tigecycline and colistin. Interestingly, only one of eight libraries constructed 
from stools of antibiotic naïve, near term infants encoded ciprofloxacin resistance (mediated by 
loci other than gyrA or parC), compared to six of fourteen libraries constructed from preterm 
infant stools. This observation, viewed in light of the scarce use of ciprofloxacin in neonates269, 
suggests that acquired (as opposed to intrinsic) ciprofloxacin resistance occurs naturally in 
preterm infant gut bacterial communities, or that organisms resistant to ciprofloxacin may be co-
selected by other antibiotics to which they are resistant.  
 We sequenced resistance-conferring inserts and assembled 874 unique, functionally 
identified ARGs. The median identity of functionally selected ARGs to sequences in the NCBI 
non-redundant protein database (retrieved May 21, 2018) was 94.4%, while their median identity 
to the Comprehensive Antibiotic Resistance Database (CARD, version 1.2.1, retrieved January 
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Figure 2.3: Preterm infants harbor an enriched gut resistome. (a) Amino acid identity 
between all functionally selected ARGs and their top hit in CARD vs their top hit in the NCBI nr 
protein database, colored by class of antibiotic used for selection. Notably, ARGs recovered by 
fluoroquinolone and polymyxin selection have very low median identity to CARD. (b) The most 
commonly predicted hosts of functionally selected ARGs based on highest identity BLAST hit in 
the NCBI nr protein database. (c) Gut resistome composition is distinct between near term 
infants, preterm infants with early only antibiotic treatment, and preterm infants with early and 
subsequent antibiotic treatment (Bray-Curtis, p<0.001, Adonis). (d) Preterm infants had fewer 
unique ARGs encoded in their gut metagenomes than near term infants. (* p<0.05, ** p<0.01 
Wilcoxon). (e) The cumulative resistome relative abundance was significantly higher in the gut 
microbiota of preterm infants with early and subsequent antibiotic treatment compared to both 
preterm infants with only early antibiotic treatment and near term infants (* p<0.05, Wilcoxon). 
(f) A random forests model trained on near term gut resistome poorly predicts chronological age 
of near term infants, suggesting distinct patterns of resistome assembly based on gestational age 
at birth and antibiotic treatment status. (g) The programmed assembly of the gut resistome in 
preterm infants differs from that of near term infants in prolonged carriage of some ARGs, 




24, 2018) 326 was 32.0% (Fig. 2.3a). Hence, while the resistance determinants discovered in our 
functional selections have largely been previously sequenced, in most cases they have not yet 
been assigned resistance functions, as we have previously noted7. The predicted sources of 
resistance conferring ORFs (determined by best BLAST hit to the NCBI non-redundant protein 
database) were predominantly uncultured bacteria or Enterobacteriaceae (Fig. 2.3b). The 
identification of Enterobacteriaceae as the likely hosts of ARGs in the infant gut microbiota is 
consistent with prior studies7 and current understanding of Enterobacteriaceae as prolific hosts 
and traffickers of ARGs327-329. Additionally, the identification of uncultured (189 ORFs) and 
unclassified (24 ORFs) bacteria as sources of ARGs highlights the value of functional 
metagenomics as a culture- and sequence-unbiased method for characterizing resistomes330.  
 To extend our resistome analysis to all samples in our cohort, we used ShortBRED235 to 
quantify translated ARG abundance in all sequenced metagenomes using a custom database that 
included canonical ARGs in CARD as well as the functionally selected ARGs identified here 
(see Methods). Resistomes clustered according to gestational age at birth and antibiotic treatment 
status (Fig. 2.3c, p<0.001, Adonis). The gut metagenomes of preterm infants encoded fewer 
unique ARGs than those of near term infants (p<0.01, Wilcoxon, Fig. 2.3d). However, the 
cumulative resistome relative abundance was significantly higher in the gut microbiota of 
preterm infants with early-plus-subsequent antibiotic treatment compared to preterm infants with 
early-only antibiotic treatment and with antibiotic naïve, near term infants (p<0.05, Wilcoxon, 
Fig. 2.3e). There was a weak inverse correlation between alpha diversity and cumulative 
resistome burden across all metagenomes (R2=0.09, Supplementary Fig. 2.6a), indicating that 
microbiota with an enriched resistome are dominated by a few samples. Indeed, in 41 of the 54 
metagenomes with a cumulative resistome of reads per kilobase per million mapped reads 
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(RPKM) > 5000, a single species comprised > 50% of microbiota relative abundance. In 25 of 
these samples, the dominant species was E. coli (Supplementary Fig. 2.6b). Other dominant 
species were Enterococcus faecalis (n=5), Klebsiella pneumoniae (n=2), Staphylococcus 
epidermidis (n=2), Enterobacter aerogenes (n=2), Bifidobacterium breve (n=2), Pseudomonas 
aeruginosa, Bifidobacterium longum and Citrobacter koseri (n=1, each). Thus, it appears that 
extreme prematurity, associated hospitalization, and antibiotic treatment select for one or two 
MDROs that dominate the infant gut microbiota rather than enriching for a greater diversity of 
resistant organisms and selecting for a diverse resistome. 
 To define the developmental progression of the infant gastrointestinal resistome over the 
first months of life, we regressed the abundance of ARGs (in RPKM) in a subset of antibiotic 
naïve, near term infant gut metagenomes (as determined by ShortBRED) against the day of life 
for these infants using random forests325. Fivefold cross-validation indicated that 50 predictors 
were sufficient for optimal model performance, so we constructed a sparse model using the 50 
most informative ARGs. The sparse model was subsequently applied to preterm samples to 
predict the apparent ‘resistome age.’ A clear developmental trajectory based on these 50 ARGs 
was evident in near term infants (Fig. 2.3g). The developmental trajectory of the preterm infant 
gut resistome deviates from that of the antibiotic naïve, near term infants in prolonged carriage of 
some ARGs (e.g.,  oqxA, oqxB, catI, fosA5, cdeA), near absence of others (e.g., abeM), and a 
general increase in the normalized abundance of these genes in the gut across all timepoints (Fig. 
2.3g). Overall, we found that the model only modestly predicted the chronological age of 
preterm infants (R2 = 0.62, Fig. 2.3f), suggesting that there are distinct patterns of resistome 
development based on antibiotic treatment status and gestational age at birth.  
77 
 
 Highlighting the potential for lateral ARG exchange within the infant microbiome, 225 
contigs (6.4% of all contigs) recovered in functional selections encoded a putative mobile genetic 
element (Supplementary Fig. 2.5a-e). Mobile genetic elements were most commonly observed in 
tetracycline selections (Supplementary Fig. 2.5f), but were also commonly observed in β-lactam, 
chloramphenicol, gentamicin, and ciprofloxacin selections. We observed an enrichment for 
mobile genetic elements on amoxicillin/clavulanate (p<0.01, hypergeometric test), tetracycline 
(p<0.01, hypergeometric test), and gentamicin (p<0.001, hypergeometric test). The synteny of 
functionally selected ARGs with mobile genetic elements provides evidence for a potentially 
mobile resistome in the infant gut microbiota. 
2.2.4 Persistence of multidrug resistant Enterobacteriaceae in the preterm 
infant gut microbiota 
 Whole metagenome shotgun sequencing is a powerful method for describing gross 
microbiota composition and function, but it is less able to elucidate strain level variation. The gut 
has been established as an early reservoir of bacteria that cause late onset bloodstream infections 
in neonates274 and is dominated by multidrug resistant Proteobacteria7, but the extent to which 
these early colonizing strains persist in the infant gut microbiota is not well understood. We 
reasoned that early life antibiotic treatment in preterm infants might create a gastrointestinal 
niche for such Proteobacteria that is not relinquished even after discharge from the NICU. To 
better understand the persistence of specific bacterial strains in the microbiota of infants in our 
cohort, we cultured pairs of stools collected 8-10 months apart from 15 infants (nine preterm and 
six near term) on a series of selective agars (see Methods). We optimized culture conditions to 
isolate opportunistic extraintestinal pathogens known to be highly prevalent and abundant in the 
preterm infant gut microbiota as well as those that are frequently multidrug resistant. In total, we 
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cultured 530 isolates from these 30 samples. We performed whole genome sequencing, 
assembly, and annotation of 277 isolates from the preterm set and 253 isolates from the near 
term set.  
The species most frequently isolated by this direct antibiotic selection were E. coli 
(n=139), K. pneumoniae (n=62), E. faecalis (n=50), Enterobacter cloacae (n=42), E. faecium 
(n=22), C. freundii (n=15), and K. oxytoca (n=14). We identified persistence of nearly identical 
strains of E. coli, E, cloacae, and K. variicola in samples collected from infants both while in the 
NICU and 8-10 months following discharge (Fig. 2.4g). Among the persistent isolates recovered 
from infants born prematurely were strains of E. coli ST405 and E. cloacae ST108 (classified by 
in silico multilocus sequence typing (MLST)), both of which are high-risk international lineages, 
with demonstrated propensity for harboring extended-spectrum β-lactamases (ESBLs) and the 
NDM-family carbapenemases331-333. Each of the E. coli strains encoded a TEM-1 β-lactamase as 
well as an aac(3)-IId aminoglycoside acetyltransferase with predicted resistance to 
aminoglycosides, and each of the E. cloacae strains encoded an AmpC type β-lactamase. The K. 
variicola strains each encoded oqxAB, the RND-type multidrug efflux pump334, and the 
chromosomal Klebsiella β-lactamase blaOKP-B-1335. The isolation of nearly identical (average 
nucleotide identity (ANI) >99.997%) multidrug resistant Enterobacteriaceae from the gut while 
infants are in the NICU and then again many months later after discharge provides evidence for 
an enduring and transmissible pathological microbiome “scar” associated with preterm birth, 
early life hospitalization, and antibiotic treatment.  
 Because Enterococcus species are highly prevalent and abundant in the preterm infant 
gut7, often multidrug resistant336, and cause nosocomial blood stream infections in preterm 
infants337, we investigated the resistance and virulence phenotypes of these strains. A particular
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Figure 2.4: Multidrug resistant Enterobacteriaceae lineages persist in preterm infant gut 
microbiota. Maximum likelihood core genome phylogenies of E. coli (a), Klebsiella spp. (c), 
and E. cloacae (e) isolated from infant stool. Annotations to the right of metadata indicate 
timepoints of isolation and sequence type (determined by in silico MLST) for E. coli and E. 
cloacae or species for Klebsiella. Persistent isolates are highlighted in red. Average nucleotide 
identity heat maps for E. coli (b), Klebsiella spp. (e), and E. cloacae (f) indicate that persistent 
isolates are isogenic, i.e., they share >99.997% nucleotide identity. (g) Timeline of isolation of 




 concern among neonatal populations is vancomycin resistant Enterococci (VRE)338. Of the 15 
unique Enterococcus strains we isolated, ten were E. faecalis and five were E. faecium 
(Supplementary Fig. 2.7a). Each E. faecalis isolate was susceptible to vancomycin, while two E. 
faecium isolates were resistant to vancomycin339. However, no E. faecium strain formed a 
biofilm, while four of the E. faecalis strains formed robust biofilms at room temperature and an 
additional six formed biofilms at 37˚C (Supplementary Fig. 2.7b). Interestingly, all strains that 
formed biofilms were isolated from preterm infant stools. This is consistent with the prevailing 
understanding that early colonizers of the preterm infant gut are largely surface adapted strains 
that are prevalent in the NICU environment279. Concurringly, E. faecalis that form biofilms, 
while susceptible to vancomycin when planktonic, were resistant to this antibiotic when in 
biofilms (Supplementary Fig. 2.7c). Thus, despite the apparent tradeoff between vancomycin 
resistance and biofilm formation observed among Enterococcus strains, nearly all have evolved 
strategies for surviving vancomycin exposure. This finding is disturbing because of the 
widespread usage of vancomycin (Table 2.1) and high prevalence of Enterococcus colonization 
(Fig. 2.1b) in NICUs.   
2.2.5 Persistent metagenomic signature of antibiotic treatment in premature 
infants 
To understand if there are persistent effects of prematurity, hospitalization, and early life 
antibiotic treatment on gut microbial content and function, we sought to identify metagenomic 
features that distinguish post-NICU discharge samples in preterm infants from age-matched 
samples from antibiotic naïve, near term infants. We used a supervised learning approach to 
classify samples as originating from a hospitalized preterm infant (including both early-only and 
early-plus-subsequent antibiotic treatment groups) or an antibiotic-naïve near term infant 
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residing at home, based on the relative abundance of bacterial taxa and ARGs in their gut 
microbiota. Using a support vector machine, we identified the fifteen most informative features 
and constructed a sparse model consisting of only these variables, which correctly classified all 
preterm samples and misclassified only two near term samples (96.4% accuracy, Fig. 2.5a). Of 
the fifteen variables most important to model performance, six were ARGs and nine were 
bacterial taxa (Fig. 2.5b). The ARGs important to classification were the class A β-lactamase 
cfxA6340, and three and two genes functionally selected on piperacillin and tetracycline, 
respectively. The highest identity BLAST hit of four of the functionally selected ARGs was an 
ABC transporter, while the other was a MATE family efflux transporter. The predictive species 
were primarily members of the order Clostridiales (Eubacterium rectale, Ruminococcus obeum, 
R. lactaris, Dorea formicigenerans, E. ventriosum, E. ramulus, and E. eligens) and Bacteroidales 
(Prevotella copri, Barnesiella intestinihominis). Our model identified with high accuracy if a 
Figure 2.5: Enduring damage to the preterm infant gut microbiota. (a) 
Support vector machine confusion matrix for classification of gestational age 
based on the species, metabolic pathways, and ARGs present in the microbiota 
following discharge from the NICU or at matched timepoints in nonhospitalized 
near term infants. (b) Twenty predictors most important to classification. A sparse 
model trained using only these twenty predictors was highly accurate (96.4% 
classification accuracy), a persistent metagenomic signature of preterm birth and 
associated hospitalization and antibiotic treatment.    
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preterm infant was hospitalized and received early life antibiotic treatment based on the 
taxonomic and functional microbiota composition following discharge from the NICU despite 
the apparent recovery observed at a gross architectural level.  
2.3 Materials and Methods  
2.3.1 Sample and metadata collection  
All samples and patient metadata used in this study were collected as part of the Neonatal 
Microbiome and Necrotizing Enterocolitis Study (P.I.T., P.I.) or the St. Louis Neonatal 
Microbiome Initiative (B.B.W., P.I.) at Washington University in St. Louis School of Medicine 
and approved by the Human Research Protection Office (approval numbers 201105492 and 
201104267, respectively). Samples were obtained from infants after parents provided informed 
consent. We stratified our cohort by antibiotic exposure and gestational age at birth, with a 
subset of individuals with early antibiotic exposure only (N=9) with no antibiotic exposure 
outside the first week of life, a subset of individuals with early and subsequent antibiotic 
exposure (N=32), and a subset of late preterm or early term infants (N=17) who were not 
hospitalized and were antibiotic naïve over the first months of life (Table 2.1). All stools 
produced were collected and stored as previously described 249,341. In total, 444 samples collected 
longitudinally from 58 infants were shotgun sequenced and included in all metagenomic 
analysis.  
2.3.2 Metagenomic DNA extraction 
Metagenomic DNA was extracted from approximately 100 mg of stool samples using the 
PowerSoil DNA Isolation Kit (MoBio Laboratories) following the manufacturer’s protocol with 
the following modification: samples were lysed by two rounds of two minutes of bead beating at 
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2.5k oscillations per minute for 2 minutes followed by 1 minute on ice and 2 additional minutes 
of beadbeating using a Mini-Beadbeater-24 (Biospec Products). DNA was quantified using a 
Qubit fluorometer dsDNA BR Assay (Invitrogen) and stored at -20˚C. 
2.3.3 Metagenomic sequencing library preparation 
Metagenomic DNA was diluted to a concentration of 0.5 ng/µL prior to sequencing library 
preparation. Libraries were prepared using a Nextera DNA Library Prep Kit (Illumina) following 
the modifications described in Baym et al, 2015342. Libraries were purified using the Agencourt 
AMPure XP system (Beckman Coulter) and quantified using the Quant-iT PicoGreen dsDNA 
assay (Invitrogen).  For each sequencing lane, 10 nM of approximately 96 samples were pooled 
three independent times. These pools were quantified using the Qubit dsDNA BR Assay and 
combined in an equimolar fashion. Samples were submitted for 2×150 bp paired-end sequencing 
on an Illumina NextSeq High-Output platform at the Center for Genome Sciences and Systems 
Biology at Washington University in St. Louis with a target sequencing depth of 2.5 million 
reads per sample.  
2.3.4 Rarefaction analysis 
To determine the appropriate sequencing depth necessary to fully characterize infant gut 
microbiota composition and function, 17 representative metagenomes that were sequenced most 
deeply were subsampled at the following read depths: 8000000, 7000000, 6000000, 5000000, 
4000000, 3000000, 2000000, 1000000, 100000, and 10000. Subsampled metagenomes were 
profiled using MetaPhlAn 2.0280 to determine species richness at each depth.  
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2.3.5 Metagenome profiling 
Prior to all downstream analysis, Illumina paired-end reads were binned by index sequence. 
Adapter and index sequences were trimmed and sequences were quality filtered using 
Trimmomatic v0.36343 using the following parameters: java -Xms2048m -Xmx2048m -jar 
trimmomatic-0.33.jar PE -phred33 ILLUMINACLIP: NexteraPE-PE.fa:2:30:10:1:true 
SLIDINGWINDOW:6:10 LEADING:13 TRAILING:13 MINLEN:36. Relative abundance of 
species was calculated using MetaPhlAn 2.0204 (repository tag 2.2.0). Relative abundance tables 
were merged using the merge_metaphlan_tables.py script. Abundance of metabolic pathways 
was determined using HUMAnN2. Raw count values were normalized for sequencing depth, 
collapsed by ontology, and tables were merged using the humann2_renorm_table, 
humann2_regroup_table, and humann2_join_tables utility scripts278.   
2.3.6 Construction of metagenomic libraries from infant gut samples for 
functional selection 
Approximately 5 µg purified extracted total metagenomic DNA was used as starting material for 
metagenomic library construction. To create small-insert metagenomic libraries, DNA was 
sheared to a target size of 3,000bp using the Covaris E210 sonicator following manufacturer’s 
recommended settings (http://covarisinc.com/wp-content/uploads/pn_400069.pdf). Sheared 
DNA was concentrated by QIAquick PCR Purification Kit (Qiagen) and eluted in 30 μl 
nuclease-free H2O. Then the purified DNA was size-selected by using BluePippin instrument 
(Sage Science) to a range of 1000-6000 bp DNA fragment through a premade 0.75% Pippin gel 
cassette. Size selected DNA was then end-repaired using the End-It DNA End Repair kit 
(Epicentre) with the following protocol: 
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(1) Mix the following in a 50 μl reaction volume: 30 μl of purified DNA, 5 μl dNTP mix (2.5 
mM), 5 μl 10X End-Repair buffer, 1 μl End-Repair Enzyme Mix and 4 μl nuclease-free 
H2O.  
(2) Mix gently and incubate at room temperature for 45 min. 
(3) Heat-inactivate the reaction at 70°C for 15 min. 
End-repaired DNA was then purified using the QIAquick PCR purification kit (Qiagen) and 
quantified using the Qubit fluorometer BR assay kit (Life Technologies) and ligated into the 
pZE21-MCS-1 vector at the HincII site. The pZE21 vector was linearized at the HINCII site 
using inverse PCR with PFX DNA polymerase (Life Technologies): 
(1) Mix the following in a 50 μl reaction volume: 10 μl of 10X PFX reaction buffer, 1.5 μl of 
10 mM dNTP mix (New England Biolabs), 1 μl of 50 mM MgSO4, 5 μl of PFX enhancer 
solution, 1 μl of 100 pg μl 21 circular pZE21, 0.4 μl of PFX DNA polymerase, 0.75 μl 
forward primer (5’ GAC GGT ATC GAT AAG CTT GAT 3’), 0.75 μl reverse primer (5’ 
GAC CTC GAG GGG GGG 3’) and 29.6 μl of nuclease free H2O to a final volume of 50 
μl.  
(2) PCR cycle temperature as follows: 95°C for 5 min, then 35 cycles of [95°C for 45 s, 55°C 
for 45 s, 72°C for 2.5 min], then 72°C for 5 min. 
Linearized pZE21 was size-selected (~2,200bp) on a 1% low melting point agarose gel (0.5X 
TBE) stained with GelGreen dye (Biotium) and purified by QIAquick Gel Extraction Kit 
(Qiagen). Pure vector was dephosphorylated using calf intestinal alkaline phosphatase (CIP, New 
England BioLabs) by adding 1/10th reaction volume of CIP, 1/10th reaction volume of New 
England BioLabs Buffer 3, and nuclease-free H2O to the vector elute and incubating at 37°C 
overnight before heat inactivation from 15 min at 70°C. End-repaired metagenomic DNA and 
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linearized vector were ligated together using the Fast-Link Ligation Kit (Epicentre) at a 5:1 ratio 
of insert:vector using the following protocol: 
(1) Mix the following in a 15 μl reaction volume: 1.5 μl 10X Fast-Link buffer, 0.75 μl ATP 
(10 mM), 1 μl FastLink DNA ligase (2 U/μl), 5:1 ratio of metagenomic DNA to vector, 
and nuclease-free H2O to final reaction volume.  
(2) Incubate at room temperature overnight.  
(3) Heat inactivate for 15 min at 70°C. 
After heat inactivation, ligation reactions were dialyzed for 30 min using a 0.025 um cellulose 
membrane (Millipore catalogue number VSWP09025) and the full reaction volume used for 
transformation by electroporation into 25 μl E. coli MegaX (Invitrogen) according to the 
manufacturer’s recommendations. Cells were recovered in 1 ml Recovery Medium (Invitrogen) 
at 37°C for one hour. Libraries were titered by plating out 0.1 μl and 0.01 μl of recovered cells 
onto Luria–Bertani (LB) agar plates containing 50 μg/ml kanamycin. For each library, insert size 
distribution was estimated by gel electrophoresis of PCR products obtained by amplifying the 
insert from 36 randomly picked clones using primers flanking the HincII site of the multiple 
cloning site of the pZE21 MCS1 vector (which contains a selectable marker for kanamycin 
resistance). The average insert size across all libraries was determined to be 3 kb, and library size 
estimates were calculated by multiplying the average PCR-based insert size by the number of 
titered colony forming units (CFUs) after transformation recovery. The rest of the recovered cells 
were inoculated into 50 ml of LB containing 50 μg/ml kanamycin and grown overnight. The 
overnight culture was frozen with 15% glycerol and stored at -80°C for subsequent screening. 
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2.3.7 Functional selections for antibiotic resistance 
Each metagenomic library was selected for resistance to each of 16 antibiotics (at concentrations 
listed in Supplementary Table 2.2 plus 50 μg/ml kanamycin for plasmid library maintenance) 
was performed using LB agar. Of note, as our library host, E. coli, is intrinsically resistant to 
vancomycin, we are unable to functionally screen for loci conferring resistance to this antibiotic. 
Further, the use of kanamycin as the selective marker for the metagenomic plasmid library 
results in low-level cross-resistance with other aminoglycoside antibiotics, resulting in a higher 
required minimum inhibitory concentration for gentamicin. For each metagenomic library, the 
number of cells plated on each antibiotic selection represented 10x the number of unique CFUs 
in the library, as determined by titers during library creation. Depending on the titer of live cells 
following library amplification and storage, the appropriate volume of freezer stocks were either 
diluted to 100 μl using MH broth + 50 μg/ml kanamycin or centrifuged and reconstituted in this 
volume for plating. After plating (using sterile glass beads), antibiotic selections were incubated 
at 37°C for 18 hours to allow the growth of clones containing an antibiotic resistance conferring 
DNA insert. Of the 352 antibiotic selections performed, 296 yielded antibiotic-resistant E. coli 
transformants (Supplementary Fig. 2.4). After overnight growth, all colonies from a single 
antibiotic plate (library by antibiotic selection) were collected by adding 750 μl of 15% LB-
glycerol to the plate and scraping with an L-shaped cell scraper to gently remove colonies from 
the agar. The slurry was then collected and this process was repeated a second time for a total 
volume of 1.5 mL to ensure that all colonies were removed from the plate. The bacterial cells 
were then stored at -80°C before PCR amplification of antibiotic-resistant metagenomic 
fragments and Illumina library creation. 
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2.3.8 Amplification and sequencing of functionally selected fragments 
Freezer stocks of antibiotic-resistant transformants were thawed and 300 μl of cells pelleted by 
centrifugation at 13,000 revolutions per minute (r.p.m.) for two minutes and gently washed with 
1 mL of nuclease-free H2O. Cells were subsequently pelleted a second time and re-suspended in 
30 μl of nuclease-free H2O. Re-suspensions were then frozen at -20°C for one hour and thawed 
to promote cell lysis. The thawed re-suspension was pelleted by centrifugation at 13,000 r.p.m. 
for two minutes and the resulting supernatant was used as template for amplification of 
resistance-conferring DNA fragments by PCR with Taq DNA polymerase (New England 
BioLabs): 
(1) Mix the following for a 25 μl reaction volume: 2.5 μl of template, 2.5 μl of ThermoPol 
reaction buffer (New England BioLabs), 0.5 μl of 10 mM deoxynucleotide triphosphates 
(dNTPs, New England Biolabs), 0.5 μl of Taq polymerase (5 U/μl), 3 μl of a custom 
primer mix, and 16 μl of nuclease-free H2O. 
(2) PCR cycle temperature as follows: 94°C for 10 min, then 25 cycles of [94°C for 45 s, 
55°C for 45 s, 72°C for 5.5 min], then 72°C for 10 min. 
The custom primer mix consisted of three forward and three reverse primers, each targeting the 
sequence immediately flanking the HincII site in the pZE21 MCS1 vector, and staggered by one 
base pair. The staggered primer mix ensured diverse nucleotide composition during early 
Illumina sequencing cycles and contained the following primer volumes (from a 10 mM stock) in 
a single PCR reaction: (primer F1, CCGAATTCATTAAAGAGGAGAAAG, 0.5 μl); (primer F2, 
CGAATT CATTAAAGAGGAGAAAGG, 0.5 μl); (primer F3, 
GAATTCATTAAAGAGGAGAAAGGTAC, 0.5 μl); (primer R1, 
GATATCAAGCTTATCGATACCGTC, 0.21 μl); (primer R2, 
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CGATATCAAGCTTATCGATACCG, 0.43 μl); (primer R3, 
TCGATATCAAGCTTATCGATACC, 0.86 μl). The amplified metagenomic inserts were then 
cleaned using the Qiagen QIAquick PCR purification kit and quantified using the Qubit 
fluorometer HS assay kit (Life Technologies). 
For amplified metagenomic inserts from each antibiotic selection, elution buffer was added to 
PCR template for a final volume of 200 μl and sonicated in a half-skirted 96-well plate on a 
Covaris E210 sonicator with the following setting: duty cycle, 10%; intensity, 5; cycles per burst, 
200; sonication time, 600s. Following sonication, sheared DNA was purified and concentrated 
using the MinElute PCR Purification kit (Qiagen) and eluted in 20 μl of pre-warmed nuclease-
free H2O. In the first step of library preparation, purified sheared DNA was end-repaired: 
(1) Mix the following for a 25 μl reaction volume: 20 μl of elute, 2.5 μl T4 DNA ligase 
buffer with 10 mM ATP (10X, New England BioLabs), 1 μl dNTPs (1 mM, New 
England BioLabs), 0.5 μl T4 polymerase (3 U/μl, New England BioLabs), 0.5 μl T4 PNK 
(10 U/μl, New England BioLabs), and 0.5 μl Taq Polymerase (5 U/μl, New England 
BioLabs). 
(2) Incubate the reaction at 25°C for 30 min followed by 20 min at 75°C. 
Next, to each end-repaired sample, 5 μl of 1 μM pre-annealed, barcoded sequencing adapters 
were added (adapters were thawed on ice). Barcoded adapters consisted of a unique 7-bp 
oligonucleotide sequence specific to each antibiotic selection, facilitating the de-multiplexing of 
mixed-sample sequencing runs. Forward and reverse sequencing adapters were stored in TES 
buffer (10 mM Tris, 1 mM EDTA, 50 mM NaCl, pH 8.0) and annealed by heating the 1 μM 
mixture to 95°C followed by a slow cool (0.1°C per second) to a final holding temperature of 
4°C. After the addition of barcoded adapters, samples were incubated at 16°C for 40 min and 
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then for 10 min at 65°C. Before size-selection, 10 μl each of adapted-ligated samples were 
combined into pools of 12 and concentrated by elution through a MinElute PCR Purification Kit 
(Qiagen), eluting in 14 μl of elution buffer (10 mM Tris-Cl, pH 8.5). The pooled, adaptor-ligated, 
sheared DNA was then size-selected to a target range of 300-400 bp on a 2% agarose gel in 0.5X 
TBE, stained with GelGreen dye (Biotium) and extracted using a MinElute Gel Extraction Kit 
(Qiagen). The purified DNA was enriched using the following protocol: 
(1) Mix the following for a 25 μl reaction volume: 2 μl of purified DNA, 12.5 μl 2X Phusion 
HF Master Mix (New England BioLabs), 1 μl of 10 mM Illumina PCR Primer Mix (5’-
AAT GAT ACG GCG ACC ACC GAG ATC-3’ and 5’-CAAGCAGA A GAC GGC 
ATA CGA GAT-3’), and 9.5 μl of nuclease-free H2O.  
(2) PCR cycle as follows: 98°C for 30 s, then 18 cycles of [98°C for 10s, 65°C for 30 s, 72°C 
for 30s], then 72°C for 5 min. 
Amplified DNA was measured using the Qubit fluorometer HS assay kit (Life Technologies) and 
10 nM of each sample were pooled for sequencing. Subsequently, samples were submitted for 
paired-end 101-bp sequencing using the Illumina Next Seq platform at the DNA Sequencing and 
Innovation Lab at the Edison Center for Genome Sciences and Systems Biology, Washington 
University in St Louis, USA). In total, three sequence runs were performed at 10 pM 
concentration per lane. 
2.3.9 Assembly and annotation of functionally selected fragments 
Illumina paired-end sequence reads were binned by barcode (exact match required), such that 
independent selections were assembled and annotated in parallel. Assembly of the resistance-
conferring DNA fragments from each selection was achieved using PARFuMS344 (Parallel 
Annotation and Reassembly of Functional Metagenomic Selections), a tool developed 
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specifically for the high-throughput assembly and annotation of functional metagenomic 
selections.  
Open reading frames (ORFs) were predicted in assembled contigs using MetaGeneMark345 
and annotated by searching amino acid sequences against an ARG specific profile hidden 
Markov model (pHMM) database, Resfams346, with HMMER3347. MetaGeneMark was run using 
default gene-finding parameters while hmmscan (HMMER3) was run with the option --cut_ga as 
implemented in the script annotate_functional_selections.py. Selections were excluded from 
analysis if (a) more than 200 contigs were assembled or (b) the number of contigs assembled 
exceeded the number of colonies on the selection plate by a factor of ten. Further, assembled 
contigs less than 500 bp were discarded. Proteins were classified as resistance determinants using 
the following hierarchical scheme: If a contig encoded a protein with a 100% amino acid identity 
hit to the CARD database326, it was considered the causative resistance determinant on that 
contig. Next, if a contig encoded a protein with a significant hit to a Resfams pHMM using 
profile specific gathering thresholds, it was considered the causative resistance determinant on 
that contig. In absence of a high scoring hit to the CARD or Resfams databases, contigs were 
manually curated to identify plausible resistance determinants on an antibiotic specific basis. 
Using these criteria, 1184 of the 5658 unique predicted proteins (20.9%) were classified as 
resistance determinants.    
The percent identity of all resistance determinants were determined using BlastP116 query 
against both the NCBI non-redundant protein database (retrieved May 21, 2018) and the 
CARD326 database (version 1.2.1, retrieved January 24, 2018). Once the top local alignment was 
identified with BlastP, it was used for a global alignment using the Needleman-Wunsch 
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algorithm as implemented in the needle program of EMBOSS348 version 6.6.0 as previously 
described7. 
Putative mobile genetic elements were identified on functionally selected based on string 
matches to one of the following keywords in Pfam and TIGRfam annotations: ‘transposase’, 
‘transposon’, ‘conjugative’, ‘integrase’, ‘integron’, ‘recombinase’, ‘conjugal’, ‘mobilization’, 
‘recombination’, or ‘plasmid’. 
2.3.10 Bacterial isolation from infant stools 
Approximately 50 mg of frozen stool was resuspended in 1 mL Tryptic Soy Broth (TSB) and 
incubated with shaking at 37˚C for four hours. 50 µL of culture was streaked for isolation using 
the four quadrant method on each of the following agars: Bile Esculin Agar, ESBL Agar, 
MacConkey Agar, MacConkey Agar+cefotaxime, MacConkey Agar+ciprofloxacin, and Blood 
Agar (Hardy Diagnostics catalog numbers G12, G321, G35, G121, G258, A10, respectively). 
Plates were incubated for 18-24 hours at 37˚C. Four colonies of each distinct morphology on 
each plate were substreaked onto blood agar and incubated for 18-24 hours at 37˚C. Following 
confirmation of morphology, a 1 mL TSB was inoculated with a single colony and grown 
overnight at 37˚C with shaking. Overnight cultures were frozen in 15% glycerol in TSB. 
2.3.11 Genomic DNA isolation 
1.5 mL TSB was inoculated from isolate glycerol stocks and grown overnight at 37˚C with 
shaking. DNA was extracted using the BiOstic Bacteremia DNA Isolation Kit (MoBio 
Laboratories) following manufacturer’s protocols.  Genomic DNA was quantified using a Qubit 
fluorometer dsDNA BR Assay (Invitrogen) and stored at -20˚C. 
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2.3.12 Isolate sequencing library preparation 
Isolate sequencing libraries were prepared in the same manner as described for metagenomic 
sequencing libraries, following the protocol described in Baym et al., 2015. For each sequencing 
lane, 10 nM of approximately 300 samples were pooled three independent times. These pools 
were quantified using the Qubit dsDNA BR Assay and combined in an equimolar fashion. 
Samples were submitted for 2×150 bp paired-end sequencing on an Illumina NextSeq High-
Output platform at the Center for Genome Sciences and Systems Biology at Washington 
University in St. Louis with a target sequencing depth of 1 million paired end reads per sample. 
2.3.13 Assembly of isolate genomes 
Prior to all downstream analysis, Illumina paired end reads were binned by index sequence. 
Adapter and index sequences were trimmed using Trimmomatic v0.36343 using the following 
parameters: java -Xms2048m -Xmx2048m -jar trimmomatic-0.33.jar PE -phred33 
ILLUMINACLIP: NexteraPE-PE.fa:2:30:10:1:true. Contaminating human reads were removed 
using DeconSeq349 and unpaired reads were discarded. Reads were assembled using SPAdes350 
with the following parameters: spades.py -k 21,33,55,77 –careful. Contigs less than 500 bp were 
excluded from further analysis. Assembly quality was assessed using QUAST351. Average 
coverage across the assembly was calculated by mapping raw reads to contigs using bbmap 
(https://jgi.doe.gov/data-and-tools/bbtools/).  
2.3.14 Isolate genomic analysis 
A total of 406 assemblies had an N50 greater than 50,000 and fewer than 500 total contigs longer 
than 1000 bp, and were included in further analysis. Genomes were annotated using Prokka352 
with default parameters. Multilocus sequence types were determined using in silico MLST 
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(https://github.com/tseemann/mlst). Species assignments were determined by querying 
assemblies against a RefSeq sketch using Mash identifying RefSeq hit with the minimum Mash 
distance353. Assemblies were binned by species according to Mash designation. For each of the 
seven most commonly occurring species, pangenome analysis was performed using Roary, with 
core genome alignments created with PRANK354. An outgroup assembly of the same genus but 
different species was downloaded from NCBI and included in each pangenome analysis 
(Supplementary Table 2.1). Maximum likelihood core genome phylogenies were constructed 
using RAXML under the GTRGAMMA model with 1000 bootstraps and maximum likelihood 
optimization initialized from a random starting tree.   
2.3.15 Enterococcus biofilm formation assay 
Mid-log phase cultures in freshly-prepared tryptic soy broth containing 0.5% glucose (TSBG) 
were diluted to OD 0.1. 200ul of the diluted culture was added in quadruplicate to 96 well 
polystyrene plates and incubated at room temperature or 37˚C without shaking. After 24 hours of 
growth, wells were decanted, washed three times with sterile PBS, and fixed for 30 minutes with 
200 µl Bouin’s solution. Fixative was removed by washing three times with sterile PBS, then 
wells were stained with 0.1% crystal violet for 30 minutes. Excess stain was removed by 
washing three times with sterile PBS, the stain was solubilized in 200ul ethanol, and absorbance 
read at 590nm. E. faecalis strains TX5682 (biofilm negative) and TX82 (biofilm positive) were 
used as controls355.  
2.3.16 Enterococcus vancomycin susceptibility testing 
Isolates identified as Enterococcus were phenotyped for vancomycin resistance using microbroth 
dilution according to the CLSI guidelines339.  ATCC29212 (vancomycin susceptible) and 
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ATCC51299 (vancomycin-resistant) were included in all assays as controls. Isolates were grown 
to mid-log phase, diluted in culture media to 1×106 CFU/ml, and used to inoculate plates 
containing vancomycin ranging from 128-2ug/ml. After 24 hours of static growth at 37˚C, 
optical density was read at 600 nm and MIC was determined by scoring by eye for turbidity.  
Vancomycin resistance of biofilms was assayed after establishing biofilms as above. After 24 
hours of static growth at 37˚C, planktonic cells were removed by washing three times with sterile 
water, and then 200 µl of TSBG containing 5 mg/ml, 5 µg/ml, or no vancomycin, and the plates 
incubated at 37˚C for an additional 24 hours. After washing planktonic cells three times with 
sterile water, 200 µl sterile water was added to each well and the viability of the cells in the 
biofilm was assessed using an XTT Cell Viability Kit (Cell Signaling Technology, #9095) 
according to manufacturer’s protocols, reading absorbance at 450nm 60 minutes after addition of 
reagents.  
2.3.17 Microbiota age regression using random forests 
Random forests was used to regress the relative abundances of all species predicted by 
MetaPhlAn2 in infant stool samples against their chronological age using the R package 
“randomForest”356 as previously described251.  The default parameters were used with the 
following exceptions: ntree=10,000, importance=TRUE. Fivefold cross-validation was 
performed using the rfcv function over 100 iterations to estimate the minimum number of 
features needed to accurately predict microbiota age. The features most important for prediction 
were identified over 100 iterations of the importance function, and a sparse model consisting of 
the 50 most important features was constructed and trained on a set of nine antibiotic naïve near 
term infants randomly selected from the larger near term infant set. This model was validated in 
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the remaining eight antibiotic naïve near term infants, and then applied preterm infants to predict 
microbiota age. Microbiota for age Z-score was computed as previously described251.  
2.3.18 Classification of post-discharge samples 
A single sample from each individual was selected (the final post-discharge sample collected 
from each preterm infant and a roughly age matched sample from each near term infant). All 
metagenomic data (species and ARG abundances, centered and scaled) were initially used as 
input for a support vector machine as implemented in the R package e1071. Feature importance 
was determined by computing the elementwise absolute value of the matrix of weights by the 
matrix of support vectors357. A sparse model was subsequently constructed consisting of only the 
fifteen most important features.  
2.4 Discussion 
 By combining metagenomic sequencing, selective and differential stool culture paired 
with isolate sequencing, functional metagenomics, and machine learning, we demonstrate for the 
first time persistent and potentially pathological metagenomic signatures of early life antibiotic 
treatment and hospitalization in preterm infants. This is manifest in an enriched gut resistome 
and persistent carriage of multidrug resistant Enterobacteriaceae, despite apparent recovery at 
the gross taxonomic level. Our work highlights the need to integrate high resolution and culture-
based approaches for deeply interrogating the gut microbiota to reveal metagenomic signatures 
of microbiota perturbation. These complementary methods provide the first evidence of a 
persistent metagenomic signature of early life antibiotic treatment in the dynamic microbial 
community housed in the infant gut. This provides compelling evidence for an underappreciated 
lasting effect of preterm birth and associated hospitalization and antibiotic treatment on the 
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microbiome, which may play a role in chronic pathologies associated with prematurity for which 
the etiology is unclear. From a clinical standpoint, our findings emphasize a necessity for 
alternatives to broad-spectrum antimicrobial therapy for managing infection in the NICU. While 
it is possible that the metagenomic scars we identified are implicated in sequelae of preterm birth 
such as neurodevelopmental 358-360, metabolic 361,362, cardiac 363,364, and respiratory 365,366 defects, 
further experiments with model systems including gnotobiotic animals are needed to establish a 
link between these persistent dysbioses and lasting pathologies.  
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2.6 Supplementary Figures 
 
 
Supplementary Fig. 2.1. Rarefaction curve of species identified by Metaphlan by sequencing 
depth. Rarefaction curve for the number of unique species identified by subsampled sequencing 
depth. Black bar indicates median sequencing depth for all samples, gray shading indicates one 




Supplementary Fig. 2.2. Temporal changes in relative abundance of top eight classes by group. 
The changes in relative abundance of the eight most abundant classes of bacteria in the gut 









































Supplementary Fig. 2.3. Timeline of samples and antibiotic treatments for infants in this study. 
Sampling timeline for near term (top) and preterm (bottom) infants included in this study. 





Supplementary Fig. 2.4. Functional selections of 22 metagenomic libraries constructed from 
infant stool. Heatmap of resistance phenotypes observed in functional metagenomic selections. 





Supplementary Fig. 2.5. Synteny of functionally selected ARGs with mobile genetic elements. 
Putative mobile genetic elements were identified syntenic to ARGs recovered from tetracycline 
(A), gentamicin (B), chloramphenicol (C), cefoxitin (D), and piperacillin (E) selections. (F) 





Supplementary Fig. 2.6. Microbiota with enriched resistome are low in diversity and dominated 
by Enterobacteriaceae. (A) There is a negative correlation between cumulative relative resistome 
and alpha diversity (R2=0.092). (B) Composition of the microbiota in samples with a resistome 
relative abundance > 5000 RPKM. Samples are low in diversity and dominated by a few 
organisms. In 41 out of 54 samples (76%), a single species comprises >50% of the microbiota. 
These organisms are most commonly E. coli, Enterococcus faecalis, Klebsiella pneumoniae, 




Supplementary Fig. 2.7. Genomic and phenotypic heterogeneity in Enterococcus isolated from 
infant stool. (A) Maximum likelihood core genome phylogeny of Enterococcus strains isolated 
from infant gut microbiota. Persistent strains are highlighted in red. Annotations indicate time 
point and species. (B) Biofilm formation phenotypes of E. faecalis and E. faecium strains at 37˚C 
and at room temperature. (C) Viability of Enterococcus strains in biofilms following 
vancomycin treatment.   
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Supplementary Table 2.1. Assemblies used as outgroups for maximum likelihood phylogenies 
Species Count Outgroup to include 
Outgroup assembly 
accession 
Escherichia coli 30 Escherichia fergusonii ATCC 35469 ASM2622v1 
Enterococcus spp. 19 Lactococcus garvieae ATCC 49156 ASM26992v1 
Enterobacter 
cloacae 
11 Enterobacter asburiae ATCC 35953 ASM152171v1 
Klebsiella spp. 21 
Salmonella enterica subsp. enterica serovar 





Supplementary Table 2.2. Antibiotic concentrations used for functional selections 
Antibiotic Abbreviation Screening 
Concentration - µg/ml 




Ampicillin AP 64 
Aztreonam AZ 8 
Cefepime CP 8 
Cefoxitin CX 64 
Ceftazidime CZ 16 
Chloramphenicol CH 8 
Ciprofloxacin CI 0.5 
Colistin COL 8 
Gentamicin GE 16 
Meropenem ME 16 
Penicillin G PE 128 
Piperacillin PI 16 
Tetracycline TE 8 





Chapter 3: Tetracycline resistance by 
inactivation across environmental, 
commensal, and pathogenic microbes  
3.1 Introduction 
3.1.1 Abstract 
Many antibiotic resistance genes have their evolutionary origins in benign environmental 
microbes. Identification of environmental antibiotic resistance genes that are not yet widespread 
in the clinical setting can allow for the proactive mitigation of the threat posed by these genes. 
Tetracycline resistance by antibiotic inactivation (e.g. by Tet(X)), has been identified in 
numerous environmental microbes, but occurrences in pathogens or clinical isolates have thus far 
been limited. Here, we identify putative genes encoding tetracycline resistance by inactivation 
across diverse human associated and environmental metagenomes by antibiotic selection of 
metagenomic libraries. We find that identified genes formed two distinct clades by microbial 
habitat of origin, and that resistance phenotypes were similarly correlated. Each of the genes 
isolated from the human gut encode resistance to next generation tetracycline antibiotics 
including eravacycline and omadacycline (recently approved for human use). We report a 
comprehensive biochemical and structural characterization of one of these enzymes, TE_7F_3. 
Further, we identify TE_7F_3 in a clinical Pseudomonas aeruginosa isolate, indicating that this 
family of genes has already disseminated to pathogens of serious clinical concern. Lastly, we 
show that highlight the need for further surveillance of this family of emerging resistance 
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determinants and provide the foundation for an inhibition based strategy for countering this 
resistance.  
3.1.2 Introduction 
Benign environmental microbes are ancient and diverse reservoirs of antibiotic resistance 
genes, and are the likely evolutionary progenitors of most clinical resistance15,20,25,58. Non-
pathogenic bacteria from habitats as varied as soils and healthy human guts have recently 
exchanged multidrug-resistance cassettes with globally distributed human pathogens4. With 
widespread antibiotic use in the clinical and agricultural settings, there is strong selective 
pressure for pathogens to acquire resistance genes with novel activities and substrate specificities 
from environmental resistomes93,367. The discovery and characterization of environmental 
resistance genes with novel activities before they are acquired by and widely disseminated into 
pathogens can help lessen their potential clinical impact, as well as improve fundamental 
understanding of the ecology, evolution, and transmission of resistance genes across habitats25,94. 
Further, understanding the evolutionary origins, genetic contexts, and molecular mechanisms of 
antibiotic resistance is critical to devising strategies to curb the spread of resistant organisms and 
their antibiotic resistance genes, and for sustainable development of new strategies for 
countering infection. 
Since their discovery from extracts of Streptomyces aureofaciens in 1948, the 
tetracyclines have become one of the most widely used classes of antibiotics in agriculture, 
aquaculture, and the clinic due to their broad antimicrobial spectrum, oral availability, and low 
cost368,369. Extensive use over the past seven decades has selected for the expansion of 
tetracycline resistance in environmental microorganisms21, human and animal commensals370, 
and among bacterial pathogens371. Tetracycline use is particularly prevalent in agriculture, with 
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tetracyclines comprising 66% of total therapeutic antibiotic use in livestock372. Widespread 
anthropogenic use has resulted in detectable ng/uL to µg/L quantities of tetracyclines in livestock 
manure and wastewater373, with tetracycline concentration directly correlating with changes in 
microbial community composition and increase in antibiotic resistance374. In human pathogens, 
tetracycline resistance is typically acquired via horizontal gene transfer and occurs almost 
exclusively by ribosomal protection or antibiotic efflux368,371. This distinguishes tetracycline 
resistance from the primary enzymatic inactivation mechanisms observed against other natural-
product antibiotics26,375. Both common tetracycline resistance mechanisms have their 
evolutionary origins in the environment, but are now found widely distributed in many 
commensal and pathogenic bacteria25,94,376.  
The rise in tetracycline resistance has been partially countered by the development of 
synthetic and semisynthetic next-generation tetracyclines368. The first generation natural product 
antibiotics, including chlortetracycline (1948), oxytetracycline (1951), and tetracycline (1953), 
were followed by the semisynthetic second generation tetracyclines, including doxycycline 
(1967) and minocycline (1971), and third generation tetracyclines such as tigecycline (2005), 
eravacycline (2018) and omadacycline (2018)377. As a result, the tetracyclines are still widely 
used in agriculture and medicine378. Tetracyclines remain the frontline therapies for a range of 
indications, including Rickettsia, Mycoplasma pneumoniae, Borrelia recurrentis, Yersinia pestis, 
Vibrio cholera, Clostridium species, Chlamydia species, Neisseria species, and Bacillus 
anthracis369,379. Next-generation tetracyclines represent a promising option for treating 
recalcitrant infections caused by carbapenem non-susceptible Acinetobacter baumannii380, 
extended spectrum β-lactamase or carbapenemase producing Enterobacteriaceae381, ventilator 
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associated pneumonia382, and complicated urinary tract infections and complicated intra-
abdominal infections due to a range of bacterial pathogens383.  
Regrettably, modification of tetracycline’s napthacene scaffold is not a sustainable 
strategy for countering resistance, as clinical resistance arises soon after, or even prior to, the 
approval of next-generation antibiotics for clinical use. For example, while tigecycline is 
unaffected by efflux and ribosomal protection139,384, tigecycline is vulnerable to oxidative 
inactivation by Tet(X)385. Until recently, Tet(X) was the only known enzyme capable of 
providing both tetracycline and tigecycline resistance, identified exclusively in non-pathogenic 
bacteria. In 2013, however, tet(X) was identified in pathogens for the first time. Eleven isolates 
from the Enterobacteriaceae, Comamonadaceae, and Pseudomonadaceae families from clinical 
urine specimens in a hospital in Sierra Leone tested positive for tet(X)138, and tet(X) has now 
been reported in four out of six ESKAPE pathogens137,138,386. The discovery of a tetracycline-
inactivating gene in nosocomial pathogens foreshadows the increasing clinical resistance to next-
generation tetracycline antibiotics and emphasizes the immediate importance of studying this 
emerging mode of tetracycline resistance by enzymatic inactivation. 
 In 2015, we reported a family of tetracycline inactivating enzymes from tetracycline 
selections of soil metagenomes and a previously uncharacterized homolog from the human 
pathogen Legionella longbeachae29 . These genes were annotated as FAD-dependent 
oxidoreductases and were unable to be identified as resistance genes based on sequence alone. 
Our in vitro characterizations indicated that they were mechanistically distinct from Tet(X)387, 
consistent with their low amino acid identity to all known tet(x) genes388. Flavoenzymes are an 
abundant and diverse enzyme family, and display a proclivity for HGT and gene duplication, 
allowing them to spread between species and acquire novel functionality with relative ease389. 
112 
 
Thus, these genes are likely candidates for dissemination to the clinic, potentially compromising 
new tetracycline derivatives and motivating surveillance of the prevalence and abundance of this 
gene family across microbial habitats. 
 Understanding the current prevalence and distribution of resistance mechanisms across 
habitats and anticipating when, where, and how further resistance might spread or evolve upon 
imposition of antibiotic selective pressure is an important component of addressing antibiotic 
resistance. To this end, we sought to characterize the tetracycline resistome across diverse 
environmental and human associated metagenomes. We find that genes that encode tetracycline-
inactivating enzymes are widespread in diverse microbial communities but cluster by habitat of 
origin, and that resistance phenotypes also correlate with microbial habitat. Furthermore, we 
describe TE_7F_3, a tetracycline resistance gene recovered from a human gut metagenome that 
confers resistance to omadacycline and eravacycline, recently approved next-generation 
tetracyclines. We identify TE_7F_3 in a clinical isolate of Pseudomonas aeruginosa from a 
cystic fibrosis patient in a tertiary care hospital in Pakistan, signaling the clinical arrival of 
tetracycline resistance by inactivation, but show that inhibition of this enzyme with 
anhydrotetracycline or analogues can prevent tetracycline degradation and rescue antibiotic 




3.2.1 Ecology of tetracycline inactivation across habitats 
 In order to understand better the prevalence of tetracycline inactivation as a resistance 
mechanism across habitats, we conducted a retrospective screen of our 744 Gb of functional 
metagenomic libraries that had previously been selected on tetracycline and tigecycline 
3,4,7,23,58,103 [GenBank accession numbers: JX009202-JX009380, KJ691878-KJ696532, 
KU605810-KU608292, KF626669-KF630360, KX125104-KX128902, KU543693-KU549046]. 
In addition to the 10 tetracycline inactivating genes from soil metagenomes that had previously 
been described29, we discovered an additional 69 potential tetracycline inactivating enzymes 
based on growth in the presence of a tetracycline or tigecycline selective agent and annotation as 
an FAD-dependent oxidoreductase (Fig. 3.1a). We found that these genes formed two distinct 
Figure 3.1: Diversity in tetracycline inactivating enzyme sequence corresponds to microbial 
habitat of origin. (a) Seventy tetracycline inactivators were identified from tetracycline and 
tigecycline selections of diverse metagenomic libraries. Genes selected for further analysis are 
indicated by gray dots at branch tips. (b) A phylogeny of the 70 genes selected for further 
analysis reveals that genes cluster by microbial habitat of origin. Genes from soil metagenomes 
are shown with red branches, and genes from gut metagenomes are shown with blue branches. 
(c) Percent amino acid identity heatmap indicates greater relative sequence diversity in the soil 




clades that were correlated with habitat of origin (Fig. 3.1b). There was greater sequence 
diversity within the soil-derived subset (mean ± s.d. percent amino acid identity 66.48% ± 
9.37%) compared to the gut-derived subset (mean ± s.d. percent amino acid identity 91.42% ± 
4.72%), but very low identity between the two habitats (mean ± s.d. percent amino acid identity 
20.81% ± 1.45%, Fig. 3.1c).  
 We selected ten genes from this set (nine human gut derived and one soil derived) for 
further analysis and cloned them into E. coli DH10β. We performed antimicrobial susceptibility 
testing using the broth microdilution method for these constructs as well as the ten previously 
reported tetracycline inactivators29 against 11 tetracycline compounds as well as 
anhydrotetracycline. All but one of these computationally predicted tetracycline inactivators had 
a bona fide resistance function when subcloned into E. coli. We found that resistance 
phenotypes, like genotypes, were highly correlated to habitat of origin (Fig. 3.2). While all gut-
derived tetracycline inactivators were capable of conferring high-level resistance to tigecycline, 
minocycline, eravacycline, and omadacycline, soil-derived enzymes were all susceptible or 
intermediate to these drugs. Thus, resistance to next-generation tetracyclines mediates functional 
clustering between the soil-derived and gut-derived genes and discriminates between habitat of 
origin.  




 Each of the gut-derived tetracycline inactivators encoded resistance to every tetracycline 
currently approved for use in the clinic, including minocycline, tigecycline, eravacycline, and 
omadacycline. Tigecycline was approved for human use in 2005, and is an antibiotic of last 
resort for recalcitrant infections including those caused by carbapenem resistant 
Enterobacteriaceae134,381. Eravacycline was approved in August 2018 for treatment of complex 
intra-abdominal infections, and omadacycline was approved in October 2018 for treatment of 
community acquired bacterial pneumonia and acute skin and skin structure infections. Reports of 
resistance to eravacycline and omadacycline have to date been limited. Eravacycline resistance 
Figure 3.2: Phenotypic profiles of heterologously expressed tetracycline inactivating 
enzymes correlate with habitat of origin. Antimicrobial susceptibility testing was performed 
by microbroth dilution on a subset of predicted tetracycline inactivators. We observed broad 
high-level resistance to tetracyclines within this class. Resistance phenotypes clustered by 
microbial habitat of origin, with resistance to next-generation tetracyclines (e.g. minocycline, 




in Klebsiella pneumoniae has been attributed to overexpression of the OqxAB and MacAB 
efflux pumps390, and nonsusceptibility (MIC 4 µg/mL) has been observed in Escherichia coli 
DH10β overexpressing tet(X). The recent clinical approval of these drugs and the limited reports 
of resistance motivate further study of this mode of resistance. To understand better the 
mechanistic basis of resistance to next-generation tetracyclines by these resistance determinants, 
we selected one of these genes, TE_7F_3, for further analysis. We found that media conditioned 
by E. coli expressing TE_7F_3 could support the growth of a susceptible E. coli strain, indicating 
that the mechanism of resistance is drug inactivation.  
 In vitro reactions containing purified TE_7F_3, NADPH, and tigecycline, eravacycline, 
or omadacycline exhibited a time dependent decrease in absorbance between 360 nm and 400 nm 
(Supplementary Fig. 3.1a-c). This is consistent with enzymatic disruption of tetracycline’s β-
diketone chromophore, as has previously been described for enzymatic modification of 
tetracycline29. To understand the biochemical basis of next-generation tetracycline (Fig. 3.3d) 
modification by TE_7F_3, we determined kinetic parameters of enzymatic activity by 
monitoring in vitro reaction progress using absorbance at 400 nm. For comparison, we 
determined kinetic parameters of Tet(X) mediated inactivation of tigecycline and eravacycline in 
a similar manner. The catalytic efficacy of TE_7F_3 was five times greater than that of Tet(X) 
for degradation of eravacycline (kcat/KM values of 0.068 ± 0.017 and 0.013 ± 0.002  µM
-1min-1, 
respectively), and eight times greater for degradation of tigecycline (kcat/KM values of 0.072 ± 
0.009  and 0.009 ± 0.001 µM-1min-1, respectively; Fig. 3.3a-b). The difference in catalytic 
efficacy is largely mediated by more rapid substrate turnover by TE_7F_3 compared to Tet(X), 
as KM values are of similar magnitude across all pairwise enzyme-substrate combinations, but 
TE_7F_3 kcat values are an order of magnitude greater compared to Tet(X) (Fig. 3.3c). When 
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enzymatic reactions were analyzed by liquid chromatography-mass spectrometry, we observed 
that the primary product of omadacycline, tigecycline, and eravacycline degradation is consistent 
with monohydroxylation (Supplementary Fig. 3.1d-f). For each next-generation tetracycline 
substrate, there was a time dependent decrease in the relative extracted ion counts of the 
tetracycline substrate (m/z for [M+H]+ equal to 586, 557, 559 for tigecycline, eravacycline, and 
omadacycline, respectively), and a corresponding increase in the relative extracted ion counts of 
the monooxygenated product (m/z for [M+H]+ equal to 602, 573, 575 for tigecycline, 
eravacycline, and omadacycline, respectively).  
Figure 3.3: Biochemical basis for tetracycline inactivation by TE_7F_3. Michaelis-Menten 
kinetics of tetracycline destructase-mediated degradation of next-generation tetracyclines. (a) 
Michaelis-Menten plot of Tet(X) degradation of tigecycline and eravacycline. (b) Michaelis-





, and catalytic efficiencies for the tetracycline destructase-mediated degradation of 
tigecycline, eravacycline, and omadacycline. (d) Next-generation tetracycline antibiotics 
tigecycline, eravacycline, and omadacycline. Error bars represent standard deviation for three 





3.2.3 TE_7F_3 confers resistance in clinical P. aeruginosa isolate 
While functional metagenomics is a powerful method for identifying resistance genes in a 
sequence and culture unbiased manner, it is poorly equipped to associate specific resistance 
determinants with their native hosts. Thus, we sought to identify homologues of our set of 
functionally validated resistance genes in sequenced clinical isolates. We identified Pa-3, a 
Pseudomonas aeruginosa strain isolated from a 45-year-old male cystic fibrosis patient’s 
tracheal aspirate in an ICU in a tertiary care hospital in Pakistan in December 2016. This strain 
was predicted to encode a 97% ID tet(X) homologue by BLAST, which we identified as having 
100% nucleotide identity to TE_7F_3. We conducted antimicrobial susceptibility testing on this 
strain using disk diffusion for a panel of clinical antibiotics. This isolate was resistant to all 
antibiotics tested with the exception of piperacillin/tazobactam, a β-lactam/β-lactamase inhibitor 
combination, and colistin (Table 3.1). The isolate was positive by carbapenem inactivation assay, 
indicating that it encodes a functional carbapenemase. Multidrug resistant P. aeruginosa are 
designated a serious clinical threat by CDC, and acquisition of resistance to next-generation 
tetracyclines would further exacerbate this hazard.  
In addition to antimicrobial susceptibility testing by disk diffusion, we performed broth 
microdilution for a subset of tetracycline antibiotics for which disks are not yet commercially 
available against Pa-3 (the strain encoding TE_7F_3), Pa-3 (another clinical isolate from the 
same collection which did not encode TE_7F_3), and the P. aeruginosa type strain ATCC 
27853. Each P. aeruginosa isolate phenotyped displayed at least moderate resistance to 
tigecycline, eravacycline, and omadacycline, even in the absence of a putative tetracycline 
inactivator. This is likely due to drug efflux as low-level OprM mediated tigecycline resistance  
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Table 3.1: Zone of clearance (mm) and phenotypic resistance determination for clinical 
Pseudomonas aeruginosa isolate bearing TE_7F_3. Blank interpretation indicates that no 
interpretive criteria have been established.  
Antibiotic Kirby-Bauer (mm) Interpretation 
Delafloxacin 6 Resistant 
Ceftazidime 6 Resistant 
Cefepime 6 Resistant 
Meropenem 6 Resistant 
Imipenem 6 Resistant 
Piperacillin/Tazobactam 24 Sensitive 
Ceftolozane/Tazobactam 6 Resistant 
Ceftazidime/Avibactam 6 Resistant 
Ciprofloxacin 6 Resistant 
Levofloxacin 6 Resistant 
Gentamicin 6 Resistant 
Amikacin 6 Resistant 
Trimethoprim/Sulfamethoxazole 6   
Fosfomicin 12 Resistant 
Colistin 13 Sensitive 
Aztreonam 17 Intermediate 
Doxycycline 6   
Minocycline 6   
Tigecycline 6   
Nitrofurantoin 6   
Carbapenem inactivation assay 14 Positive 
 
in P. aeruginosa PAO1 has been previously reported391. Although tigecycline, eravacycline, and 
omadacycline breakpoints do not yet exist for P. aeruginosa, Pa-3 was 4-8 fold more resistant to 
these drugs than Pa-8 and ATCC 27853. To our knowledge, this is the first description of 
resistance to either eravacycline or omadacycline via enzymatic inactivation in a clinical isolate, 
although we anticipate clinical deployment of these antibiotics will lead to selection for and 
expansion of this mode of resistance in both the hospital and community settings. Media 
conditioned by Pa-3 could support the growth of susceptible E. coli, while media conditioned by 
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27853 or Pa-8 could not, confirming that the mechanism of resistance in Pa-3 but not Pa-8 or 
27853 involves antibiotic inactivation. The resistance phenotype was not transferable to wild 
type E. coli via transformation of bulk plasmid purification from Pa-3, so it is unlikely that 
TE_7F_3 is plasmidic. Nonetheless, clinical use of next generation tetracyclines may select for 
dissemination of this strain. Furthermore, Pseudomonas has a highly plastic genome and undergo 
horizontal gene transfer at rates greater than observed for other genera392, so even 
chromosomally encoded genes are possible threats for transfer beyond this strain. Lastly, we 
observed that TE_7F_3 was syntenic with putative rolling circle transposases (Pfam:PF04986 
per Prodigal annotation, see Methods), suggesting that they may be poised for horizontal 
transfer4,393. 
3.2.4 Anhydrotetracycline analogues rescue tetracycline efficacy against 
resistant strains 
We have previously shown that anhydrotetracycline is an inhibitor of tetracycline 
inactivating enzymes in vitro, and that this inhibition is sufficient to rescue tetracycline efficacy 
against E. coli resistant via heterologous expression of a tetracycline inactivator294. We reasoned 
that this strategy might likewise prove useful to prevent degradation of next-generation 
tetracyclines by TE_7F_3. To this end, we conducted in vitro inhibition assays with purified 
TE_7F_3, all necessary cofactors, a next-generation tetracycline substrate, and an 
anhydrotetracycline inhibitor (see Methods). Reaction progress was monitored by measuring 
absorbance at 400 nm. In addition to parent anhydrotetracycline, we conducted assays using 
anhydrodemeclocycline as an inhibitor. We found that anhydrotetracycline inhibited TE_7F_3 
degradation of tigecycline, eravacycline, and omadacycline at the micromolar level (IC50s of 
1.06 ± 0.108 µM, 6.89 ± 0.655 µM, and 2.37 ± 0.510 µM, respectively). Anhydrodemeclocycline 
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was an even more potent inhibitor of TE_7F_3 degradation of these next-generation substrates, 
with IC50s of  0.262 ± 0.035 µM, 2.75 ± 0.256 µM, and 0.309 ± 0.036 µM, respectively (Fig. 
3.4a-c). We reason based on the predicted structural similarity to previously published cocrystal 
structures of Tet(50) (PDB ID: 5TUF) with anhydrotetracycline that the mechanism of inhibition 
likely occurs similarly294. Specifically, anhydrotetracycline or analogue binds slightly offset from 
Figure 3.4: Anhydrotetracycline inhibits inactivation of next-generation tetracyclines by 
TE_7F_3.  Anhydrotetracycline and analogues inhibit enzymatic inactivation of tetracycline and 
next-generation tetracyclines. (a) In vitro, anhydrotetracycline, anhydrochlortetracycline, and 
anhydrodemeclocycline inhibit Tet(X) modification of tigecycline. Likewise, 
anhydrotetracycline and anhydrodemeclocycline inhibit in vitro enzymatic modification of 
tigecycline (b), eravacycline (c), and omadacycline (d) by TE_7F_3. (e) Anhydrodemeclocycline 
at subinhibitory concentrations can partially rescue tetracycline, tigecycline, eravacycline, and 
omadacycline efficacy against Pseudomonas aeruginosa Pa-3 and E. coli DH10β heterologously 




the active site and inhibits degradation of tetracycline or analogue by both competing for 
substrate binding and sterically restricting dynamics of the FAD cofactor critical for catalysis.  
In order to extend our in vitro studies, we sought to determine whether 
anhydrotetracycline or anhydrodemeclocycline could restore the activity of next-generation 
tetracyclines against Pa-3, the clinical P. aeuruginosa isolate that encodes TE_7F_3. 32 µg/mL 
anhydrotetracycline caused a two- to four-fold increase in sensitivity of Pa-3 to tigecycline, 
eravacycline, or omadacycline (Fig 4d). In the same way, 8 µg/mL anhydrodemeclocycline was 
sufficient to cause a fourfold increase in sensitivity to tetracycline and a twofold increase in 
sensitivity to tigecycline, eravacycline, or omadacycline. Thus, this strategy has promise for 
restoring the efficacy of tetracycline antibiotics, including next-generation tetracyclines, against 
bacteria that resist tetracycline through inactivation.  
 
3.3 Materials and Methods 
3.3.1 Identification of candidate tetracycline inactivators in sequenced 
functional selections 
In order to identify additional tetracycline inactivators, we queried previously sequenced 
functional selections of human gut, animal gut, latrine, and soil metagenomes3,4,7,23,58,103 
[GenBank accession numbers: JX009202-JX009380, KJ691878-KJ696532, KU605810-
KU608292, KF626669-KF630360, KX125104-KX128902, KU543693-KU549046]. 
Functionally selected contigs were annotated using Resfams122 as previously described3, and 
annotations were queried for putative tetracycline inactivating function based on string matches 
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to one of the following keywords in Pfam and TIGRfam annotations: “FAD dependent 
oxidoreductase”, “oxidoreductase”, “FAD binding domain”.  
3.3.2 Construction of maximum likelihood phylogenies 
A multiple sequence alignment of predicted tetracycline inactivating enzymes was created with 
MAFFT using the L-INS-i method394. A maximum likelihood phylogeny was then constructed 
using RAxML with GAMMA model of rate heterogeneity and JTT empirical base frequencies 
with 100 bootstraps395. Trees were visualized and decorated with metadata using iTol 396.  
3.3.3 Subcloning predicted tetracycline inactivators from metagenomic source 
Specific predicted tetracycline inactivators were selected for subcloning for downstream 
phenotypic analysis if they met each of the following criteria: (1) the open reading frame 
contained a start codon; (2) the open reading frame contained a stop codon; and (3) the open 
reading frame was greater than 1000 base pairs but less than 1500 base pairs. Tet(47-56) and 
Tet(X) had previously been subcloned29. Additional predicted tetracycline inactivators were 
amplified from their initial metagenomic source using Phusion Hi-Fidelity Polymerase 
(ThermoFisher) and primers as specified in Supplemental Table 3.1. Amplicons were ligated into 
pZE21 at the KpnI/HindIII sites using Fast-Link DNA Ligase (Lucigen) and transformed into E. 
coli MegaX DH10β cells (Invitrogen) via electroporation. The orientation and sequence of all 
inserts was confirmed by Sanger sequencing prior to phenotypic analyses.  
3.3.4 Antimicrobial susceptibility testing by microbroth dilution 
Antibiotic susceptibility testing was performed in E. coli MegaX cells (Invitrogen) bearing the 
pZE21 expression vector with the tetracycline inactivating gene of interest. Minimum inhibitory 
concentrations were determined according to Clinical and Laboratory Standards Institute (CLSI) 
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procedures 339 using Mueller-Hinton broth with 50 µg/mL kanamycin and a range of tetracycline 
antibiotic concentrations profiled via absorbance measurements at 600nm (OD600) at 45 minute 
intervals using the Synergy H1 microplate reader (Biotek Instruments, Inc) for 48 hours at 37ºC 
and scored by eye following 20 hours of growth at 37ºC. 
3.3.5 Pseudomonas aeruginosa genomic DNA isolation 
1.5 mL TSB was inoculated from isolate glycerol stocks and grown overnight at 37˚C with 
shaking. DNA was extracted using the BiOstic Bacteremia DNA Isolation Kit (MoBio 
Laboratories) following manufacturer’s protocols.  Genomic DNA was quantified using a Qubit 
fluorometer dsDNA BR Assay (Invitrogen) and stored at -20˚C. 
3.3.6 Pseudomonas aeruginosa isolate sequencing library preparation 
Genomic DNA was diluted to a concentration of 0.5 ng/µL prior to sequencing library 
preparation. Libraries were prepared using a Nextera DNA Library Prep Kit (Illumina) following 
the modifications described in Baym et al, 2015342. Libraries were purified using the Agencourt 
AMPure XP system (Beckman Coulter) and quantified using the Quant-iT PicoGreen dsDNA 
assay (Invitrogen). For each sequencing lane, 10 nM of approximately 300 samples were pooled 
three independent times. These pools were quantified using the Qubit dsDNA BR Assay and 
combined in an equimolar fashion. Samples were submitted for 2×150 bp paired-end sequencing 
on an Illumina NextSeq High-Output platform at the Center for Genome Sciences and Systems 
Biology at Washington University in St. Louis with a target sequencing depth of 1 million reads 
per sample.  
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3.3.7 Assembly and annotation of Psuedomonas aeruginosa genome 
Prior to all downstream analysis, Illumina paired end reads were binned by index sequence. 
Adapter and index sequences were trimmed using Trimmomatic v0.36343 using the following 
parameters: java -Xms2048m -Xmx2048m -jar trimmomatic-0.33.jar PE -phred33 
ILLUMINACLIP: NexteraPE-PE.fa:2:30:10:1:true. Contaminating human reads were removed 
using DeconSeq349 and unpaired reads were discarded. Reads were assembled using SPAdes350 
with the following parameters: spades.py -k 21,33,55,77 –careful. Contigs less than 500 bp were 
excluded from further analysis. Assembly quality was assessed using QUAST351. Average 
coverage across the assembly was calculated by mapping raw reads to contigs using bbmap 
(https://jgi.doe.gov/data-and-tools/bbtools/)397. Genomes were annotated using Prokka352 with 
default parameters. 
3.3.8 Antimicrobial susceptibility testing for Pseudomonas aeruginosa 
Susceptibility testing was performed using the Kirby-Bauer disk diffusion method on Mueller-
Hinton agar (Hardy Diagnostics) in accordance with CLSI standards. Pseudomonas aeruginosa 
ATCC 27853 was used as a quality control.  
3.3.9 Cloning, expression and purification of tetracycline-inactivating enzymes 
All genes encoding tetracycline-inactivating enzymes were cloned into the pET28b(+) vector 
(Novagen) at BamHI and NdeI restriction sites. Constructs were transformed into BL21-Star 
(DE3) competent cells (Life Technologies). Cells harboring the plasmid were grown at 37ºC in 
LB medium containing a final concentration of 0.03 mg/mL kanamycin. Once cells reached an 
OD600 of 0.6, cells were cooled to 15 ºC and induced with 1 mM IPTG overnight. After this 
period, cells were harvested by centrifugation at 4000 rpm for 10 min at 4 ºC. Cell pellets were 
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suspended in 10 mL of 50 mM Tris (pH 8.0), 100 mM NaCl, 10 mM imidazole (pH 8.0), 1 mM 
PMSF, and 5 mM BME per 1 liter of LB medium and stored at -80ºC.  
Cells were thawed in the presence of 0.25 mg/mL lysozyme and disrupted using sonication on 
ice for 60 seconds. The cell extract was obtained by centrifugation at 13,000 rpm for 30 min at 4 
ºC and was applied onto nickel rapid run agarose beads (Goldbio) equilibrated with wash buffer 
(50 mM Tris (pH 8.0), 150 mM NaCl, 20 mM imidazole (pH 8.0), and 5 mM BME). The wash 
buffer was used to wash the nickel column three times with five column volumes. After washing, 
protein was eluted with five column volumes of elution buffer (wash buffer with 300 mM 
imidazole). The protein sample was further purified by gel chromatography using a HiLoad 
16/600 Superdex 200pg column (GE Healthcare) equilibrated with 10 mM Tris (pH 8.0), 150 
mM NaCl, 5 mM dithioerythritol (DTT). The fractions containing the protein of interest were 
pooled and concentrated using a 30K MWCO Amicon centrifugal filter (Millipore). 
3.3.10 In vitro tetracycline inactivation assays 
Reactions were prepared in 100 mM TAPS buffer with 100 µM substrate, 14.4 µM enzyme, and 
an NADPH regenerating system consisting of the following components (final concentrations): 
glucose-6-phosphate (40mM), NADP+ (4mM), MgCl2 (1mM), and glucose-6-phosphate 
dehydrogenase (4U/ml). The regeneration system was incubated at 37ºC for 30 minutes to 
generate NADPH before use in reactions. Reactions were sampled at various timepoints, and 
quenched in four volumes of an acidic quencher consisting of equal parts acetonitrile and 0.25 M 
HCl.  
Products generated from enzymatic inactivation of both tetracycline and chlortetracycline were 
separated by reverse phase HPLC using a Phenomenex Luna C18 column (5µm, 110 Å, 
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2×50mm) and 0.1% trifluoroacetic acid in water (A) and acetonitrile (B) as mobile phase.  
Injections of 25µl sample volume were eluted using a linear gradient from 25%B to 75%B over 
14 minutes at a flow rate of 1ml/min. 
3.3.11 Kinetic characterization of tetracycline inactivation 
The optimal enzyme concentration for steady-state kinetics assays was determined by varying 
the concentration of enzyme while keeping chlortetracycline and NADPH concentration 
constant. 0.4 μM enzyme was found to give linear slopes for all concentrations of substrate 
tested, and was used as the enzyme concentration for all kinetics experiments.   
Reactions were prepared in 100 mM TAPS buffer at pH 8.5 with 0-160 µM substrate, 1.6 mM 
NADPH, and 0.4 µM enzyme. UV-visible spectroscopy measurements were taken in triplicate at 
400nm wavelength light with a Cary 60 UV/Vis system (Agilent) for 10 minutes at room 
temperature. Initial reaction velocities were determined by linear regression using the Agilent 
Cary WinUV Software, and fitted to the Michaelis-Menten equation: 
 
using GraphPad Prism 6.  
3.3.12 LC-MS characterization of chlortetracycline degradation products 
Reactions were prepared in 100 mM phosphates buffer at pH 8.5 with 1mM CTC, 0.5 mM 
NADPH, 5 mM MgCl2 and 0.4 µM Tet(55). After 10 minutes, the reaction was centrifuge 
filtered for 10 minutes using a Millipore Amicon Ultracel (3 kDa MW cutoff) to remove enzyme. 
Prior to centrifugation, filters were triply rinsed with phosphate buffer to remove excess glycerol. 
The filtrate was collected and analyzed by LC-MS using an Agilent 6130 single quadrupole 
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instrument with G1313 autosampler, G1315 diode array detector, and 1200 series solvent 
module. Reaction products were separated using a Phenomenex Gemini C18 column, 50 × 2 mm 
(5 µm) with guard column cassette was used with a linear gradient of 0% acetonitrile + 0.1% 
formic acid to 95% acetonitrile + 0.1% formic acid over 14 min at a flow rate of 0.5 mL/min 
prior to analysis by electrospray ionization.  
3.3.13 In vitro characterization of anhydrotetracycline inhibition 
IC50 values were determined for TE_7F_3 by measuring the initial velocity of tetracycline 
degradation in the presence of varying concentrations of anhydrotetracycline or 
anhydrodemeclocycline. The concentrations of tetracycline and NADPH were kept constant at 
25 μM and 500 μM, respectively. Assays were prepared by combining all components except for 
enzyme and equilibrating to 25°C for five minutes. After the addition of enzyme, absorbance at 
400 nm was measured for five minutes. All measurements were taken in triplicate. The final 
concentrations for assay components were 100 mM TAPS buffer (pH 8.5), 25 μM tetracycline, 
500 μM NADPH, 16 mM MgCl2, 0.4 μM enzyme, and 0.05 – 150 μM inhibitor. IC50 values were 
determined by plotting the log of anhydrotetracycline concentration against v0 in GraphPad 
Prism 6.  
3.4 Discussion 
Our results indicate that tetracycline inactivation is a resistance mechanism that is 
widespread in environmental and human associated metagenomes. We describe two distinct 
clades of tetracycline resistance genes, and demonstrate that genotypes and resistance 
phenotypes are correlated with microbial habitat of origin. Amongst the gut-derived enzymes 
reported herein, we also describe the first report of resistance by inactivation to eravacycline and 
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omadacycline (recently approved for human use) in a clinical isolate. We identify TE_7F_3 in a 
clinical isolate of Pseudomonas aeruginosa, indicating that this mechanism of resistance has 
already disseminated to the clinical setting. Lastly, we show that inhibition of TE_7F_3 by 
anhydrotetracycline and derivatives may be a promising strategy for restoring efficacy of next 
generation tetracyclines in the face of high-level tetracycline resistance. The results presented 
herein motivate continued surveillance of tetracycline resistance by inactivation in environmental 
and clinical settings. Similarly, this work underscores the value in proactive screening of 
antimicrobial agents in the pipeline for resistance determinants present in diverse microbial 
communities such that strategies to minimize their eventual clinical impact can be explored.   
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3.6 Supplementary Figures 
 
 
Supplementary Figure 3.1: TE_7F_3 inactivates next-generation tetracyclines by 
monooxygenation. In vitro reactions containing purified TE_7F_3 (Tet(3)), NADPH, and 
tigecycline (a), omadacycline (b), or eravacycline (c) were assayed by absorbance scans taken at 
one minute intervals. The rainbow pattern depicts a spectral change over time. Decrease in 
absorbance over time from 360 nm to 400 nm indicates enzymatic disruption of the characteristic 
tetracycline β-diketone chromophore. In the case of tigecycline (d), omadacycline (e), and 
eravacycline (f), the product of enzymatic modification is consistent with monooxygenation. 
Plots show the relative extracted ion counts of the parent tetracycline (blue curves; m/z for 
[M+H]+ equal to 586, 557, 559, respectively ) or the monooxygenated product (orange curves; 
m/z for [M+H]+ equal to 602, 573, 575, respectively).
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Supplementary Table 3.1: Primers used in this study 
Primer sequence (5'  3') Designed specificity 
ATGACTTTGCTAAAAAATAAAAAAATTA TE_7F_Contig_3 (452_1588) 
TTATAGATTCATTAGTTTTTGGAATGA TE_7F_Contig_3 (452_1588) 
ATGAATTTACTAAACAATAAAAAAGTTACA TG_0402_Contig_27 (425_1561) 
TTATAGATTCATTAGTTTTTGGAATGA TG_0402_Contig_27 (425_1561) 
ATGACAATGCGAATAGATACAGACA TE_0402_Contig_1789 (2156_3322) 
TTATACATTTAACAATTGCTGAAACG TE_0402_Contig_1789 (2156_3322) 
ATGACTTTGCTAAAAAATAAAAAAATT TE_0402_Contig_1211 (2189_3325) 
TTATAGATTCATTAGTTTTTGGAATGA TE_0402_Contig_1211 (2189_3325) 
ATGACAATGCGAATAGATACAGACA TG_0402_Contig_45 (861_2027) 
TTATACATTTAACAATTGCTGAAACG TG_0402_Contig_45 (861_2027) 
ATGACAATGCGAATAGATACAGACA TG_0401_3a_Contig_236 (181_1347) 
TTATACATTTAACAATTGCTGAAACG TG_0401_3a_Contig_236 (181_1347) 
ATGACTTTACTAAAACATAAAAAAATTACA TE_6F_Contig_7 (1101_2237) 
TTATAGATTCATTAGTTTTTGGAATGA TE_6F_Contig_7 (1101_2237) 
ATGACTAGCGATAAGAACCCT S08_TE.2:1046-1630  Contig:2    




Chapter 4: Plasticity, dynamics, and 






While tetracyclines are an important class of antibiotics in agriculture and the clinic, their 
efficacy is threatened by increasing resistance. Resistance to tetracyclines can occur through 
efflux, ribosomal protection, or enzymatic inactivation. Surprisingly, tetracycline enzymatic 
inactivation has remained largely unexplored despite providing the distinct advantage of 
antibiotic clearance. The tetracycline destructases are a recently-discovered family of 
tetracycline-inactivating flavoenzymes from pathogens and soil metagenomes with a high 
potential for broad dissemination. Here, we show tetracycline destructases accommodate 
tetracycline-class antibiotics in diverse and novel orientations for catalysis, and antibiotic 
binding drives unprecedented structural dynamics facilitating tetracycline inactivation. We 
identify a key inhibitor binding mode that locks the flavin adenine dinucleotide cofactor in an 
inactive state, functionally rescuing tetracycline activity. Our results reveal the potential of a 
novel tetracycline/tetracycline destructase inhibitor combination therapy strategy to overcome 




Antibiotics revolutionized the treatment of infectious diseases, enabling significant 
reductions in deaths due to infection over the past 80 years. However, the prolific anthropogenic 
use of these life-saving chemotherapeutics in the clinic and agriculture has also selected for a 
steady increase in antibiotic resistance in both benign and pathogenic bacteria21. Regrettably, 
increasing antibiotic resistance has been accompanied by a decrease in development and 
regulatory approval of new antibiotics157, threatening the end of the modern antibiotic era. The 
likely origin of virtually all clinical antibiotic resistance genes are environmental microbial 
communities, which harbor ancient and diverse resistomes4,15,20,58,94,398,399. Indeed, environmental 
reservoirs have been identified for a number of recently-emerged and rapidly-disseminating 
resistance genes representing urgent clinical threats (e.g. plasmid-borne and chromosomally-
acquired carbapenem88, colistin75, and quinolone93  resistance genes). This motivates the need to 
better understand resistance mechanisms of environmental origin before they are widespread in 
the clinic and ultimately guide new drug discovery and therapeutic strategies that mitigate 
emerging mechanisms of resistance.  
Despite growing resistance, the tetracyclines remain among the most widely used 
antibiotics in clinical and agricultural settings368. Indeed, tetracyclines ranked in the top three 
antibiotics in both clinical prescriptions in the United States in 2010 (representing 15% of all 
antibiotic prescriptions) and in global sales for animal use in 2009 ($500 million in sales)400. 
Furthermore, next-generation derivatives are currently fueling a tetracycline renaissance, with 
the 2005 clinical approval of tigecycline134 and ongoing late-stage clinical trials of eravacycline 
and omadacycline139,140 justifying urgent interrogation of emerging and novel tetracycline 
resistance mechanisms. Previously, tetracycline resistance was thought to occur almost 
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exclusively by two mechanisms: ribosomal protection or antibiotic efflux368,371. However, an 
alternate mechanism – enzymatic inactivation – has been documented in benign and pathogenic 
bacteria, such as the enzyme Tet(X)28,100,136,385,401-405. We recently identified a new family of 
tetracycline-inactivating enzymes through functional metagenomic selections for tetracycline 
resistance from 18 grassland and agricultural soils58. We showed that these nine proteins, Tet(47-
55), were able to enzymatically inactivate tetracycline, resulting in 16-64 fold increases in 
minimum inhibitory concentration (MIC)406 when expressed in E. coli.  
Here, we pursued a multi-pronged structural, in vitro enzymatic, and bacterial phenotypic 
investigation of the emerging tetracycline destructases. We show that a recently identified 
tetracycline destructase confers tetracycline resistance to a known soil-derived human pathogen. 
We hypothesized that structural characteristics of tetracycline-inactivating enzymes would reveal 
useful information about their unique activity profiles and lead to the rational design of 
inhibitors, similar to the widely employed β-lactamase inhibitors110. Discerning the structural and 
mechanistic details of conformational or transitional states in target proteins has been crucial for 
the rational design of successful inhibitors in a number of cases, as exemplified by inhibitors of 
HIV-1 protease407 and mechanistic inhibitors of glycosyltransferases that involve significant 
conformational movement in the active site408. Through structure-function analyses of four 
tetracycline destructases alone and in complex with tetracycline-class ligands, we present the 
molecular basis for unexpected structural dynamics in tetracycline destructases driven by 
antibiotic binding. These unprecedented changes provide a novel mechanism for inhibition that 





4.2.1 Tetracycline inactivation by Legionella longbeachae  
The tetracycline destructase family was initially discovered by functional metagenomic 
selection for tetracycline resistance from soil samples58. We observed that the soil-derived 
human pathogen Legionella longbeachae, the causative agent of Pontiac Fever and Legionnaires’ 
Disease409,410 encodes a homolog to the tetracycline destructases, termed tet(56). Like the other 
tetracycline destructases, Tet(56) is able to inactivate tetracycline in vitro and expression of 
tet(56) in E. coli confers high-level tetracycline resistance406.  To confirm that tet(56) is a 
functional resistance determinant in L. longbeachae, we deleted the gene and examined the strain 
for changes in drug sensitivity. Deletion of the chromosomally-encoded tet(56) resulted in an 
increase in tetracycline sensitivity to L. longbeachae (Fig. 4.1). Moreover, overexpression of 
Figure 4.1: Dose-response curve showing the effect of tetracycline on 
growth of Legionella strains. Deletion of tet(56) from L. longbeachae causes 
an increase in tetracycline sensitivity. Complementation with a plasmid 
containing the tet(56) insert rescues the tetracycline resistance phenotype 
compared to strains bearing the empty-vector control. Furthermore, introduction 
of the complementing vector into L. pneumophila, which lacks a tet(56) 
homolog, results in an increase in tetracycline resistance. Data are represented 
as mean ± s.d. of three technical replicates. 
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tet(56) in the L. longbeachae Δtet(56) strain resulted in increased tetracycline resistance to levels 
even higher than the wild type L. longbeachae strain containing vector. Finally, expression of 
tet(56) in L. pneumophila, a Legionella strain lacking a tetracycline destructase homolog, also 
dramatically increased the level of tetracycline resistance of the strain. These results demonstrate 
that tetracycline destructases are already functional in a known human pathogen and their 
introduction into a related pathogen would lead to increased antibiotic resistance.   
4.2.2 Tet(50,51,55,56) crystal structures reveal a conserved domain 
architecture and a dynamic substrate loading channel 
We began our structural analysis by solving the X-ray crystal structures of four tetracycline-
inactivating enzymes: Tet(50), Tet(51), Tet(55), and Tet(56) (Fig. 4.2a and Supplementary Fig. 
4. 1a-e). Although only sharing ~24% amino acid identity with the previously crystallized Tet(X) 
and requiring initial structure determination via experimental phasing (Supplementary Table 
4.1), Tet(50,51,55,56) and Tet(X) exhibit a similar overall architecture. Each possesses a flavin 
adenine dinucleotide (FAD)-binding Rossmann-type fold domain, a tetracycline-binding domain, 
and a C-terminal -helix that bridges the two domains (Fig. 4.2a-d). Surprisingly, each of the 
new structures revealed an unexpected second -helix at the C-terminus (Fig. 4.2a-c) that is not 
present in Tet(X) (Fig. 4.2d) and could not be predicted based on their primary sequences. 
Comparisons to co-crystal structures of Tet(X) in complex with either chlortetracycline [PDB 
2Y6R] or iodtetracycline [PDB 2Y6Q]385 reveal that this helical extension comes in close 
proximity to the tetracycline binding site (Fig. 4.2d), contributing to the formation of a substrate-
loading channel. In the Tet(50) crystal structure, we observed two distinct monomers in the 
asymmetric unit. In Tet(50) monomer A (Fig. 4.2b), this substrate-loading channel is blocked by 





 allowing tetracycline to access the substrate-binding site (Fig. 4.2g,h). The absence of the 
second -helix in Tet(X) results in a widely exposed entrance to the substrate-binding site (Fig. 
4.2i,j), which likely contributes to alternate substrate specificity of this enzyme.  
4.2.3 Two FAD conformations are linked to the accessibility of the substrate 
loading channel 
Tetracycline destructases are flavoenzymes that utilize an FAD cofactor to degrade their 
substrate411,412. These enzymes bind FAD in two distinct conformations that are important for 
catalysis413. Both conformations are captured by the structures presented here (Supplementary 
Fig. 4.1f-j). Tet(50) monomer A, which has a closed substrate-loading channel, bound FAD in an 
IN conformation (Fig. 4.2k,l). In this conformation the reactive isoalloxazine moiety of the FAD 
Figure 4.2: Crystal structures of Tet(50), Tet(51), Tet(55), and Tet(56) reveal a conserved 
architecture, structural changes that enable substrate loading channel accessibility, and 
two conformations of the FAD cofactor. (a) Overlay of the Tet(50) monomer A, Tet(50) 
monomer B, Tet(51), Tet(55), and Tet(56) crystal structures. The FAD-binding domain 
(salmon), the tetracycline-binding domain (pale green), the first (cyan) and second (deep teal) C-
terminal α-helixes, and FAD molecules (orange) are shown. (b)  Cartoon depiction of Tet(50) 
monomer A. (c) Cartoon depiction of Tet(50) monomer B. (d) A previously published crystal 
structure of Tet(X) with chlortetracycline (yellow) bound – PDB ID 2Y6R. Tet(X) does not 
possess the second C-terminal α-helix. (e) Surface representation of Tet(50) monomer A reveals 
that the substrate-loading channel is closed. Rotated 180º along the y-axis compared to b. (f) 
Zoomed in view of the closed substrate-loading channel in Tet(50) monomer A. (g) Surface 
representation of Tet(50) monomer B reveals that the substrate-loading channel is open. Rotated 
180º along the y-axis compared to c. (h) Zoomed in view of the open substrate-loading channel 
in Tet(50) monomer B. (i) Surface representation of Tet(X) reveals that absence of the second C-
terminal α-helix  results in a wide-open substrate-binding site. Rotated 180º along the y-axis 
compared to d. (j) Zoomed in view of the wide open substrate-binding site in Tet(X). (k) The 
FAD cofactor adopts the IN conformation in Tet(50) monomer A, characterized by a 12.3 Å 
distance between the C8M and C2B atoms of the FAD molecule. (l) In Tet(50) monomer A, 
FAD is IN and the substrate-loading channel is closed. (m) The FAD cofactor adopts the OUT 
conformation in Tet(50) monomer B, characterized by a 5.2 Å distance between the C8M and 
C2B atoms of the FAD molecule. (n) In Tet(50) monomer B, FAD is OUT, and the channel is 
open. (o) The IN conformation of FAD allows for substrate catalysis. The OUT conformation of 
FAD allows for regeneration of the reduced FAD for the next round of catalysis. The green area 




is stretched away from the adenosine moiety and into the substrate-binding site. This allows 
reaction with molecular oxygen to produce an FAD-hydroperoxide intermediate that is in close 
proximity to the tetracycline substrate (the C4a of FAD is ~5.9 Å away from the C11a substrate 
hydroxylation site in Tet(X)), allowing for hydroxylation and subsequent spontaneous 
degradation of the tetracycline substrate (Fig. 4.2o)414. After catalysis, FAD flips away from the 
substrate-binding site, adopting the OUT conformation. Tet(50) monomer B, which has an open 
substrate-loading channel, binds FAD in an OUT conformation where the isoalloxazine moiety is 
bent towards the adenosine and away from the substrate-binding site (Fig. 4.2m,n). This 
conformational change allows for products to be released through the open channel and positions 
the oxidized FAD for reduction by NADPH in a distinct NADPH binding site during cofactor 
regeneration (Fig. 4.2o and Fig. 4.3a)414. After reduction, FAD is poised to flip back to the IN 
conformation for the next round of catalysis upon substrate binding. Our observation of FAD in 
both IN and OUT conformations imply that FAD exists in an equilibrium between the two states 
in the absence of substrate binding. 
4.2.4 Chlortetracycline binds to Tet(50) in an unprecedented mode, driving 
FAD conversion and substrate loading channel closure 
Since accessibility of the substrate-loading channel appeared to be dependent on the 
conformation of FAD in the Tet(50) crystal structures, we soaked Tet(50) with various 
tetracycline compounds. Surprisingly, chlortetracycline binds to Tet(50) in a ~180° rotated 
orientation compared to the orientation in which chlortetracycline and other tetracycline 
substrates (e.g. iodtetracycline, minocycline, tigecycline) bind Tet(X)385,415 (Fig. 4.3a-d and 
Supplementary Fig. 4.2). Tetracycline compounds have a four-ring system (labeled A-D (Figure 
3a,c), and have a distinctive three-dimensional architecture with a significant bend between rings 
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A and B, allowing for unambiguous modeling into the electron density. In the 
Tet(X)+chlortetracycline structure, the chlortetracycline D-ring with the attached chlorine faces 
away from the substrate-binding site and towards bulk solvent (Fig. 4.3c,d). This places the C11a 
substrate hydroxylation site of ring C proximal to FAD. In the Tet(50)+chlortetracycline 
structure, the D-ring chlorine now faces FAD with the dimethylamine group of the A-ring 
making van der Waals contacts with Phe-95 from the flexible loop, Val-348 from the first C-
terminal -helix, and Ile-371 from the second C-terminal -helix (Fig. 4.3a,b). Surprisingly, this 
new orientation positions C11a of chlortetracycline away from C4a of FAD.  
We observed a second notable characteristic when comparing the structures of Tet(50) in 
the presence or absence of chlortetracycline. In the absence of chlortetracycline, Tet(50) 
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monomer A had FAD in an IN conformation with a closed channel (Fig. 4.2e,f,k,l) and monomer 
B had FAD in an OUT conformation with an open channel (Fig. 4.2g,h,m,n). However, in the 
presence of chlortetracycline, we only detected bound chlortetracycline in monomer B, which 
now had FAD in an IN conformation and a closed channel (Fig. 4.3e-h). Thus, substrate binding 
to Tet(50) monomer B induced a conformational switch from FAD OUT to FAD IN and loop 
closure (Fig. 4.3h,i). 
4.2.5 Tetracycline destructases degrade chlortetracycline despite the novel 
binding mode 
Due to the unanticipated orientation of chlortetracycline binding, we examined whether 
the tetracycline destructases could degrade chlortetracycline. Enzymatic reactions were analyzed 
at several time points by reverse-phase high-performance liquid chromatography (HPLC). We 
Figure 4.3: Crystal structure of Tet(50) in complex with chlortetracycline reveals an 
unexpected mode of binding to the tetracycline-binding site that drives substrate loading 
channel closure and FAD conversion. (a) Chlortetracycline binds to the active site of Tet(50) 
in a ~180º rotated orientation relative to Tet(X)+chlortetracycline such that the D-ring of 
chlortetracycline is proximal to FAD in the IN conformation (orange). A model of FAD OUT 
(grey) is overlaid as found in the Tet(50) monomer B in the absence of chlortetracycline (see Fig. 
4.2m and 4.2n). (b) The rotated orientation of chlortetracycline in the Tet(50)+chlortetracycline 
structure is supported by van der Waals contacts provided by Val-348 (cyan) and Ile371 (deep 
teal) from the two C-terminal α-helices in Tet(50) to the dimethylamine group of the A-ring of 
chlortetracycline. Additionally, Phe-95 from the flexible loop makes contacts with the 
dimethylamine group and closes off the substrate-binding site. (c) Tet(X) with chlortetracycline 
bound with D-ring distal to FAD in the IN conformation. The substrate-binding site is widely 
exposed to bulk solvent. (d) Residue Met-375 from the first C-terminal α-helix in Tet(X) (cyan) 
makes van der Waals contacts to the D-ring of chlortetracycline. A second C-terminal helix (red 
dashed circle, colored in deep teal) does not exist in Tet(X), and substrate can potentially enter 
from various possible directions. (e) Surface representation of Tet(50)+chlortetracycline 
monomer A reveals the substrate-loading channel is closed. (f) The substrate-loading channel is 
also closed in Tet(50)+chlortetracycline monomer B. (g) In Tet(50)+chlortetracycline monomer 
A, FAD is IN, the loop is closed, and no chlortetracycline is bound. (h) In 
Tet(50)+chlortetracycline monomer B, FAD is IN, the loop is closed, and chlortetracycline is 
bound. (i) While the substrate-loading channel is open in Tet(50) monomer B, with FAD OUT, 
in the absence of chlortetracycline (grey), the flexible loop containing Phe-95 closes over the 




observed the time- and enzyme-dependent degradation of chlortetracycline by Tet(50) and 
Tet(X) (Fig. 4.4a). Kinetic parameters of enzymatic inactivation were determined by monitoring 
in vitro reaction progress using absorbance at 400 nm. The catalytic efficiency of Tet(50) was 
five times higher than that of Tet(X) (kcat/KM values of 0.55 and 0.11 µM
-1min-1, respectively) 
(Supplementary Table 4.2). This increased efficiency is primarily due to increased turnover as 
the apparent KM values are comparable between Tet(50) (6.3±2.0 µM) and Tet(X) (7.9±2.7 µM) 
in spite of different substrate binding orientations. Tet(55) and Tet(56) also degraded 
chlortetracycline in vitro with 4-fold and 15-fold greater efficiency than Tet(X), respectively 
(Supplementary Table 4.2). Furthermore, tet(50,51,55,56,X) each confer chlortetracycline 
resistance when expressed in E. coli at levels 16-32 fold greater than the vector-only control 
(Supplementary Table 4.3). As a result, despite employing a distinct mode of substrate binding, 
Tet(50,51,55,56) are able to degrade chlortetracycline more efficiently than Tet(X).    
Tetracycline inactivation by Tet(X) occurs via catalysis at C11a resulting in a product of 
m/z 461406. Because chlortetracycline binds Tet(50) in an alternative mode that positions C11a 
far away from the reactive flavin peroxide moiety, we sought to characterize the degradation 
product to establish substrate hydroxylation. Enzymatic reactions were analyzed by liquid 
chromatography-mass spectrometry (Supplementary Fig. 4.6), and found to convert 
chlortetracycline (m/z 479) to an oxidation product with an m/z of 467. This is in contrast to the 
m/z 461 monooxygenation product observed for tetracycline406, consistent with an alternate 
binding mode for chlortetracycline. To further characterize this product, reactions were subjected 
to high resolution mass spectrometry. Reactions with each enzyme assayed (Tet(50,55,56)) 
yielded a primary product with an exact m/z of 467.12 (Supplementary Fig. 4.7). In the 
alternative binding mode, the nonplanarity of the chlortetracycline substrate positions the 
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Figure 4.4: Chlortetracycline is degraded by tetracycline destructases despite the unusual 
binding mode. (a) HPLC chromatograms show the time and enzyme dependent consumption of 
chlortetracycline. (b) High-resolution MS-MS analysis of the tetracycline destructase reaction 
with chlortetracycline supports clean conversion to the m/z 467 oxidation product. MS-MS 
spectrum of the m/z 467 ion from the Tet(55) reaction with proposed fragmentation pathway. 
The closest reactive carbons to C4a of the FAD cofactor are C3 (c) and C1 (d) of the 
chlortetracycline A ring, both of which are closer than C11a (e), the hydroxylation site observed 
in Tet(X) mediated chlortetracycline degradation. (f) Two proposed mechanisms for degradation 
of chlortetracycline, consistent with MS and crystallographic data. Addition of the C4a flavin 
peroxide to C3 generates intermediate 1, which can undergo epoxide formation to give an 
equilibrating mixture of intermediates 2 and 3. Intermediate 3 can also be generated via 
intermediate 4 arising from direct attack of the C4a flavin peroxide on carbonyl C1. Intermediate 
3 can rearrange to cycloheptanone intermediate 5. Fragmentation will give intermediate 6 via 
loss of carbon monoxide followed by ring contraction resulting in formation of product 7 with 
m/z 467 for [M+H]+. 
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reactive A-ring C3 in closest proximity to the flavin cofactor. Notably, the C3 is 6.1 Å (Fig. 4.4c) 
and the C1 carbonyl is 7.4 Å (Fig. 4.4d) from the C4a of the flavin cofactor. These distances are 
similar to C11a of chlortetracycline and C4a of FAD in the Tet(X)+chlortetracycline structure385, 
and well within the C4a-reactive atom distances observed for flavin monooxygenases416. The 
C11a in the Tet(50)+chlortetracycline, on the other hand, is on the opposite side of the molecule 
and 7.9 Å away (Fig. 4.4e). Accordingly, we propose a mechanism in which the flavin peroxide 
can attack C3 of the chlortetracycline A ring, yielding intermediate 1 (Fig. 4.4f). Spontaneous 
epoxide formation gives intermediates 2 and 3, which rearranges to a cycloheptanone 
intermediate 5 via Baeyer-Villiger ring expansion. Expulsion of carbon monoxide yields 
intermediate 6, and ring contraction yields oxidation product 7, with an m/z of 467. Alternatively, 
intermediate 3 can be formed by flavin peroxide attack of C1 of the chlortetracycline A ring, via 
intermediate 4, and then similarly continuing through products 5-7. The final product 7 is 
consistent with the fragmentation pattern observed in tandem mass spectrometry (Fig. 4.4b). 
Similar oxidative cascades proceeding through Baeyer-Villiger reactions have been observed in 
the biosynthesis of the cyclic type II polyketide mithramycin by the flavin monooxygenase 
MtmOIV417. The discovery of alternative substrate binding modes and characterization of 
degradation products demonstrates the plasticity of tetracycline destructases for adapting 
flavoenzyme-mediated degradation chemistries to achieve resistance in the presence of diverse 




4.2.6 Anhydrotetracycline is a mechanistic and competitive inhibitor that 
locks the FAD in an unproductive conformation 
Due to the global dissemination of the β-lactamases, nearly all β-lactam antibiotics are 
co-developed with β-lactamase inhibitors110, an approach that has successfully prolonged their 
clinical utility. We reasoned that a similar strategy might be useful to counteract tetracycline 
resistance by inactivation, and therefore sought to identify small molecule inhibitors of these 
enzymes. Previously, we observed that anhydrotetracycline, a key biosynthetic precursor418 and 
degradation product419 of tetracycline with poor antibiotic activity was not degraded by Tet(47-
56)406. Nonetheless, it is known to be an effector of tetracycline producers and tetracycline-
resistant bacteria by inducing expression of energetically expensive tetracycline efflux pumps, 
Figure 4.5: Anhydrotetracycline binds to the active site of Tet(50), trapping FAD in the 
unproductive OUT conformation. (a) Anhydrotetracycline binds the active site of Tet(50) and 
traps the FAD cofactor in the unproductive OUT conformation (orange) in monomer B. The IN 
conformation of FAD from monomer A is superimposed in grey for comparison, and sterically 
clashes with the D-ring hydroxyl of anhydrotetracycline. (b) Surface representation of 
Tet(50)+anhydrotetracycline reveals that the substrate-loading channel remains open, which 
corresponds to FAD locked in the OUT conformation. (c) In Tet(50)+anhydrotetracycline 
monomer B, FAD is OUT, the loop is open, and anhydrotetracycline is bound (not shown: in 
monomer A, FAD is IN, the loop is closed, no anhydrotetracycline is bound). (d) Residue Thr-
207 in Tet(50) makes van der Waals interactions with the planar 6-methyl group of 
anhydrotetracycline (aTC) (yellow) in the bound orientation, but would sterically clash with the 
6-methyl and 6-hydroxyl groups that branch from the C ring of tetracycline or chlortetracycline 




permitting tetracycline producers to survive and selecting against tetracycline resistance112. 
Based on the structural similarity to tetracycline and the intimate role that anhydrotetracycline 
plays in tetracycline biology, we hypothesized that anhydrotetracycline represents an 
evolutionarily-privileged chemical lead for inhibitor design. 
 We obtained a co-crystal structure of Tet(50) with anhydrotetracycline bound, and 
observed two unique features in comparison to our Tet(50)+chlortetracycline and the earlier 
Tet(X)+chlortetracycline structures. First, anhydrotetracycline binds to Tet(50) in a flipped 
orientation and in a position distinct from where chlortetracycline binds (Fig. 4.5a-c and 
Supplementary Fig. 4.3-4). The unique binding mode for anhydrotetracycline is enabled by the 
lack of a 6-hydroxyl group of ring C present in tetracycline or chlortetracycline (Fig. 4.5a).  
Without this substitution at the 6 position, the tetracycline gains additional aromatic stabilization. 
The resultant planar structure allows the 6-methyl group to make van der Waals interactions with 
a conserved Thr/Ser at residue position 207 in Tet(47-56) (Fig. 4.5d and Supplementary Fig. 4.4-
5). Thr-207 would cause a steric clash with the 6-methyl and 6-hydroxyl groups of ring C in 
tetracycline or chlortetracycline, explaining the distinct binding modes.  
The second interesting feature is that when anhydrotetracycline was bound, FAD was in 
the OUT conformation and the substrate-loading channel was open (Fig. 4.5b,c). The unique 
binding location of anhydrotetracycline locks the isoalloxazine moiety of FAD away from the 
substrate-binding site and sterically blocks the transition to the FAD IN conformation observed 
in the Tet(50)+chlortetracycline monomer B. This unexpected binding mode establishes a novel 
mechanism for inhibitors that stabilize the inactive OUT conformation of the FAD cofactor in 
flavoenzymes and prevents transition to the necessary FAD IN conformation for catalysis. 
148 
 
Therefore, anhydrotetracycline is a mechanistic inhibitor of the tetracycline destructases that also 
competitively blocks substrate binding. 
4.2.7 Anhydrotetracycline inhibits tetracycline destructases and functionally 
rescues tetracycline 
We examined the effect of anhydrotetracycline on tetracycline destructase activity in 
vitro. We performed in vitro enzymatic reactions in the presence or absence of 
anhydrotetracycline followed by HPLC. For clinical relevance, we first focused on Tet(56), the 
tetracycline destructase from pathogenic L. longbeachae. We observed the Tet(56)-dependent 
degradation of 0.1 mM tetracycline over time, as demonstrated by the decrease in the tetracycline 
peak (Fig. 4.6a).  However, in the presence of 1 mM anhydrotetracycline, the tetracycline peak 
does not change, indicating that tetracycline is not degraded (Fig. 4.6b). Similar results were 
observed for Tet(50,51,55,X) (Supplementary Fig. 4.8, Supplementary Table 4.4). We also 
monitored enzymatic inactivation of tetracycline using absorbance at 400 nm in the presence of a 
range of anhydrotetracycline concentrations. Anhydrotetracycline inhibited Tet(50,55,56) with 
IC50 values of 83.2±1.2 µM, 25.6±1.2 µM, and 37.1±1.1 µM, respectively (Fig. 4.6c). Thus, 
anhydrotetracycline prevents the enzyme-dependent degradation of tetracycline. Together with 
our structural data, this indicates a common mechanism of inhibition for tetracycline-inactivating 
enzymes, and establishes anhydrotetracycline as a lead compound that presents a flexible starting 
point for generating tetracycline destructase inhibitors with improved activity420. This inhibition 
strategy that stabilizes inactive cofactor states is widely applicable to the larger superfamily of 
flavoenzymes and offers new avenues for inhibiting any member of this superfamily, many of 
which have been implicated in human disease and represent promising targets for 
hypercholesterolemia and antifungal drugs421. 
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4.2.8 The novel inhibition mechanism restores tetracycline activity against 
tetracycline destructase-expressing bacteria 
Our data suggest that a tetracycline/tetracycline-destructase-inhibitor (e.g. 
anhydrotetracycline) combination therapy strategy could potentially be employed to rescue 
antibiotic activity of tetracyclines against bacteria that encode tetracycline-inactivating enzymes. 
Tet(X) and Tet(56) are of particular interest due to their clinical significance. tet(X) has been 
recently identified in a number of human pathogens, including 11 nosocomial uropathogens from 
Sierra Leone138 and 12 Acinetobacter baumannii isolates from a hospital in China137. We also 
showed that tet(56) is present and functional in L. longbeachae406 – a pathogen responsible for 
Figure 4.6: Anhydrotetracycline prevents enzymatic tetracycline degradation, functionally 
rescuing tetracycline antibiotic activity. (a) Tetracycline (TC) is degraded by Tet(56) in vitro 
HPLC chromatograms show in vitro reactions with UV detection at 363 nm and separation on a 
C18 column. (b) TC degradation is attenuated by the addition of an excess of aTC. (c) Dose-
dependent inhibition of Tet(50,51,56) activity by anhydrotetracycline. Velocity is determined by 
measuring tetracycline consumption via change in absorbance at 400 nm. Data are represented as 
mean ± s.d. of three technical replicates. (d) Dose-response curve showing effect of aTC on 
sensitivity of Tet(56)-expressing E. coli to TC in liquid culture. Data are represented as mean ± 
s.e.m. of three technical replicates. (e) TC and aTC synergistically inhibit growth of E. coli 
expressing Tet(56), FICI = 0.1875. Points show minimum inhibitory concentrations of two drugs 
in combination. Dashed line indicates the theoretical concentration of additive drug interaction. 




causing Pontiac Fever and Legionnaires’ Disease409,410. Accordingly, we tested whether 
anhydrotetracycline rescues tetracycline efficacy against E. coli expressing tet(56). Two µg/mL 
anhydrotetracycline caused a greater than 5-fold change in sensitivity of E. coli expressing 
tet(56) to tetracycline in liquid culture, as indicated by a change in IC50 from 47.4 to 8.27 µg/mL 
(Fig. 4.6d). Further, anhydrotetracycline and tetracycline acted synergistically to inhibit growth 
of E. coli expressing Tet(50,51,55,56), with fractional inhibitory concentration indices (FICI) of 
0.625, 0.5, 0.375 and 0.1875, respectively (Fig. 4.6e and Supplementary Fig. 4.9). Although 
anhydrotetracycline is not degraded by Tet(47-56), it is slowly degraded by Tet(X)406. However, 
anhydrotetracycline still was able to prevent tetracycline degradation by Tet(X) in vitro 
(Supplementary Fig. 4.8). Our proof of concept experiment, taken together with our structural 
and in vitro data, reveals that a co-administration strategy based on inhibition of tetracycline-
inactivating enzymes could be effective for the treatment of tetracycline-resistant bacterial 
infections. 
4.3 Materials and Methods 
4.3.1 Legionella plasmid construction 
The Tet(56) deletion plasmid, pJB7204, was constructed by amplifying 2 kb of DNA 
upstream and downstream of the Tet(56) ORF using primers JVP2913/JVP2910 and 
JVP2911/JVP2912 and Legionella longbeachae chromosomal DNA.  The PCR products were 
digested with SalI/NotI and NotI/SacI, respectively, and ligated into SalI/SacI-digested suicide 
vector pSR47S422.  The ligated product was transformed into EC100D::Δpir and selected on LB 
plates containing 20 µg/ml kanamycin.  The Tet(56) complementing clone, pJB7207, was 
constructed by amplifying the Tet(56) ORF using primers JVP2921/JVP2922 and Legionella 
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longbeachae chromosomal DNA.  The PCR product was digested with BamHI/SalI and cloned 
into BamHI/SalI-digested expression vector pJB1625 (Supplementary Table 4.5). 
4.3.2 Legionella strain construction 
The Tet(56) deletion strain, JV8858, was constructed by a traditional loop-in/loop-out 
strategy.  Briefly, the wild type Legionella longbeachae strain JV595 was transformed by 
electroporation with the ΔTet(56) suicide plasmid pJB7204 and integrants were selected on CYE 
plates423 containing 30 µg/ml kanamycin.  Resolution of the merodiploid was obtained on CYE 
plates containing sucrose.  Strains were then electroporated with the vector pJB1625 or the 
Tet(56) complementing clone pJB7207 and transformants were selected on CYE plates 
containing 5 µg/ml chloramphenicol. 
4.3.3 Tetracycline inactivation in Legionella 
Antibiotic susceptibility testing was performed using L. longbeachae wild type and 
deletion strains and L. pneumophila424,  bearing either the vector pJB1625425 or the Tet(56) 
complementing clone pJB7207.  Minimum inhibitory concentrations were determined according 
to Clinical and Laboratory Standards Institute (CLSI) procedures with the following 
modifications.  Results are representative of three independent experiments. The strains were 
initially grown as a patch on CYE plates containing chloramphenicol for 2 days at 37 degrees.  
The bacteria were swabbed into distilled water, washed one time, and resuspended at an 600 nm 
absorbance (OD600) of 1 (~1E9 CFU/ml).  The culture was diluted 200 fold into 10 mL of 
buffered AYE media containing 2 µg/ml chloramphenicol and a range of tetracycline but lacking 
supplemental iron, as iron can interfere with tetracycline activity.  The cultures were grown for 
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48 hours at 37ºC on a roller drum and the absorbances (OD600) were periodically measured using 
a Genesys 20 Spectrophotometer.  
4.3.4 Cloning, expression and purification of tetracycline-inactivating enzymes 
All genes encoding tetracycline-inactivating enzymes were cloned into the pET28b(+) 
vector (Novagen) at BamHI and NdeI restriction sites. Constructs were transformed into BL21-
Star (DE3) competent cells (Life Technologies). Cells harboring the plasmid were grown at 37ºC 
in LB medium containing a final concentration of 0.03 mg/mL kanamycin. Once cells reached an 
OD600 of 0.6, cells were cooled to 15 ºC and induced with 1 mM IPTG overnight. After this 
period, cells were harvested by centrifugation at 4000 rpm for 10 min at 4 ºC. Cell pellets were 
suspended in 10 mL of 50 mM Tris (pH 8.0), 100 mM NaCl, 10 mM imidazole (pH 8.0), 1 mM 
PMSF, and 5 mM BME per 1 liter of LB medium and stored at -80ºC.  
Cells were thawed in the presence of 0.25 mg/mL lysozyme and disrupted using 
sonication on ice for 60 seconds. The cell extract was obtained by centrifugation at 13,000 rpm 
for 30 min at 4 ºC and was applied onto nickel rapid run agarose beads (Goldbio) equilibrated 
with wash buffer (50 mM Tris (pH 8.0), 150 mM NaCl, 20 mM imidazole (pH 8.0), and 5 mM 
BME). The wash buffer was used to wash the nickel column three times with five column 
volumes. After washing, protein was eluted with five column volumes of elution buffer (wash 
buffer with 300 mM imidazole). The protein sample was further purified by gel chromatography 
using a HiLoad 16/600 Superdex 200pg column (GE Healthcare) equilibrated with 10 mM Tris 
(pH 8.0), 150 mM NaCl, 5 mM dithioerythritol (DTT). The fractions containing the protein of 
interest were pooled and concentrated using a 30K MWCO Amicon centrifugal filter (Millipore). 
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4.3.5 Tet(55) selenomethionine-labelling 
For selenomethionine-labelled Tet(55) (Se-Met Tet(55)), cells were grown in 1 L of 
SelenoMetTM Medium supplemented with SelenoMet Nutrient Mix (Molecular Dimensions 
Limited). Once cells reached an OD600 of 0.6, feedback inhibition amino acid mix (0.1 g of 
lysine, threonine, phenylalanine; 0.05 g of leucine, isoleucine, valine; 0.05 g of L(+) 
selenomethionine (ACROS Organics 259960025)) was added and the cells were shaken for 15 
minutes at 15 ºC. After 15 minutes, cells were induced at 15 ºC with 1 mM IPTG overnight. All 
other purification conditions were the same as for the native tetracycline-inactivating enzymes. 
4.3.6 Crystallization, data collection, and structure determination 
For crystallization, Se-Met Tet(55) was concentrated to 25 mg/mL. Crystals were 
obtained by vapor diffusion using hanging drops equilibrated at 18 °C. Se-Met Tet(55) 
crystallized in 0.1 M Tris-HCl (8.5) and 20-25% PEG 3000. Se-Met Tet(55) crystals were 
harvested directly from the growth condition and flash-frozen under liquid nitrogen.  
Native Tet(55) was concentrated to 50 mg/mL and crystallized in 0.1 M Tris-HCl (8.5) 
and 25-27% PEG 4000. Native Tet(55) crystals were harvested directly from the growth 
condition and flash-frozen. Tet(50) was concentrated to 35 mg/mL and crystallized in 0.1 M 
MES (pH 6.0-6.5), 1.6-2.0 M ammonium sulfate, 2-10% 1,4-Dioxane. Crystals were harvested 
directly from the growth condition and flash-frozen. For co-crystal structures, Tet(50) was 
concentrated to 17 mg/mL, and Tet(50) crystals were soaked with mother liquor plus 5 mM 
chlortetracycline or 4mM anhydrotetracycline for 30 minutes before flash-freezing. Tet(51) was 
concentrated to 13 mg/mL and crystallized in 0.1 M MES (pH 6.0) and 10% PEG 6000. Crystals 
were cryo-protected with 0.1 M MES (pH 6.0), 10% PEG 6000, and 30% glycerol before flash-
freezing. Tet(56) was concentrated to 38 mg/mL and crystallized in 0.1 M tri-sodium citrate (pH 
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5.6), 10% PEG 4000, 10% isopropanol. Tet(56) crystals were cryo-protected in 0.1 M tri-sodium 
citrate (pH 5.6), 10% PEG 4000, 10% isopropanol, and 20% glycerol before flash-freezing. 
The crystal structure of Tet(55) was solved by seleno-methionine labeling and single-
wavelength anomalous dispersion (SAD) (Supplementary Table 4.1), as molecular replacement 
using the previously published Tet(X) structures was unsuccessful. The inability to solve the 
structure by molecular replacement demonstrates that tetracycline-inactivating enzymes are 
structurally diverse and multiple structures are required to capture the diversity within the family. 
X-ray data for selenomethionine-labelled Tet(55) were collected from a single crystal using a 
wavelength of 0.976289 Å at synchrotron beamline 4.2.2 of the Advanced Light Source in 
Berkeley, CA. All other native data sets were collected at a wavelength of 1 Å. Data were 
collected on the CMOS detector and were processed with XDS426. Structure solution for Se-Met 
Tet(55) was performed using PHENIX AutoSol. Thirteen selenium sites were found, which gave 
a figure of merit of 0.370. The resulting Tet(55) model was refined against the native Tet(55) 
data set. R and Rfree flags were imported from the Se-Met Tet(55) mtz file using UNIQUEIFY 
within the CCP4 package427. Tet(50,51,56) structures were solved my PHENIX AutoMR using 
an ensemble of three domains of Tet(55) (domain 1 = aa1-70, aa100-172, aa276-319; domain 2= 
aa71-99, 173-275; domain 3= aa320-387). Structure solution for the Tet(50) chlortetracycline 
and anhydrotetracycline structures were performed by refinement with the apo Tet(50) structure, 
from which the R and Rfree flags were imported using UNIQUEIFY. 
Subsequent iterated manual building/rebuilding and refinement of models were 
performed using Coot428 and PHENIX429, respectively. The structure validation server 
MolProbity430 was used to monitor refinement of the models. All final refined models have 
favorable crystallographic refinement statistics, as provided in Supplementary Table 4.1. Figures 
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were generated and rendered in PyMOL Molecular Graphics System, Version 0.99rc6, 
Schrödinger, LLC.  
4.3.7 In vitro tetracycline and chlortetracycline inactivation assays 
Reactions were prepared in 100 mM TAPS buffer with 100 µM substrate, 14.4 µM 
enzyme, and an NADPH regenerating system consisting of the following components (final 
concentrations): glucose-6-phosphate (40mM), NADP+ (4mM), MgCl2 (1mM), and glucose-6-
phosphate dehydrogenase (4U/ml). The regeneration system was incubated at 37ºC for 30 
minutes to generate NADPH before use in reactions. Reactions were sampled at various 
timepoints, and quenched in four volumes of an acidic quencher consisting of equal parts 
acetonitrile and 0.25 M HCl.  
Products generated from enzymatic inactivation of both tetracycline and chlortetracycline 
were separated by reverse phase HPLC using a Phenomenex Luna C18 column (5µm, 110 Å, 
2×50mm) and 0.1% trifluoroacetic acid in water (A) and acetonitrile (B) as mobile phase.  
Injections of 25µl sample volume were eluted using a linear gradient from 25%B to 75%B over 
14 minutes at a flow rate of 1ml/min. 
Chlortetracycline reactions analyzed by high resolution tandem mass spectrometry were 
sampled at 75 minutes. The quenched samples were diluted 6X with 50% methanol in 0.1% 
formic acid and run on the Q-Exactive Orbitrap by direct infusion using the Advion Triversa 
nanomate. The data were acquired with resolution of 140,000. The MS scan was acquired from 
m/z 300 – 550. MS/MS spectra were acquired on the m/z 467.12 compounds. 
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4.3.8 Tetracycline inactivation in E. coli 
Antibiotic susceptibility testing was performed in E. coli MegaX cells (Invitrogen) 
bearing the pZE21 expression vector with the tetracycline inactivating gene of interest. 
Minimum inhibitory concentrations were determined according to Clinical and Laboratory 
Standards Institute (CLSI) procedures339 using Mueller-Hinton broth with 50 µg/mL kanamycin 
and a range of chlortetracycline concentrations profiled via absorbance measurements at 600nm 
(OD600) at 45 minute intervals using the Synergy H1 microplate reader (Biotek Instruments, Inc) 
for 48 hours at 37ºC.  
4.3.9 Kinetic characterization of tetracycline and chlortetracycline 
inactivation 
The optimal enzyme concentration for steady-state kinetics assays was determined by 
varying the concentration of enzyme while keeping chlortetracycline and NADPH concentration 
constant. 0.4 μM enzyme was found to give linear slopes for all concentrations of substrate 
tested, and was used as the enzyme concentration for all kinetics experiments.   
Reactions were prepared in 100 mM TAPS buffer at pH 8.5 with 0-160 µM substrate, 1.6 
mM NADPH, and 0.4 µM enzyme.  UV-visible spectroscopy measurements were taken in 
triplicate at 400nm wavelength light with a Cary 60 UV/Vis system (Agilent) for 10 minutes at 
room temperature. Initial reaction velocities were determined by linear regression using the 
Agilent Cary WinUV Software, and fitted to the Michaelis-Menten equation: 
 
using GraphPad Prism 6.  
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4.3.10 LC-MS characterization of chlortetracycline degradation products 
Reactions were prepared in 100 mM phosphates buffer at pH 8.5 with 1mM CTC, 0.5 
mM NADPH, 5 mM MgCl2 and 0.4 µM Tet(55). After 10 minutes, the reaction was centrifuge 
filtered for 10 minutes using a Millipore Amicon Ultracel (3 kDa MW cutoff) to remove enzyme. 
Prior to centrifugation, filters were triply rinsed with phosphate buffer to remove excess glycerol. 
The filtrate was collected and analyzed by LC-MS using an Agilent 6130 single quadrupole 
instrument with G1313 autosampler, G1315 diode array detector, and 1200 series solvent 
module. Reaction products were separated using a Phenomenex Gemini C18 column, 50 × 2 mm 
(5 µm) with guard column cassette was used with a linear gradient of 0% acetonitrile + 0.1% 
formic acid to 95% acetonitrile + 0.1% formic acid over 14 min at a flow rate of 0.5 mL/min 
prior to analysis by electrospray ionization.  
4.3.11 In vitro characterization of anhydrotetracycline inhibition 
IC50 values were determined for Tet(50), Tet(55), and Tet(56) by measuring the initial 
velocity of tetracycline degradation in the presence of varying concentrations of 
anhydrotetracycline. The concentrations of tetracycline and NADPH were kept constant at 25 
μM and 500 μM, respectively. Assays were prepared by combining all components except for 
enzyme and equilibrating to 25°C for five minutes. After the addition of enzyme, absorbance at 
400 nm was measured for five minutes. All measurements were taken in triplicate. The final 
concentrations for assay components were 100 mM TAPS buffer (pH 8.5), 25 μM tetracycline, 
500 μM NADPH, 16 mM MgCl2, 0.4 μM enzyme, and 0.05 – 150 μM anhydrotetracycline. A 
control assay using no anhydrotetracycline was assigned a concentration of 1.0×10-15 μM for 
analysis. A second control using no enzyme and 100 μM anhydrotetracycline was assigned a 
concentration of 1.0×1015 μM to simulate full inhibition of enzyme. IC50 values were determined 
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by plotting the log of anhydrotetracycline concentration against v0 in GraphPad Prism 6. 
Functional Tet(51) expressed poorly, so Tet(51) was omitted from these and other in vitro 
experiments. 
4.3.12 Checkerboard synergy assay 
Tetracycline (1024 µg/mL) and anhydrotetracycline (256 µg/mL) were dissolved in 
cation-adjusted Mueller-Hinton broth supplemented with 50 ug/mL kanamycin. A twofold 
dilution series of each drug was made independently across 8 rows of a 96 well master plate 
before 100 uL of each drug dilution series were combined into a 96 well culture plate (Costar), 
with rows included for no-drug and no-inocula controls. A sterile 96-pin replicator (Scinomix) 
was used to inoculate plates with ~1 uL of E. coli MegaX (Invitrogen) expressing a tetracycline 
inactivating enzyme, diluted to OD600 0.1 using. Plates were sealed with Breathe-Easy 
membranes (Sigma-Aldrich) and incubated at 37˚C with shaking at 220 rpm. Endpoint growth 
was determined by OD600  at 20 and 36 hours of growth using a Synergy H1 plate reader 
(BioTek, Inc.). Three independent replicates were performed for each strain on separate days. 
Synergy of anhydrotetracycline and tetracycline combinations was determined using the 
fractional inhibitory concentration index (FICI) method431, 
 
where FICI>1 indicates antagonism, FICI = 1 indicates additivity, and FICI <1 indicates 
synergy. The efficacy of the drug combination was also evaluated in the L. longbeacheae 




The widespread anthropogenic use of tetracycline antibiotics motivates the immediate 
study of emerging mechanisms of tetracycline resistance, such as enzymatic inactivation. Our 
data provide unprecedented insight into the dynamics of tetracycline-inactivating enzymes and 
reveal a novel mode of inhibition. Substrates like chlortetracycline are loaded into enzymes in 
the FAD OUT conformation through the substrate-loading channel (Supplementary Fig. 4.10a), 
which is open as a flexible loop is pulled away from the channel. Upon substrate binding, the 
enzyme converts to FAD IN, the channel closes, and catalysis can occur due to the proximity of 
FAD to the substrate. Mechanistic inhibitors like anhydrotetracycline also enter the enzyme 
through the same channel but bind at a distinct site (Supplementary Fig. 4.10b). Binding of 
inhibitor in this location sterically blocks FAD conversion to the IN conformation and prevents 
subsequent substrate binding and catalysis. Our model predicts that compounds that either bind 
with higher affinity to the inhibitor binding pocket, or that concomitantly bind to the inhibitor 
and substrate-binding sites will provide enhanced inhibition for the control of tetracycline 
resistance. This novel mechanism of inhibition is not only applicable to preventing antibiotic 
resistance, but is highly relevant to additional FAD dependent enzymes that comprise the 
flavoenzyme superfamily and are of clinical interest421. 
The rise in resistance to early-generation tetracyclines has spurred the development of 
next-generation derivatives, including tigecycline (approved for human use in 2005)134, and 
eravacycline and omadacycline (currently in late-stage clinical trials)139,140. These newer drugs 
are designed to evade resistance by efflux or ribosomal protection, but they are largely untested 
against tetracycline-inactivating enzymes. Alarmingly, tigecycline was found to be vulnerable to 
oxidative inactivation by Tet(X)385, which was recently identified for the first time in numerous 
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pathogens of high clinical concern137,138. These challenges highlight the immediate importance of 
studying mechanisms of emerging tetracycline resistance, such as those described here that 
expand substrate scope.   
Tetracycline resistance by enzymatic inactivation has thus far been rarely documented 
compared to resistance by efflux or ribosomal protection. Growing evidence, however, indicates 
that enzymatic tetracycline inactivation is a widespread feature in soil microbial communities406, 
and is a recently observed emerging threat in human pathogens137,138,386. Flavoenzymes display a 
proclivity for horizontal gene transfer and gene duplication, bestowing the potential to spread 
between bacteria and acquire novel functions389. Interestingly, the contigs on which tet(47-55) 
were discovered also contained mobility elements and other resistance genes58,406, suggesting 
that their original genomic context may be as part of a multidrug resistance cassette or mobile 
genetic element. This indicates that tetracycline-inactivating enzymes pose a threat for facile 
acquisition by additional human pathogens. Indeed, we show that tet(56) is present and 
functional in the human pathogen L. longbeachae, and tet(X) has now been reported in four out 
of six ESKAPE pathogens137,138,386, demonstrating the urgency of this threat. Our results reveal 
the structural basis for plasticity and dynamics in substrate binding in these enzymes. We 
propose a novel combination therapy strategy to retain tetracycline efficacy against bacteria that 
harbor tetracycline-inactivating resistance genes. Our results provide the structural and 
biochemical foundation to counter the alarming emergence of tetracycline resistance via 
enzymatic inactivation. 
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4.6 Supplementary Figures 
 
Supplementary Figure 4.1: Overall structures and FAD conformation states of 
Tet(50,51,55,56) 
Crystal structures of (a) Tet(50) monomer A, (b) Tet(50) monomer B, (c) Tet(51), (d) Tet(55), 
and (e) Tet(56).  
(f) In Tet(50) monomer A, FAD is bound non-covalently in the IN conformation, characterized 
by a 12.3 Å distance between the C8M and C2B atoms of the FAD molecule. 
(g) In Tet(50) monomer B, FAD is bound in the OUT conformation (5.2 Å between the C8M and 
C2B atoms). 
(h) In Tet(51), FAD is bound in the OUT conformation (4.5 Å between the C8M and C2B 
atoms). 
(i) In Tet(55), no electron density for ordered FAD is observed. 







Supplementary Figure 4.2: Tetracycline compounds have a distinctive three-dimensional 
architecture with a significant bend between rings A and B, allowing for unambiguous 
modeling into the electron density 
(a) The Fo - Fc map (contoured at 2.0) before modeling of chlortetracycline. 
(b) The 2Fo - Fc map (contoured at 1.0) after modeling of chlortetracycline. 
(c)The Fo - Fc map (contoured at 2.0) before modeling of anhydrotetracycline. 





Supplementary Figure 4.3: Multiple sequence alignment of Tet(47-56). Tetracycline 
destructases have high levels of sequence similarity in the residues important for binding of 
anhydrotetracycline (aTC, orange) or chlortetracycline (CTC, pink). Conserved FAD binding 










Supplementary Figure 4.5: Anhydrotetracycline restores tetracycline efficacy against E. 





Supplementary Figure 4.6: Anhydrotetracycline synergizes with tetracycline to kill E. coli 






Supplementary Figure 4.7: Model for binding dynamics, substrate plasticity, and inhibition 
of tetracycline-inactivating enzymes 
(a) Substrate (e.g. chlortetracycline) can enter and bind the active site of a tetracycline 
destructase, resulting in a conformational switch from FAD OUT (grey) to FAD IN (orange) and 
closure of the substrate site. 
(b) A mechanistic inhibitor (e.g. anhydrotetracycline) enters and binds the active site, but 
sterically prevents the FAD cofactor from switching from the OUT to IN conformation and 
thereby preventing catalysis. Further, it can act synergistically to competitively prevent substrate 
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Supplementary Table 4.2: Kinetic parameters for Tet(50,55,56,X) 
 Tetracycline Chlortetracycline 
 KM (µM) Vmax (s-1) kcat/KM (µM-1s-1) KM (µM) Vmax (s-1) kcat/KM (µM-1s-1) 
Tet(50) 16.84 ± 3.555 0.02852 ± 
0.001555  
0.004234 6.298 ± 2.035 0.02302 ± 
0.001634 
0.009138 
Tet(55) 4.562 ± 1.684 0.01233 ± 
0.0009667 
0.006757 6.001 ± 1.315 0.0194 ± 
0.0002397 
0.008082 
Tet(56) 7.665 ± 1.630  0.0425 ± 
0.002051 
0.013862 3.654 ± 1.080 0.04389 ± 
0.002619 
0.030029 
Tet(X) 10.77 ± 2.613 0.00448 ± 
0.0002618 







Supplementary Table 4.3: Relevant strains, plasmid, and primers employed in this study 
Strains, Plasmids, Primers Reference or source 
Strains 
Lp02  Legionella pneumophila Philadelphia I  424 
JV595 Legionella longbeachae  ATCC 33462 
JV8858 Legionella longbeachae ∆tet(56) This study 
JV8861 JV595 + pJB7207 This study 
JV8864 JV595 + pJB1625 This study 
JV8868 JV8858 + pJB7207 This study 
JV8870 JV8858 + pJB1625 This study 
JV8874 Lp02 + pJB7207 This study 
JV8876 Lp02 + pJB1625 This study 
Plasmids 
pSR47S Suicide plasmid R6K suicide vector (KanR sacB)  422 
pJB1625 Complementing vector  (CmR version of pJB908) 425 
pJB7204 ∆tet(56) suicide plasmid This study 











Chapter 5: Conclusions 
5.1 The effects of early life antibiotic therapy on the preterm 
infant gut microbiota and resistome 
A reservoir of antibiotic resistance genes of critical interest lies in human associated 
microbes, encompassing both benign or commensal organisms and pathogens. The human gut 
hosts a diverse commensal microbial community, whose collective genomes (the microbiome) 
encode an arsenal of functions, including vital activities that modulate host health and 
physiology as well as antibiotic resistance genes295. During the first years of life, the infant gut 
microbiota plays crucial roles in pathogen exclusion, nutrient acquisition, and immune system 
maturation295,432. Microbiota development can be altered by factors including gestational age at 
birth, delivery and feeding modes, and antibiotic exposure7,432,433. Perturbation of the gut 
microbiota during early infancy may be disproportionately damaging272,316, and has been linked 
to a variety of morbidities such as metabolic and immune disorders263,264,295,298. This is 
particularly relevant for preterm infants, who almost all receive antibiotics in the first days of 
life249,272,316.  
The infant gut microbiota is shaped by both prenatal and postnatal factors246,247. 
Following birth, the infant gut microbiota undergoes a patterned maturation process248-250. 
Perturbation of the gut microbiota during this key developmental window can have lasting 
effects on host physiology and disease risk254-259. One of the most common perturbations during 
this period, antibiotic therapy258,260, can substantially alter the gut microbiota and infant 
physiology255,261-266. Antibiotic-induced gut microbiota dysbioses in this population are linked to 
the pathogenesis of necrotizing enterocolitis270-272, late onset sepsis273,274, and other adverse 
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health outcomes275. While these correlations exist, the underlying etiologies remain unclear, 
motivating the study of microbiota development in the context of antibiotic therapy in this 
vulnerable population276. 
During early-life hospitalization in the NICU, the preterm infant gut microbiota is 
characterized by an extensive antibiotic resistome and a high relative proportion of MDROs, 
which are further enriched following antibiotic exposure7. However, the persistence of these 
microbiome disruptions is unclear. To this end, I conducted a longitudinal sequencing and 
culture based interrogation of the preterm infant gut microbiota compared to age-matched, 
antibiotic naïve near term infant controls to quantify the effects of early life antibiotic therapy on 
microbiota and resistome development over the first twenty months of life. Using random 
forests, I trained a model of healthy microbiota development in the absence of early life 
hospitalization and antibiotic treatment. I applied this model to preterm infants in my cohort and 
identified acute but transient microbiota immaturity that resolves concomitant with discharge 
from the NICU. By sequencing isolates cultured from infant stools at multiple timepoints, I 
identified prolonged and persistent carriage of multidrug resistant Enterobacteriaceae in the gut 
microbiota of preterm infants. This suggests that these potentially pathogenic strains establish a 
gastrointestinal niche while infants are hospitalized, and retain that niche following discharge to 
home. In order to characterize the gut resident resistome of the infants in my cohort, I used 
functional metagenomics to assay 320 Gb of metagenomic DNA for resistance function in high 
throughput. I assembled and annotated 874 unique antibiotic resistance genes from these 
microbiota. After computing the relative abundance of these genes across all microbiota in my 
cohort, I identified a persistently enriched resistome as well as perturbed patterns of resistome 
assembly in the gut microbiota of preterm infants over the twenty months of life. Lastly, to 
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synthesize my findings on enduring effects of early life antibiotic treatment on the preterm infant 
gut microbiota, I used a support vector machine to classify post-discharge samples as originating 
from an antibiotic treated preterm infant or an antibiotic naïve near term infant based on the 
metagenomic features present in the stool. I was able to classify with high accuracy the group to 
which a stool belonged despite inability to distinguish these stools based on species composition 
alone. This provides evidence of a persistent metagenomic signature of early life antibiotic 
treatment in preterm infants that lasts beyond discharge from the NICU and may play a role in 
long-term adverse health outcomes in preterm infants for which the etiology is currently unclear.  
This work has the potential to improve antibiotic stewardship in NICU settings, as well as 
inform antibiotic treatment strategies in neonatal settings such that infections are appropriately 
treated while microbiota diversity is spared. My results underscore the need for narrow spectrum 
alternative to the antibiotic regimens currently used widely in neonatal medicine. While it is 
possible that the persistent metagenomic signatures of early life antibiotic treatment which I 
identified play a role in the long term neurological, metabolic, and immune pathologies from 
which preterm infants suffer, further experiments using model systems including gnotobiotic 
animals are required to substantiate this link. Additional future work in this space could  
5.2 Emergence of tetracycline resistance by inactivation 
across habitats 
Tetracycline resistance is typically acquired via horizontal gene transfer and occurs 
almost exclusively by ribosomal protection or antibiotic efflux368,371. A third mechanism, 
enzymatic inactivation of tetracycline, is rarely observed, with Tet(X) being the only previously 
characterized example28,401,434. Both common tetracycline resistance mechanisms have their 
evolutionary origins in the environment25,94,376, but are now widely distributed in many 
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commensal and pathogenic bacteria4,23,122. Tetracycline antibiotics have been widely used in 
clinical, agricultural, and industrial settings for the past seven decades, and medicinal chemists 
and pharmaceutical companies continue to revisit the tetracycline scaffold as a source for new 
antibiotics. These new developments include tigecycline (approved for human use in 2005)134, 
eravacycline383 (approved for human use in 2018), and omadacycline (currently in late stage 
clinical trials)140. 
We recently discovered a novel family of ten tetracycline inactivating enzymes from 
functional selection of grassland and agricultural soil metagenomes58,406. The set included a 
functionally validated but previously unknown tetracycline destructase homolog from the human 
pathogen Legionella longbeachae. These genes were annotated as flavin adenine dinucleotide 
(FAD) dependent oxidoreductases. The tetracycline destructases confer high-level resistance 
against tetracycline and oxytetracycline when heterologously expressed in E. coli, and degrade 
tetracycline in vitro with a dependence on time, enzyme, and reduced nicotinamide adenine 
dinucleotide phosphate (NADPH). Furthermore, tetracycline inactivation by the tetracycline 
destructases proceeds via diverse mechanisms, producing decay products not seen in tetracycline 
inactivation by Tet(X)28,387,406. The tetracycline destructases are likely candidates for 
dissemination to the clinic and expansion of substrate tolerance, potentially compromising next-
generation tetracyclines139 and motivating deep mechanistic analysis of their activities and 
surveillance of their prevalence across microbial habitats. 
This work has importantly identified tetracycline resistance by inactivation as a 
mechanism of resistance that is more widespread in commensal, environmental, and pathogenic 
organisms than had previously been appreciated. By elucidating the mechanism of action of 
these enzymes prior to their broad clinical dissemination, we were able to devise rationally an 
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inhibitor-based strategy to counter the action of these resistance genes. I described 
anhydrotetracycline, and inhibitor that blocks tetracycline degradation by tetracycline 
inactivating enzymes in vitro and is sufficient to restore tetracycline efficacy in the face of 
resistant bacteria which encode a tetracycline inactivator. Using biochemistry and structural 
biology, we revealed a twofold mode of inhibition in which anhydrotetracycline both competes 
with tetracycline for binding in the active site and restricts critical dynamics of the FAD cofactor, 
thus halting the catalytic cycle. Should tetracycline resistance by inactivation expand to become 
a dominant mechanism of resistance to tetracycline antibiotics, coadministration of 
anhydrotetracycline and tetracycline (or derivatives thereof) is a promising method for 
circumventing this resistance threat. Additionally, and more broadly, this work has established 
and expanded a paradigm in which surveillance of environmental resistance threats allows for 
proactive development of strategies to mitigate the eventual threat posed by clinical emergence 
of said resistance threat. In the face of increasing antibiotic resistance and decreasing antibiotic 
development, this model holds promise as a means for preemptive and sustainable development 
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